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LIST OF ABBREVIATIONS
D = change in
%PV = % of predicted value
AUC = area under curve
av = average
bd = twice daily
BDP = Budesonide
BEC = Beclomethasone
BMB = Bambuterol
cf = compared with
CFC = chlorofluorocarbon propellant
CIR = CirculaireÔ
CNV = Conventional nebuliser
CO = randomised controlled trial, cross over design
CON = Continuous dose
COPD = Chronic obstructive pulmonary disease
CYC = Cyclohaler
D/A = Diskus/Accuhaler
D-inh = diskhaler
DPI = Dry powder inhaler
DU = Diskus
ED = Emergency department
FEV1 = Forced expiratory volume in one second
FNS = Flunisolide
FP = Fluticasone
FRM = Formoterol
HFA = hydrofluoroalkane propellant
ICS = Inhaled corticosteroids
ICU = Intensive care unit
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IM = intramuscular
inh = inhaler
int = Intermittent dose
IPR = Ipratropium
ITT = intention to treat
IV = intravenous
MA = meta-analysis
mane = once in morning
MDI = metered dose inhaler
mg = milligrams
MNT = Montelukast
N/A = Not applicable or not available
neb = nebuliser
NNH = numbers needed to harm using the drug of least efficacy to achieve one
unfavourable outcome over a period of time (study duration in this report)
NNT = numbers needed to treat using the drug of efficacy to achieve one favourable
outcome over a period of time (study duration in this report)
nocte = once at night
n.s. = not statistically significant
OCS = Oral corticosteroids
PC20 = challenge (usually methacholine or histamine) concentration that caused a 20% fall
in FEV1
PEFR = Peak expiratory flow rate
po = oral
PRD = Prednisone
PRN = as required
q4h = every four hours
qd = once daily
Qid = four times daily
QoL = Quality of life
RCT = randomised controlled trial
IV
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ROT = Rotahaler
se  = standard error
SLB = Salbutamol
SLM = Salmeterol
SOB = shortness of breath
SR = systematic review
TAA = Triamcinolone
TBH = Turbuhaler
TEB = Terbutaline
THP = Theophylline
mg = micrograms
URTI = upper respiratory tract infection
ZAF = Zafirlukast
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Scope of systematic review of
asthma pharmaceuticals
The development of this systematic review protocol involved extensive consultation between the
NZHTA and the Pharmaceuticals sub-committee of the Asthma Working Group of the New Zealand
Asthma Guideline Group.
SEARCH METHODOLOGY
Search strategy
Searches were restricted to information published from 1st January 1997 onwards, in all languages.
Original searches were carried out in December 2000.  An update of Pre-Medline, Current Contents
and the Science Citation Index was performed in March 2001.
An additional very broad combined search of the Pre-Medline, Medline, Embase, Current Contents,
and Cinahl databases for papers on any aspect of asthma in New Zealand was also completed in March
2001.
Principal sources of information
The following databases were searched using the search strategies outlined in Appendix 1:
Bibliographic databases
§ Medline
§ Embase
§ Current Contents
§ Science Citation Index
§ Cinahl
§ Cochrane Library Controlled Trials Register
§ Index New Zealand
Review databases
§ Cochrane Library Systematic Reviews & Protocols
§ Database of Abstracts of Reviews of Effectiveness
§ NHS Economic Evaluation Database
§ Best Evidence
Library catalogues
§ New Zealand Ministry of Health library
§ New Zealand Bibliographic database - Te Puna
§ US National Library of Medicine
§ World Health Organisation
Websites
§ Health Canada
§ US Centers for Disease Control
§ British Thoracic Society
§ EGuidelines (UK)
§ University of Dundee Asthma Research Unit
§ UK General Practice Airways Group
§ UK Department of Health publications
§ Meta-register of Controlled Trials
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§ TRIP - Turning Research into Practice
§ Health Evidence Bulletins Wales
§ OMNI - Organised Medical Networked Information
§ European Federation of Asthma and Allergy Associations
§ GINA - Global Information Network on Asthma
§ Canadian Office for Health Technology Assessment
§ Canadian Network for Asthma Care
§ Canadian Lung Association
§ Canadian Thoracic Society
§ Asthma Society of Canada
§ ClinicalTrials.gov
§ American Academy of Allergy Asthma and Immunology
§ JAMA Asthma Information Center - Physicians Section
§ US National Heart, Lung, and Blood Institute
§ US Asthma Clinical Research Network
§ US National Institute of Allergy and Infections Diseases
§ Thoracic Society of New Zealand and Australia
§ Australian Department of Health & Aged Care
§ Ministerial Asthma Working Party
Note: hand searching of journals, contacting of manufacturers, or contacting of authors for unpublished
research was not undertaken during the search process.
Major search terms used
§ index terms from Medline (MeSH headings): asthma, asthma-drug therapy, anti-asthmatic agents,
bronchodilator agents, randomized controlled trials, controlled clinical trials, meta-analysis,
guidelines, practice guidelines, double-blind method, single-blind method, comparative study,
treatment outcome
§ index terms from Embase: asthma, asthma-drug therapy, randomized controlled trial, drug
comparison, double-blind procedure, single-blind procedure, meta-analysis
§ additional keywords used (not standard index terms): systematic review, systematic overview,
effectiv*, efficacy
§ keywords used for exclusions:  child* , infan*, pediatric*, paediatric* as title words when adult*
was not also in the title; copd, chronic obstructive, rhinitis, as title words when asthma was not
also in the title
Search filters used to identify randomized controlled trials, meta-analyses, and guidelines in the
literature were adapted from those produced by the Center for Reviews and Dissemination at the
University of York.
The complete search strategies are given in Appendix 1.
STUDY INCLUSION CRITERIA
Studies published in English, French and German language from 1997 onwards (final search completed
March 2001) are included. The population of interest is defined as adults with acute or chronic asthma,
including aspirin and exercise induced asthma. A strict definition of adult based on age inclusion
criteria has been avoided. Where both children and adults make up the study population these studies
have been included.
Studies conducted in hospital, emergency department, outpatient clinic, general practitioner and
pharmaceutical usage settings are included. Only randomized controlled trials and systematic reviews
and meta-analyses (as a subset of systematic reviews) of randomized controlled trials are included.
Systematic reviews were only included if the researchers searched Medline and at least one other
database.
Studies conducted using double blinding are included.  If no double blinding studies in a particular
class comparison were available then studies conducted using single blinding were included or open if
no double blinding or single blinding studies were available in a particular class comparison.
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Only studies with an enrollment sample size of 30 patients or more have been included.
Only drugs available in New Zealand were included in the review.
STUDY EXCLUSION CRITERIA
Studies were excluded if they included:
§ any patients with Chronic obstructive pulmonary disease (COPD)
§ only children (classified as 12 years or younger or an article using the term ‘child’ or ‘children’ or
‘paediatric’ or ‘pediatric’)
§ any patients who were pregnant
§ a pharmacoeconomic analysis alone
§ a comparison between efficacy drug and placebo alone. Exclusions: Immunotherapy
§ letters, non-systematic reviews, editorials and comments were also excluded.
THERAPEUTIC INTERVENTIONS
Following is a list of the main systematic review comparisons between different classes of asthma
medications:
Anticholinergics combined with short-acting b- go ists v short-acting b-a onists
Long-acting b-agonists v long-acting b-a onists
Long-acting b-agonists v short-acting b-a onists
Long-acting b-agonists v inhaled steroids
Long-acting b-agonists  v leukotriene antagonist
Long-acting b-agonists  v oral b-agonists
Long-acting b-agonists v theophylline
Short-acting b-agonists v short-acting b-a onists
Short-acting b-agonists v inhaled steroids
Short-acting b-agonists v theophylline
Short-acting b-agonists v nedocromil
Inhaled steroids v inhaled steroids
Inhaled steroids v oral steroids
Inhaled steroids v leukotriene antagonists
Inhaled steroids v theophylline
Leukotriene antagonists v cromoglycate
Leukotriene antagonists v theophylline
Acupuncture v other treatment
Immunotherapy v placebo
Device v device
CFC propellant v HFA propellant
Several relevant interventions have been subjected to Cochrane Reviews. Topics covered include
immunotherapy, acupuncture, antileukotrienes compared to inhaled corticosteroids, corticosteroids in
acute and post-acute asthma, holding chambers versus nebulisers in acute asthma, long-acting beta-
agonists versus theophylline and nedocromil for preventing exercise induced bronchoconstriction. The
studies covered in these reviews have been excluded from individual appraisal. The Cochrane
systematic reviews themselves have been included as high quality appraised literature. Only studies
meeting the following criteria have been appraised in intervention areas covered by these Cochrane
reviews:
§ sample size greater than 100
§ published after the latest substantial amendment to those Cochrane reviews.
PATIENT OUTCOMES
Studies with all or some of the following patient outcome endpoints have been included. These relate to
commonly assessed POEM (Patient Oriented Evidence that Matters) endpoints.
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Endpoints:
§ relapse
§ rescue medicine use
§ symptom ratings
§ quality of life
§ spirometric outcomes (e.g. FEV1, P FR)
§ methacholine challenge
§ exercise challenge
§ time to onset of effect and maximal effect
§ safety endpoints – cortisol, bone density, pulse, BP, tremor
§ health care usage – hospital admission, ED attendance, length of stay
STUDY SELECTION
Studies were selected for appraisal using a two-stage process. Initially the titles and abstracts (where
available) identified from the search strategy were scanned and excluded as appropriate. The full text
articles were retrieved for the remaining studies and these were appraised if they fulfilled the study
selection criteria outlined above.
There were 1292 studies identified by the search strategy (see appendix 1). Two hundred and ninety
two full text articles were obtained after excluding studies based on examination of the search titles and
abstracts. A further 164 of these full text articles did not fulfil the inclusion criteria. Therefore 128
articles were fully appraised and are included in this report.
EVIDENCE TABLES
Key information summaries include study reference, study design, study grading, treatment arms,
patient inclusion and exclusion criteria, number of patients randomized, primary and secondary
efficacy results with p-values and/or 90%/95% confidence intervals and comments on internal validity
issues arising from the study appraisal. Number needed to treat (NNT) was calculated when sufficient
information was presented to allow calculation of this statistic.
Unless otherwise stated the drug(s) of efficacy are presented in the left-hand column of the results
section. P-values unless otherwise stated relate to between treatment group comparisons. Refer t
Appendix 2 for detailed description of table items.
All studies were appraised using modified SIGN (Scottish Intercollegiate Guidelines Network)
methodology checklists (see Appendix 3). The evaluation criteria are defined by a series of questions
covering study internal validity. These questions addressed the quality of the study research
question(s), randomisation methods, study population demographics, concealment and blinding
methods, type of outcome measures, study group treatment regimens, patient dropout rates and
statistical power adequacy, intention to treat (ITT) analysis methodology and the degree of industry
support.
For systematic reviews and meta-analyses appraisal questions addressed the review methodology,
literature search rigour, potential benefits and harms of intervention and the synthesis and conclusions
drawn by combining studies in the review.
The final grading (1++, 1+ or 1-) code was allocated based upon the study design and study quality.
For a study to receive a 1++ grading the following criteria needed to be fulfilled:
§ clearly defined study question
§ a clear description of an adequate randomisation process
§ absence of baseline differences in demographic variables, markers of asthma severity and other
potential confounding variables between intervention groups post-randomisation
§ an adequate concealment method and use of double blinding
§ outcomes measured in a standard, valid and reliable way
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§ all study arms treated equally
§ at least 80% of the sample randomised were included in the presented analyses
§ an ITT analysis was presented
§ pharmaceutical company involvement was restricted to either funding alone or no involvement.
Factors that automatically consigned studies to a 1- grading included:
§ open study
§ study groups were not treated equally
§ ITT analysis not presented
§ significant omissions or errors in patient demographic information and outcome results.
Combinations of two or more of the following also resulted in a 1- grading:
§ baseline study differences, single blind, less than 80% of the participant’s randomised were
analysed, and pharmaceutical company staff were included at authorship level.
All other studies were graded as 1+.
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Study limitations
Systematic reviews are limited by the quality of the studies included in the review and the methodology
of the systematic review.
In the review of asthma therapeutic agents the quality of the included articles was such that there were
no studies graded as 1++. Ninety-one of 128 (71%) were graded as 1+ and 37 of 128 (29%) as 1-.
Ordinarily 1- studies would be excluded from a systematic review. They were included on this occasion
so the therapeutics arm of the asthma guidelines group could assess them for relevance to the
development of the New Zealand based guideline. However, the results of these studies should be
viewed with considerable caution.
Common limitations to the study designs included:
§ lack of description on the study methodology
§ differences between study groups post randomisation or a lack of comparison between key
variables post randomisation (particularly in studies using the cross over design)
§ use of open and single blind designs
§ inadequate power
§ not using an ITT analysis
§ pharmaceutical company involvement in all aspects of the study.
Individual study limitations are described in the comments section of the evidence tables.
Limitations to the review methodology that need to be considered in developing an asthma therapeutics
guideline include restriction to:
§ articles published from 1997 onwards
§ the published literature
§ English, French and German language articles
§ reviewing each study by one researcher only
§ study evaluation criterion did not cover aspects of statistical methodology such as the
appropriateness of the data collected and the statistical tests used to analyse this.
In developing a guideline for asthma therapeutics consideration will need to be given to studies
published pre 1997. The vast majority of articles of interest were published in the pre 1997 time period
so methods should be developed by the guidelines group to assess whether the new evidence presented
in this review is sufficient to alter any recommendations included in previous evidence based
guidelines.
Restriction to the published literature is likely to lead to bias since the unpublished literature tends to
consist of studies not identifying a significant result.
Restriction by language may result in study bias but the direction of this bias cannot be determined.
Although two researchers appraised the articles included in this review they did not cross validate the
data extraction and appraisal process.
The majority of articles appraised were not set in New Zealand. Therefore, the generalisability of these
studies to the New Zealand setting needs to be considered.
The studies were initially selected by examining the abstracts of these articles. Therefore, it is possible
that some studies were inappropriately excluded prior to examination of the full text article.
There is a limitation on space in evidence tables. Therefore, study details have been summarised
rigorously. In particular, inclusion and exclusion criteria listed in the tabl s represent a small proportion
of the criteria most articles provided. In general, data about the basis of the diagnosis of asthma has not
been included and common exclusion criteria such as pregnancy have not been included in the tables.
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The comment “pharmaceutical limitations” indicates the presence of restrictions on pharmaceutical
agents used by study participants but the reader is referred to the individual studies for more detail as
required. The phrase “pharmaceutical company funded and supported trial” is commonly encountered
in the comments section. This indicates pharmaceutical companies have provided both financial
support and investigational support in the form of staff inclusion among the study authors.
This review was conducted over a limited time frame (November 2000 – April 2001).
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Evidence Tables
Anticholinergic:
Acute asthma
Table 1: Summary of studies investigating the effect of pharmaceuticals (short-acting b-agonists + ipratropium versus short-acting b-agonists) in acute asthma
Study
Source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Rodrigo
and
Rodrigo
2000)
RCT
Grade 1+
Country:
Uruguay
Salbutamol mdi
120 mg/puff +
Ipratropium mdi
21 mg/puff in a
dose of 4 puffs at
10 min intervals
(480 mg/84 mg)
V
Salbutamol mdi
120 mg/puff in a
dose of 4 puffs at
10 min intervals
(480 mg)
3 hours of
treatment (24
puffs or 2,880 mg
salbutamol and
504 mg
ipratropium per
hour)
Inclusion:
Age 18-50 yrs
FEV1/PEFR < 50% PV
180
Improvement over
salbutamol control group %
PEFR (95%CI)
FEV1 (95%CI)
Hospital admissions n (%)
Pre ED use of b-agonists by ipr
patients: increase in FEV1
previous use
no previous use
Symptoms
24+ hours
< 24 hours
FEV1£ 30PV%
       > 30PV%
SLB+IPR
+20%
(2.6,38.4)
+48%
(19.8,76.4)
18 (20%)
N/A
N/A
N/A
N/A
N/A
N/A
SLB
36 (39%)
N/A
N/A
N/A
N/A
N/A
N/A
P value
P=.02
P=.001
P=.01
P=.01
P=.03
P=.01
P=.09
P=.001
P=.60
NNT
5
· Mean age 35 and female 37%,
PEFR 32%PV in SLB+IPR group;
mean age 33 and female 34%,
PEFR 33%PV in SLB group
· Acute asthma, Emergency
Department setting
Study design abbreviations
RCT = Randomised controlled trial, parallel design
CO = randomised controlled trial, cross over design
MA = meta-analysis
SR = Systematic review
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Table 1: Summary of studies investigating the effect of pharmaceuticals (short-acting b-agonists + ipratropium versus short-acting b-agonists) in acute asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Weber et
al. 1999)
RCT
Grade 1+
Country:
United
States
All patients
received
prednisone po 60
mg
Salbutamol neb
10 mg/hour +
Ipratropium neb
1.0 mg/hour
V
Salbutamol neb
10 mg/hour +
Ipratropium neb
1.0 mg/hour
£ 3 hours of
treatment
Inclusion:
Age 18+ yrs
FEV1/PEFR < 70% PV after
2.5 mg Salbutamol in 3 mL
normal saline
67
Improvement over
salbutamol control group %
PEFR (95%CI)
Adjusted for baseline PEFR
 Median length of stay
(minutes)
Adjusted for baseline PEF
Hospital admissions n (%)
Adjusting for baseline PEF
OR (95%CI)
SLB+IPR
+6.3%
(-1.5,27%)
210
N/A
8 (23%)
0.88 (0.28,
2.8)
SLB
245
N/A
13 (39%)
P value
n.s.
P=.03
P=.26
N/A
· Mean age 46 and female 75%,
PEFR 50%PV and smoking history
48% in SLB+IPR group; mean age
49 and female 66%, PEFR 40%PV
and smoking history 74% in SLB
group
· Significant P<.05 baseline
differences in PEFR%PV and
smoking history. P<.10 differences
in previous hospitalization and
intubation
· Results have been adjusted for
baseline differences
· Acute asthma, Emergency
Department setting
· Pharmaceutical (producer of
ipratropium) involvement in supply
of ipratropium and pharmacy
costs
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Table 1: Summary of studies investigating the effect of pharmaceuticals (short-acting b-agonists + ipratropium versus short-acting b-agonists) in acute asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Lin et al.
1998)
RCT
Grade 1+
Country:
United
States
Salbutamol 2.5
mg + Ipratropium
0.5 mg (first dose
only) then every
20 min 2 more
doses of
salbutamol only
(total 3 doses)
neb
V
Salbutamol 2.5
mg + placebo
(first dose only)
then every 20 min
2 more doses of
salbutamol only
(total 3 doses)
neb
Treatment period
1 hour
Inclusion:
Age 18+ yrs
PEFR <200 L/min
Exclusion:
20 pack years+ smoker
b-agonists preceding 4
hours
55
Number of patients admitted
to hospital n (%)
Difference and 95%CI of
proportion admitted
PEFR L/min mean
BL
20 min
40 min
60 min
PEFR L/min %PV mean
BL
20 min
40 min
60 min
SLB+IPR
3 (11%)
25%
(3%,46%)
131
197
252
269
28
42
53
57
SLB
10 (36%)
142
197
218
228
29
37
45
47
P value
P=.03
Over  1
hour
period
P=.001
Over 1
hour
period
P<.001
NNT
41
· Mean age 40 and female 54% in
SLB + IPR group, mean age 41and
female 59% in SLB group
· Acute asthma. Convenience
sample selected from Emergency
Department
1 NNT calculated using the formula NNT= 1/Absolute risk reduction. Therefore, the number needed to treat to avoid one admission was 1/0.25 (ie. 4) for combination therapy of one
hour duration compared with salbutamol alone for one hour.
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Table 1: Summary of studies investigating the effect of pharmaceuticals (short-acting b-agonists + ipratropium versus short-acting b-agonists) in acute asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Rodrigo et
al. 1999)
MA
Grade 1+
Ipratropium inh
0.5 mg (single
dose) plus b-
agonists
(Salbutamol 8
studies, fenoterol
2 studies) after
arrival in ED
V
b-agonists alone
First 90 minutes of
treatment
Inclusion:
Age 16+ yrs
English language studies
RCT, double blind
Patients with acute
asthma, treated in ED with
b-agonists
Search:
1978-1999 (April)
MEDLINE, Science Citation
Index, Current Contents,
reviews (articles and
primary research), experts
1483
Overall effect size (std units)
cf. control group
FEV1  (95%CI)
Homogeneity test
Study specific effects
Mean FEV1 at admission
<35%PV (4 studies)
(95%CI)
Use of corticosteroids
(7 studies) (95%CI)
Hospital admissions (5 studies)
(Odds Ratio, 95%CI)
b-agonist  +
IPR
0.14
(0.04,0.24)
(10%) (2%,
18%)
(0.03-0.63)
0.38
(0.09,0.67)
0.14
(0.00,0.28)
0.62
(0.44,0.88)
P value
P=.008
P>.5
N/A
N/A
N/A
P=.007
NNT
18
· 10 studies included, acute asthma,
mean age 32 ± 13 years and
female 64%
· Mean methodology quality score
0.66 (max = 1)
· Criteria for discharge and
admission not clearly defined
· Reported adverse effects not
assessed nor delivery devices
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Table 1: Summary of studies investigating the effect of pharmaceuticals (short-acting b-agonists + ipratropium versus short-acting b-agonists) in acute asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Stoodley
et al. 1999)
MA
Grade 1+
Country:
Canada
Ipratropium plus
b-agonists mdi or
neb after arrival
in ED
V
b-agonists alone
30-90 minutes
duration of
treatment
Inclusion:
Age 18+ yrs
RCT (double blinding not
necessary but all included
studies double blind)
Patients with acute
asthma, treated in ED or
similar with b-agonists
Search:
MEDLINE (1966-97), EMBASE
(1980-97), CINAHL (1982-
97), Biological Abstracts
(1990-97), Cochrane
database and Current
Contents (1996-97)
1377
Overall effect size (std units)
cf. control group
PEFR/ FEV1 (95%CI)
% improvement in FEV1 (4
studies)
% improvement PEFR
(5 studies)
Hospital admissions (3 studies,
n=1064) (Relative Risk, 95%CI)
Effect size of studies with IV
steroids (4 studies) to all
enrolled patients
b-agonist  + IPR
0.38
(0.27,0.48)
7.3%
(3.8%, 10.9%)
22.1%
(11.0%, 33.2%)
.73 (53, .99)
.25
(.10,.40)
· 10 studies included, acute asthma,
mean age range for treatment
group 29.5-50.4 years, control
group 29.6-53.2.
· Study quality assessment limited to
randomization, double blinding
and inclusion of data for dropouts
and withdrawals
· Dosages of ipratropium not
specified
· Changes in airflow assessment FEV1
(4 studies) PEFR (5 studies) both (1
study)
· Significant Cochran Q test for
homogeneity (p=.047) suggesting
included trials were a
heterogeneous group. One trial
had much lower baseline PEFR
values. Removal resulted in Q test
P= .37, summary effect value 0.35
(.24,.47). Study results reported
including 10 studies.
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Table 1: Summary of studies investigating the effect of pharmaceuticals (short-acting b-agonists + ipratropium versus short-acting b-agonists) in acute asthma (continued)
Study
Source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Garrett et
al. 1997)
RCT
Grade 1-
Country:
New
Zealand
All patients
received IV
hydrocortisone
200 mg within 15
minutes of
treatment start
(Combivent)ä
Ipratropium neb
1.5 mg in a dose
+ Salbutamol neb
2.5 mg
V
Salbutamol neb
2.5 mg
Duration 90
minutes
Inclusion:
Age 18-55 yrs
FEV1< 70% PV
Exclusion:
Smoking history of 10+
pack years
Complicating illness eg
COPD
338
Mean absolute difference
over salbutamol group
Baseline FEV1ml (se)1
45 minutes
90 minutes (primary efficacy)
FEV1< 1 L at baseline:
D FEV1 (mls)
FEV1³ 1 L/min at baseline:
D FEV1 (mls)
Hospital admissions (%)
SLB + IPR
40 (57)
93 (24)
113 (18)
22
176
15.3%
SLB
22.3%
P value
P=.4485
P=.03
P=.02
n.s.
P<.005
NNT
14
· Mean age 30 and % female not
specified, FEV1 40%PV in SLB+IPR
group; mean age 30, % female not
specified, FEV1 40%PV in SLB group
· Overall % female 61%, 17% Maori,
24% Pacific Island ethnicity
· 13% of patients reported using
OCS, 32% ICS, 80% inh b-agonist
within 6 hours of presentation to ED
· Acute asthma, Emergency
Department setting
· No intention to treat based
analysis, 58 patients (27 in
combiventä group and 31 in
salbutamol group) withdrawn after
treatment received (no FEV1
recorded).
· Pharmaceutical company
supported study
1se = standard error
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Table 1: Summary of studies investigating the effect of pharmaceuticals (short-acting b-agonists + ipratropium versus short-acting b-agonists) in acute asthma (continued)
Study
source,
design and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(FitzGerald
et al. 1997)
RCT
Grade 1-
Country:
Canada
All patients
received
oxygen and IV
bolus of 125 mg
methyl-
prednisone
(within 15
minutes of
nebulization)
(Combination)
Ipratropium neb
0.5 mg in a dose
+ salbutamol
neb 3.0 mg
V
Salbutamol neb
3.0 mg
Duration 90
minutes
Inclusion:
Age 18-55 yrs
FEV1< 70% PV
Exclusion:
Smoking history of 10+
pack years
COPD or significant other
medical illness
342
Mean change from baseline
Baseline FEV1 L (se)
45 minutes
90 minutes (primary efficacy)
Hospital admissions (%)
SLB+IPR
1.62 (0.05)
0.58 (0.04)
0.61 (0.04)
5.9%
SLB
1.53 (0.05)
0.52 (0.04)
0.52 (0.04)
11.2%
P value
n.s.
n.s.
n.s.
NNT
19
· Mean age 31 and female 60%,
FEV1 1.62L in SLB+IPR group; mean
age 30, % female 64%, FEV1  1.53L
in SLB group
· Prior asthma medication in
combination and salbutamol
alone groups: 12% and 12% of
patients reported using OCS, 46%
and 40% ICS, 88% and 90% inh b-
agonist within 24 hours of
presentation to ED
· Acute asthma, Emergency
Department setting
· Poor description of randomisation,
concealment and blinding
methodology
· Not strict intention to treat based
analysis
· Criteria for discharge and
admission not clearly defined
· Pharmaceutical company partly
funded study
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Table 1: Summary of studies investigating the effect of pharmaceuticals (short-acting b-agonists + ipratropium versus short-acting b-agonists) in acute asthma (continued)
Study
source,
design and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Kamei et al.
1999)
RCT
Grade 1-
Country:
Japan
Fenoterol 1 puff
(200 mg/puff)
every 1 minute
for 5 minutes,
total 1000 mg +
Oxitropium
bromide 2 puffs
(100 mg/puff)
every 1 minute
for 5 minutes,
total 1000 mg
mdi with
InspirEase™
holding
chamber
V
Fenoterol 1 puff
(200 mg/puff)
every 1 minute
for 5 minutes,
total 1000 mg
Treatment
duration 60
minutes
Inclusion:
FEV1 < 70% PV
Exclusion:
Pulmonary emphysema
Complicating drugs
69 At 60 minutes
Mean value cf. baseline
PEFR L/min (se)
From baseline PEFR % impr
1   min
15 min
30 min
60 min
FRM + OTB
261 (18)
N/A
N/A
N/A
N/A
FRM
210 (17)
N/A
N/A
N/A
N/A
P value
P<0.05
P<0.02
P<0.01
P<0.02
P<0.001
· Mean age 55 and female 46%,
best FEV1 1.81L in FRM+OTB group;
mean age 56and female 65%, best
FEV1 1.86L in FRM group
· Acute asthma, Emergency
Department setting
· Open study, no detail on
randomisation nor statistical power
· Intention to treat based analysis
not evident, 31/34 and 33/35 in
respective randomised groups
analyzed for efficacy
· Some data results for primary
efficacy outcome not reported
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Cromoglycate
Chronic asthma
Table 2: Summary of studies investigating the effect of pharmaceuticals (cromoglycate versus inhaled steroid) in chronic asthma
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Hoshino et
al. 1998)
RCT
Grade 1+
Country:
Japan
Ketotifen po
1 mg bd
V
Disodium
cromoglycate
(DSCG) inh
2 mg Qid
V
Beclomethasone
inh 100 mg Qid
12 weeks
Inclusion:
Age 16-50 yrs
20+% increase in FEV1 or
PEFR
Daily/as needed b-agonists
with no I/OCS previous 6
months
Exclusion:
FEV1 PV < 50%
Smoker
I/OCS or DSCG in previous
4 months
32 12 weeks
Asthma symptoms
Median FEV1 (%PV)
Before
After
Median PEFR(L/min)
Before
After
Ketotifen
72.0
80.0
n.s.
450
500
n.s.
DSCG
63.2
72.5
P<.05
350
450
P<.01
BDP
66.0
74.3
P<.05
425
475
P<.01
P value
DSCG v
Ketotifen
P<.01
BDP v
Ketotifen
P<.05
DSCG v
Ketotifen
P<.05
BDP v
Ketotifen
P<.05
· N=13, mean age 27 and female
46%, FEV1 72%PV, PEFR(l/min) 450
in ketotifen group; N=9, age 26
and female 33%, FEV1 63%PV,
PEFR(l/min) 350 in DSCG group;
N=9, age 30 and female 30%,
FEV1 66%PV, PEFR(l/min) 425 in
BEC group
· Small numbers in study treatment
arms. Baseline differences in FEV1
PV% and PEF
· The study also included analysis
of fibreoptic bronchoscopy and
immunohistochemistry data
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Immunotherapy
Chronic asthma
Table 3: Summary of studies investigating the effect of pharmaceuticals (immunotherapy with placebo) in chronic asthma
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Bousquet
et al. 1999)
RCT
Grade 1-
Country:
France
Sublingual
immunotherapy
with standardized
Dermato-
phagoides
pteronyssinus
(DP)-D. farinae
(DF) 50/50 extract
Progressive
dosage from 1,
10, 100, 300 IR/ml
daily for 4 weeks
then 3 times a
week for 24
months
V
Placebo
25 months
Inclusion:
Age 7-42 years
FEV1 > 70%PV
Clinical history of allergy to
house dust-mites
Exclusion:
Patients on ICS >1000 mg
daily, I/O b-agonists > 4
times daily
Sensitization to animal
danders
Presence of a household
pet
85
AM PEFR L/min (base)
Mean (last entry)
PM PEFR L/min (base)
Mean (last entry)
Nighttime asthma (base)
Mean (last entry)
Daytime asthma (base)
Mean (last entry)
QoL assessment scores
Mental health
Perception of health
Physical pain
Safety assessment
Adverse events (no.  pat/%)
IMM
404.1
426.3
P=.01
414.1
433.2
P=.03
0.20
0.17
n.s.
0.32
0.17
P=.02
79.7
76.5
86.2
15/42
(35.7%)
Placebo
415.7
424.3
n.s.
429.6
437.7
n.s.
0.26
0.11
n.s.
0.37
0.19
n.s.
60.7
56.8
68.3
14/43
(32.6%)
P value
n.s.
n.s.
n.s.
n.s.
P=.07
P=.01
P=.02
P=.84
· Mean age 21 and female 45%,
MCh PD20 mean 105 mg in IMM
group; mean age 22 and female
42%, MCh PD20 mean 229 mg in
placebo group
· Significantly greater sensitivity to
methacholine in active treatment
at baseline
· No strict intention to treat analysis.
Detailed study outline shows 20
patients (24% or 10 in each group)
discontinued within first 6 months of
study not included in efficacy
analysis at 11 & 25 months. Only
23/42 in IMM group and 27/43
patients in placebo completed 25
months. Safety efficacy evaluated
at 25 months
· QoL analysis includes only 38
(18/20) patients
· Pharmaceutical company
supported trial
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Leukotriene antagonists
Chronic asthma
Table 4: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus leukotriene antagonists) in chronic asthma
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Villaran et al.
1999)
RCT
Grade 1+
Country:
12 countries
Salmeterol inh 50
mg bd
V
Montelukast po
10 mg daily
8 weeks
Inclusion:
Age 15-45 yrs
FEV1 improved by ³12% post
b-agonist
PC20 0 in FEV1 in response to
£ 4mg/ml methacholine or
histamine
£ 20 pack years smoking
Exclusion:
Asthma requiring
emergency care – past
month
197
Maximal % fall in FEV1 post
exercise (cf. baseline)
Recovery time to within 5% of
prechallenge level at 8 weeks
compared with pre
intervention (min)
Adverse respiratory events
(SLM cf. MNT)
MNT
17.2%
-23.9
39%
SLM
10.7%
-11.3
54%
P value
P < .001
P = .002
P < 0.05
NNH
7
· Mean age 27 and female 50%
· Exercise induced
bronchoconstriction
· Pharmaceutical sponsored trial
(producers of montelukast)
· Similar study design, authors and
sponsor to next study
(Edelman et al.
2000)
RCT
Grade 1+
Country:
United States
Salmeterol inh 50
mg bd
V
Montelukast po
10 mg nocte
8 weeks
Inclusion:
Age 15-45 yrs
FEV1 ³ 65%PV
<15 pack-years smoking
Exclusion:
Asthma or URTI requiring
emergency care – past
month
191
Maximal % challenge fall in
FEV1
MNT
57.2%
SLM
33.0%
P value
P = .002
· Mean age 26 and female 50%
· Mod-severe activity limitation in
60% in past month at baseline
· No baseline ethnicity data
presented
· Pharmaceutical company input
(producers of montelukast) in
funding, design, conduct and
analysis of trial
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Table 4: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus leukotriene antagonists) in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Busse et al.
1999a)
RCT
Grade 1+
Country:
United States
Salmeterol inh 42
mg bd
V
Zafirlukast po 20
mg bd
4 weeks
Inclusion:
Age ³ 12 yrs
FEV1 50-80%PV
Exclusion:
>10 pack years tobacco
smoking
289
Improvement in am PEFR
(L/min)
Symptom free days
% days with no rescue
medication use
SLM
29.6
22.4%
30.5%
ZAF
13.0
8.8%
11.3%
P value
P £ 0.001
P £ 0.001
P £ 0.001
NNT
7
5
· Mean age 38 and female 80%
· Mean FEV1 66%PV
· 80% on inhaled steroid pre-study
· Exercise induced
bronchoconstriction
· Unknown proportion of
participants identified through
advertisements – may limit
generalisability
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Table 5: Summary of studies investigating the effect of pharmaceuticals (inhaled steroids versus leukotriene antagonists) in chronic asthma
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Malmstrom et
al. 1999)
RCT
Grade 1+
Country:
Multinational
Beclomethasone
inh 200 mg bd
V
Montelukast po
10 mg nocte
V
Placebo
12 weeks
Inclusion:
Age ³ 15 yrs
FEV1 50-85%PV
Nonsmoker
Exclusion:
Pharmaceutical limitations
895
% D am FEV1
% D daytime symptom score
% D nocturnal awakenings
(n/wk)
Asthma attacks (% patients)
BEC
13.1
-0.62
-2.4
10.1
MNT
7.4
-0.41
-1.7
15.6
95%CI (diff)
3, 8.5
-0.33, -0.09
-1.08, -0.32
P value
P<0.05
NNT
18
· Median age 35 and female 61%
· Mean FEV1 65%PV
· Pharmaceutical company
funded and supported trial
· Baseline differences in gender
mix between interventions which
were of uncertain significance
· Unclear whether ITT analysis was
used
(Bleecker et al.
2000)
RCT
Grade 1+
Country:
United States
Fluticasone inh 88
mg bd
V
Zafirlukast po 20
mg bd
12 weeks
Inclusion:
Age ³12 yrs
FEV1 50-80%PV
Exclusion:
History of life threatening
asthma
Use of tobacco in past year
or >10 pack-years total
Resp infection within 2
weeks of screening
Pharmaceutical limitations
451
D am FEV1 (L)
D symptom free days (%)
D rescue free days (%)
D nights with no awakenings
(%)
FP
0.42
28.5
40.4
21.2
ZAF
0.2
15.6
24.2
8.0
P value
P<0.001
P<0.001
P<0.001
P<0.001
NNT
8
6
8
· Mean age 41 and female 50%
· Mean FEV1 68%PV
· Supported by fluticasone
producers
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Table 5: Summary of studies investigating the effect of pharmaceuticals (inhaled steroids versus leukotriene antagonists) in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Westbroek and
Pasma 2000)
CO
Grade 1+
Country:
Netherlands
Fluticasone inh
100 mg bd
V
Zafirlukast po 20
mg bd
2 weeks each
Inclusion:
Age 18-70 yrs
FEV1 ³ 50%PV
Non smoker
Exclusion:
Resp infection or asthma
admission within a month of
screening
Pharmaceutical limitations
30
PC20 histamine (mg/ml)
AM PEFR (L/min)
FP
1.61
409
ZAF
0.99
391
95%CI (diff)
0.05, 1.50
-0.08, 35.3
· Mean age 45 and female 70%
· Financial support from producers
of fluticasone
· No comparison of asthma
severity at baseline
· Adequate concealment could
not be determined
(Laviolette et al.
1999)
RCT
Grade 1+
Country:
18 countries
Montelukast po
10 mg nocte +
beclomethasone
inh 200 mg bd
V
Beclomethasone
inh 200 mg bd
V
Montelukast po
10 mg nocte
V
Placebo
Inclusion:
Age ³15 yrs
FEV1 50-85%PV
Non-smoker
Exclusion:
Resp infection within 3
weeks of screening
Pharmaceutical limitations
642
% D am FEV1
D daytime asthma symptom
score
D night awakenings (n/week)
Asthma attacks (% patients)
BEC/MNT
5.08
-0.13
-1.04
6.2
BEC
0.72
-0.02
-0.45
12.0
P value
P < 0.001
P = 0.04
P = 0.01
P = 0.06
· Mean age 39 and female 51%
· Mean FEV1 72%PV
· Other study comparisons not
presented in full
· Baseline differences in placebo
group from other interventions
· Pharmaceutical company
funded and supported trial
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Table 6: Summary of studies investigating the effect of pharmaceuticals (leukotriene antagonists versus leukotriene antagonists) in chronic asthma
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Dockhorn et al.
2000)
CO
Grade 1+
Country:
United States
Montelukast po
10 mg
V
Montelukast IV 7
mg
V
Placebo
24 hours each
Inclusion:
Age 15-56 yrs
FEV1 40-80%PV
Current non-smoker (history
< 7 pack-years)
Exclusion:
Pharmaceutical limitations
51
% D FEV1 AUC
(conc.time)
Rescue
medication
required (%)
IV MNT
20.7
18
PO MNT
15.7
24
Diff in means
(LS)1
5.8
N/A
95% CI
-0.41, 12.06
P value
n.s.
· Mean age 30 and female 44%
· Mean FEV1 64%PV
· Pharmaceutical company
producing montelukast funded
and supported trial
· Limited baseline data between
initial randomised groups (FEV1
comparison only)
· 90% power to detect a 6.5% point
difference in FEV1 between
montelukast groups
· 1LS = Least squares
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Long-acting beta-agonists
Chronic asthma
Table 7: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma
Study
source,
design and
evidence
grading
Intervention
Comparison
And study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Shrewsbury
et al. 2000)
MA
Grade 1+
Salmeterol +
inhaled
steroids (Beclo-
methasone 5
studies or
fluticasone 4
studies)
V
At least
doubling dose
of inhaled
steroids
(Beclo-
methasone 5
studies or
fluticasone 4
studies)
12+ weeks
Inclusion:
Age 12+ yrs
RCT, double blind
All languages
Patients with symptomatic
asthma, treated on current
dose of inhaled steroids
Search:
1985-1999 (September
1999 last search)
MEDLINE, EMBASE,
GlaxoWellcome
databases
3685 Treatment with salmeterol
plus inhaled steroids versus
increased dose inhaled
steroids (double+ dose)
Mean difference (95% CI) in
lung function
AM PEFR L/min
AM FEV1 L
Mean % difference (95% CI)
Days without symptoms
Nights without symptoms
Days without rescue
treatment
Nights without rescue
treatment
Difference (95% CI) in mean
numbers of patients with
exacerbation:
Any exacerbation
Moderate/severe
exacerbation
3 months
22.4 (15,30)
0.10
(0.04, 0.16)
11% (8,15)
5% (2,8)
16% (13,20)
9% (5,12)
2.73
(0.43,5.04)
2.42
(0.24,4.60)
6 months
27.7 (19,38)
0.08
(0.02,0.14)
15%(11,19)
6% (3,9)
19% (14,24)
9% (5,13)
P value
3 months
P<.001
P<.001
P<.001
P<.001
P<.001
P<.001
P=.02
P=.03
P value
6 months
P<.001
P<.01
P<.001
P<.001
P<.001
P<.001
· 9 studies included
· No evidence of heterogeneity
between studies for PEFR and
FEV1 and exacerbation analysis.
For symptoms and rescue
comparison P<.10 in all cases.
Comparison of 95% CI under fixed
and random effects model cited
by authors as small and clinically
unimportant (data not provided)
· Pharmaceutical company
supported meta-analysis
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Table 7: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Baraniuk
et al. 1999)
RCT
Grade 1+
Country:
United
States
Fluticasone  mdi
220 mg bd
V
Triamcinolone
mdi 600 mg bd
V
Fluticasone  mdi
88 mg bd +
salmeterol mdi 42
mg bd
12 weeks
Inclusion:
Age 12+ yrs
FEV1 40-65%PV
Patients with FEV1 65-
85%PV
15+% increase in FEV1 %PV
after 30 min with 180 mg
salbutamol
BDP dosage 252-672 mg, or
TAA 600-1000 mg, or FP
1000 mg daily 3+ months
pre-study
Exclusion:
Smoker
Serious asthma
exacerbation previous 4
weeks
680 12 weeks
(mean change cf. baseline)
(se)
AM FEV1 (L)
FEV1 (L) %PV
Symptom score
% symptom-free days
% rescue-free days
Adverse event related to
treatment (% patients)
(mean change cf. baseline)
(se)
AM FEV1 (L)
FEV1 (L) %PV
Symptom score
% symptom-free days
% rescue-free days
Adverse event related to
treatment (% patients)
FP plus SLM
0.58 (0.03)
16.7 (1.0)
-0.44(0.05)
29.2(2.9)
45.0(2.9)
14%
FP
0.48(0.03)
14.0(0.6)
-0.46(0.05)
22.6(2.6)
28.9(2.7)
13%
TAA
0.34 (0.03)
10.4 (0.80
-0.31(0.05)
11.9(2.1)
27.4(2,5)
8%
TAA
0.34(0.03)
10.4(0.80
-0.31(0.05)
11.9(2.1)
27.4(2,5)
8%
P value
P<.001
P£.004
P£.004
P£.004
P£.004
N/A
P£.027
P£.035
P£.035
P<.001
n.s.
N/A
NNT
NNH
17
NNT
NNH
20
· Mean age 41 and female 59%,
FEV1 63%PV, non-white ethnicity
13%  in FP + SLM group; mean
age 40and female 61%, FEV1
63%PV, non-white ethnicity 17% in
FP group; mean age 39 and
female 65%, FEV1 63%PV, non-
white ethnicity 11% in TAA group
· No detail on randomisation
method
· Pharmaceutical company
funded and supported trial
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Table 7: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Aubier et
al. 1999)
RCT
Grade 1+
Country:
Netherlands,
France
Combination:
Fluticasone 500
mg + salmeterol
50 mg bd Diskus
inh
and placebo bd
V
Concurrent:
Fluticasone  500
mg + salmeterol
50 mg bd Diskus
inh and placebo
bd
V
Fluticasone  500
mg bd diskus inh
and placebo bd
12 weeks
Inclusion:
Age 12-78 yrs
ICS 12 weeks prior to run-in
and BEC or BDP
1500-2000 mg or FP 750-
1000 mg daily 4 weeks prior
Symptomatic patients
(score ³2)
Patients with FEV1 50-
100%PV
PEFR 50-85%PV max PEFR
after 15 min with 400 mg
salbutamol
503 12 weeks
(adj mean difference cf.
baseline) (se)
Relative to FP plus SLM
combination. –ve values
indicate higher overall value
for combination therapy
AM PEFR (l/min)
*=90% CI
**=95% CI
PM PEFR (l/min)
*=90% CI
**=95% CI
28 weeks
Adverse event related to
treatment (% patients)
Combination
Concurrent
FP alone
FP plus SLM
concurrent
-3 (4.3)
-10, 4*
P=.535
-6 (4.3)
-13, 1*
P=.160
17%
14%
19%
FP
-21 (4.4)
-29, -12**
P<.001
-21 (4.3)
-29, -12**
P<.001
· Mean age 46 and female 43%,
FEV1 2.44L in FP + SLM combo
group; mean age 48 and female
50%, FEV1 2.32L in FP + SLM
concurrent group; mean age 50
and female 47%, FEV1 2.33L in FP
group
· Little detail on randomisation,
concealment and blinding
methodology
· Post-randomization 100 patients
withdrew, 19% of combo group,
16% of concurrent group and 25%
from FP group
· Pharmaceutical company
funded and supported trial
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Table 7: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Condemi
et al. 1999)
RCT
Grade 1+
Country:
United
States
Fluticasone mdi
88 mg bd +
Salmeterol mdi 42
mg bd
V
Fluticasone mdi
220 mg bd
2-4 weeks
pre-trial:
Fluticasone
88 mg bd and as
needed
salbutamol
Treatment
24 weeks
Inclusion:
Age 12-75 yrs
FEV1 40-65%PV
or 65-85%PV plus one or
more of:
³4 puffs salbutamol daily, 2
days AM/PM PEFR
variance ³20%, 2+ nights
asthma awakenings, 2+
days symptom score ³2
Exclusion:
Current tobacco use
Hospital asthma admission
previous month
437 24 weeks
(cf. baseline) (se)
(Change)
AM PEFR L/min
FEV1 (L)
Symptom free days %
Rescue salbutamol use
(Mean no.  puffs daily)
FP plus SLM
+46.5(3.5)
0.43 (0.04)
+26%
-2.51(0.17)
FP
+23.8(3.2)
0.33 (0.03)
+10%
-1.55(0.15)
P value
P<.001
P=.013
P<.001
P<.001
· Mean age 37 and female 62%,
FEV1 2.12L in FP + SLM  group;
mean age 37and female 60%,
FEV1 2.14L in FP group
· No detail on randomisation
methodology
· Pharmaceutical company
funded and supported trial
· Study drop out rate 9% in FP +
SLM group 14% in FP group
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Table 7: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Kavuru et
al. 2000)
RCT
Grade 1+
Country:
United
States
Fluticasone  100
mg plus salmeterol
50 mg bd Diskus
inh
V
Salmeterol 50 mg
bd Diskus inh
V
Fluticasone  100
mg bd Diskus inh
V
Placebo inh bd
12 weeks
Inclusion:
Age 12-70 yrs
Patients with FEV1 40-
85%PV and ±15% of the
screening FEV1
Either ICS previous 12
weeks and dose (either
BDP 252-420mg daily,TAA
600-1000 mg daily, FP 176
mg daily) previous 4 weeks
OR SLM 1+ weeks prior
Exclusion:
ICS group and 12+ puffs
salbutamol daily for 3+
days or SLM group 6+ puffs
daily or 3+ days
3+ nighttime awakenings
previous 7 days req
salbutamol
Smoker previous 12 months
>10 pack years smoker
356 12 weeks
(cf. baseline)
FEV1 (L) mean change (se)
Asthma symptom score
mean change (se)
% days no symptoms
mean change (se)
Adverse event related to
treatment (% patients)
(cf. baseline)
FEV1 (L) mean change (se)
Asthma symptom score
Mean change (se)
% days no symptoms
mean change (se)
Adverse event related to
treatment (% patients)
(cf. baseline)
FEV1 (L) mean change (se)
Asthma symptom score
Mean change (se)
% days no symptoms
mean change (se)
Adverse event related to
treatment (% patients)
FP plus SLM
0.51(0.05)
-0.7(0.11)
22.6(4.59)
3%
FP plus SLM
0.51(0.05)
-0.7(0.11)
22.6(4.59)
3%
FP plus SLM
0.51(0.05)
-0.7(0.11)
22.6(4.59)
3%
SLM
0.11(0.06)
-0.1(0.1)
8.0(3.29)
35%
FP
0.28(0.05)
-0.2(0.09)
7.2(4.09)
11%
Placebo
0.01(0.07)
0.4(0.10)
-3.8(3.01)
49%
P Value
P£.013
P£.013
P£.013
N/A
P<.001
P£.025
P£.025
N/A
P£.027
P£.013
P£.013
N/A
· Mean age 38 and female 41%,
no completing study 83% in FP +
SLM group; mean age 37 and
female 49%, completion rate 56%
in SLM group; mean age 39 and
female 48%, completion rate 74%
in FP group; mean age 35 and
female 49%, completion rate 34%
in placebo group
· Post-randomization, 21 patients
from one site excluded because
of poor practice standards. ITT
analysis excludes these, small
difference (non-quantified) in
results if included.
· Pharmaceutical company
funded and supported trial
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Table 7: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design and
evidence
grading
Intervention
comparison
and study duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(van Noord
et al. 1999)
RCT
Grade 1-
Country:
Netherlands
Low steroid requirement:
Fluticasone inh (100 mg bd
open) + Fluticasone inh (100 mg
bd blind)
OR
Fluticasone inh (100 mg bd
open) +
Salmeterol inh (50 mg bd blind)
V
High steroid requirement:
Fluticasone inh (250 mg bd
open) + Fluticasone inh (250 mg
bd blind)
OR
Fluticasone inh (250 mg bd
open) +
Salmeterol inh (50 mg bd blind)
Run in: 4 weeks
Treatment:
12 weeks
Inclusion:
Age 12-75 yrs
FEV1 ³ 50%PV
10+% increase in FEV1 PV
with
400mg salbutamol mdi or
800 mg inh (3 visits or pre-
run in period 4 weeks)
Daily symptom score ³1, or
diurnal var in PEFR 15+%, or
rescue salbutamol 2+ times
daily on 4/14 days run in
period
Exclusion:
Change in asthma
medication previous 6
weeks
OCS previous 3 months
274 12 weeks
PEFR L/min (mean increase
cf. baseline) (se)
AM
PM
FEV1 (L) visit 4 (4 weeks)
             visit 5 (12 weeks)
Odds Ratios
(FP high dose plus SLM
relative to FP low dose plus
SLM)
Rescue salbutamol use
                          Day
                          Night
Days with symptoms
FP
low dose
plus SLM
+18.6
(3.8)
+16.2
(4.0)
2.53 (0.8)
2.47 (0.8)
FP
High dose
plus SLM
N/A
N/A
2.45 (0.8)
2.48 (0.9)
1.47
2.19
1.52
P value
P<.001
P<.001
P=.04
P=.18
P=.03
P<.001
P=.04
· Mean age 46 and female 53%,
FEV1 (mean L) 2.33 in FP low
dose + SLM  group; mean age
47 and female 51%, FEV1 (mean
L) 2.34 in FP high dose group
· High and low steroid
requirements determined pre-
study and at run-in
· No detail on randomisation,
blinding and concealment
methodology
· Intention to treat based analysis
not evident. Study drop out rate
4% in FP low dose + SLM group
7% in FP high dose group
· Several key study results lack
data detail
· Pharmaceutical company
funded and supported trial
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Table 7: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Jenkins et
al. 2000)
RCT
Grade 1+
Country:
9 countries
Salmeterol disk
inh 50 mg +
Fluticasone  disk
inh 250 mg +
placebo turb inh
bd
V
Budesonide turb
inh 800 mg +
placebo disk inh
bd
24 weeks
Inclusion:
Age 14-80 yrs
4+ weeks pre-study:
FEV1 or PEFR³
50-85%PV
15+% increase in FEV1 or
mean AM PEFR£85% after
b-agonist
Salbutamol 2+ times daily
2+ daytime symptom score
on 4+/7 days
Exclusion:
Asthma requiring
hospitalization previous 4
weeks
Smoker
³10 pack years smoker
353 24 weeks
adjusted mean over
treatment period (se)
AM PEFR L/min
PM
Median % symptom-free days
Adverse events related to
treatment (% patients)
FP plus SLM
406 (3.67)
416 (3.14)
60%
14%
BDP
380 (3.81)
398 (3.25)
34%
19%
P value
P<.001
P<.001
P£.001
N/A
NNT
4
NNH
20
· Mean age 45 and female 50%,
FEV1 (mean% PV) 68 in FP + SLM
group; mean age 48 and female
50%, FEV1 (mean% PV) 72 in BDP
group
· International based study (9
countries)
· Little detail on randomisation,
blinding and concealment
methodology
· Pharmaceutical company
funded and supported trial
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Table 7: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Pearlman
et al. 1999)
RCT
Grade 1-
Country:
United
States
Placebo mdi bd
V
Salmeterol mdi 42
mg bd
V
Fluticasone mdi
88 mg bd
V
Fluticasone mdi
220 mg bd
V
Salmeterol mdi 42
mg bd +
Fluticasone mdi
88 mg bd
V
Salmeterol mdi 42
mg bd +
Fluticasone mdi
220 mg bd
4 weeks
Inclusion:
Age 12-62 yrs
FEV1 50-80%PV
15+% increase in FEV1 15
min after 180 mg
(2 puffs) salbutamol
Daily or as needed b-
agonists previous 6 months
Exclusion:
Smoker previous 12 months
>10 pack years
O/I/IVCS previous 1 month
Daily OCS previous 6
months
136 4 weeks
Placebo
SLM (42mg )
FP (88mg)
FP (220mg),
SLM (42mg) + FP (88mg)
SLM (42mg) + FP (220mg)
* vs placebo
^ vs SLM 42mg, FP 88mg and
FP220mg
Asthma symptom score
Placebo
SLM (42mg )
FP (88mg)
FP (220mg),
SLM (42mg) + FP (88mg)
SLM (42mg) + FP (220mg)
* vs placebo
^ vs FP 88mg
Baseline
FEV1 (L)
2.39 (0.13)
2.75 (0.1)
2.91 (0.13)
2.52 (0.14)
2.31 (0.12)
2.62 (0.12)
Baseline
1.3 (0.2)
1.3 (0.2)
1.2 (0.1)
1.3 (0.2)
1.2 (0.2)
1.1 (0.2)
Endpoint
mean
change
FEV1 (L)
0 (0.09)
0.29 (0.12)
0.27 (0.07)
0.30 (0.09)
0.59 (0.10)
0.75 (0.16)
Mean
change
-0.2 (0.2)
-0.5 (0.1)
-0.1 (0.1)
-0.3 (0.1)
-0.8 (0.2)
-0.4 (0.1)
P value
P£.05*
P<.05*^
P<.05*^
P<.05*
P<.05*^
· Poor comparative baseline
demographics between groups
· Placebo N=23, mean age 35 and
female 57%, Non-Caucasian 9%
· SLM (42mg ) N=21, mean age 29
and female 33%, Non-Caucasian
0%
· FP (88mg) N=23, mean age 27
and female 26%, Non-Caucasian
0%,
· FP (220mg), N=23, mean age 32
and female 43%, Non-Caucasian
9%
· SLM (42mg) + FP (88mg) N=25,
mean age 33 and female 60%,
Non-Caucasian 16%
· SLM (42mg) + FP (220mg) N=21,
mean age 26 and female 33%,
Non-Caucasian 19%
· Pharmaceutical company
funded and supported trial
· Study drop out rate 4% in FP low
dose + SLM group, 7% in FP high
dose group
· Several key study results lack
data detail
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Table 7: Summary of studies investigating the effect of pharmaceuticals (long-acting b- go ists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Weersink et
al. 1997)
RCT
Grade 1-
Country:
Netherlands
Salmeterol mdi 50
mg bd
V
Fluticasone  mdi
250 mg bd
V
Fluticasone  mdi
250 mg bd +
salmeterol mdi 50
mg bd
Methacholine
challenge (MCh)
Or
Adenosine
5’mono-
phosphate
challenge (AMP)
To FEV1 PC20 or
MCh (19.6mg/ml)
or AMP
(640mg/ml)
6 weeks
Inclusion:
Age 18-45 yrs
Circadian variation in
PEFR15+%
BHR to MCh PC20 <9.6
mg/ml
IgE elevated to house dust
mite (RAST³2)
Short-acting b-agonist on
demand previous 4 weeks
Exclusion:
Smoker
Acute asthma
exacerbation, OCS
previous 8 weeks
ICS previous 4 weeks
50 6 weeks
Mean Circadian PEFR
variation 100*(highest-lowest
24-h value)/mean 24-h value
per day over 3 days
Baseline
End of period
FEV1 (L) (%PV increase cf.
baseline)
4 PM  (se)
4 AM  (se)
PC20 MCh (se)
4 PM
4 AM
SLM
22.4%
9.1%
+10.8%
(2.4)
+19.6%
(3.6)
+1.5(0.5)
+2.4(0.5)
FP
24.0%
7.9%
+7.6%
(3.4)
+15.9%
(3.0)
+2.1(0.5)
+3.0(0.5)
SLM+FP
24%
10%
+5.9%
(3.8)
+17.9%
(3.8)
2.5(0.6)
2.9(0.8)
P Value
Between
n.s.
Within
P<.0001
Between
P=.2
Within
P=.0001
Between
times
P=.0005
PC20 MCh
Between
P=.04
Within
P<.0001Bet
ween
times
P=.1
· Mean age 28 and female 50%,
FEV1 77%PV, in SLM group; mean
age 28 and female 56%, FEV1
88%PV, in FP group; mean age 26
and female 50%, FEV1 83%PV, SLM
+ FP group
· Baseline differences post-
randomisation
· Patients recruited from 1
outpatient clinic and newspaper
advertisements
· No intention to treat analysis, 4
treated patients not included in
analysis
· Pharmaceutical company
funded and supported trial
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Table 7: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Murray et
al. 1999)
RCT
Grade 1+
Country:
United
States
Beclomethasone
mdi 168 mg bd +
salmeterol mdi 42
mg bd
V
Beclomethasone
mdi 336 mg bd
24 weeks
Inclusion:
Age 18-82 yrs
FEV1 45-80%PV
12+% increase in FEV1 PV
with 180 mg salbutamol
Symptomatic while taking
336 mg beclomethsone or
800 mg triamcinolone daily
Constant immunotherapy
ok if 12+ weeks
Exclusion:
Patients on other asthma
medication except
theophylline, as needed
salbutamol and asthma
exacerbation medication
514 24 weeks
FEV1 (L) baseline
             24 weeks
(cf. BDP)
Symptom score (mean
change cf. baseline at 24
weeks)
Wheeze
Shortness of breath
Chest tightness
Asthma exacerbations %
patients
BDP + SLM
2.30
2.68
-0.49
-0.71
-0.62
17%
BDP
2.31
2.54
-0.27
-0.25
-0.33
18%
P value
P<.05
P£.05
P£.05
P£.05
n.s.
· Mean age 42 and female 59%,
FEV1 65%PV in BDP + SLM  group;
mean age 42 and female 55%,
FEV1 64%PV in BDP dose group
· Pharmaceutical company
funded and supported trial
· Several key study results
(salbutamol use, drug safety) lack
data detail
· Unclear if intention to treat
analysis used
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Table 7: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Kelsen et
al. 1999)
RCT
Grade 1+
Country:
United
States
Beclomethasone
mdi 168 mg bd +
Salmeterol
mdi 42 mg bd
V
Beclomethsone
mdi 336 mg bd
Run-in:
2 weeks
Treatment:
24 weeks
Inclusion:
Age 18-77 yrs
FEV1 45%-80%PV
³12% increase in FEV1 after
180 mg salbutamol
³3/7 days symptoms,
rescue medication in
previous week
ICS 336 mg daily BDP or 800
mg daily 2 weeks prior
Non-smoker
483 24 weeks
(mean change over
treatment period)
Mean AM PEFR L/min
Baseline L/min
Treatment period L/min
Mean PM PEFR L/min
Baseline L/min
Treatment period L/min
% of symptom free days
Mean change over 24 weeks
(se)
% nights with no awakenings
(baseline) (se)
mean change
% nights no salbutamol use
baseline (se)
mean change
n and % patients reporting
exacerbations
n and % patients with drug
related adverse events
BEC+
SLM
389.7
N/A
N/A
37.5
23.6%
67.0 (2.3)
18.8 (1.7)
60.2 (2.5)
23.2 (2.0)
38 (16%)
26 (11%)
BEC
390
N/A
N/A
14.8
12.5%
68.0 (2.2)
13.4 (1.6)
60.4 (2.4)
14.7 (1.9)
44 (18%)
34 (14%)
P value
P<.001
P<.001
P£.05
N/A
P£.05
N/A
P£.05
N/A
N/A
NNT
9
· Mean age 42 and female 57%,
FEV1 65%PV in BEC+SLM group;
mean age 42 and female 65%,
FEV1 64%PV in BEC group
· Of the 483 patients randomized
20.1% did not complete study.
Dropout rates 20% in each
treatment arm. Results use ITT
based analysis
· Some primary PEFR data values
are not reported, only p values
given
· Pharmaceutical company
funded and supported trial
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Table 7: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Nathan et
al. 1999)
RCT
Grade 1+
Country:
United
States
Salmeterol mdi 42
mg bd
V
Beclomethasone
mdi 84 mg Qid
V
Placebo mdi bd
Methacholine
challenge (MCh)
To FEV1 PC20 or
MCh 75 (mg/ml)
in neb
26 weeks
Inclusion:
Age 12+ yrs
FEV1 65-90%PV
12+% increase in FEV1
within 30 min of 180 mg
salbutamol mdi
Daily/as needed b-agonists
with no I/OCS previous 6
months
Exclusion:
Decline in FEV1 of
³ 15% after saline
inhalation
Asthma requiring
hospitalization previous 4
weeks
386 26 weeks
mean increase (se) over
treatment period
FEV1 (L)
Salbutamol free nights (mean
% increase)
Mean increase PD20
MCh (se)
Week 14
Week 26
SLM
0.28 (0.04)
23%
1.39 (0.24)
1.29 (0.26)
BEC
0.23 (0.04)
23%
1.57 (0.26)
1.42 (0.24)
Placebo
0.08 (0.04)
9%
0.16 (0.22)
0.24 (0.29)
P value
cf.
placebo
P£.014
P£.014
P<.001
P£.033
· Mean age 31 and female 54%,
FEV1 79%PV, AM PEFR(L/min) 405
in SLM group; mean age 30 and
female 57%, FEV1 78%PV,
PEFR(L/min) 394 in BDP group;
mean age 29 and female 50%,
FEV1 81%PV, PEFR(L/min) 417 in
placebo group
· Significantly higher baseline AM
PEFR in placebo group
· ITT analysis but 81/368 (22%)
withdrawals. Across treatment
arms 23% SLM, 18% BEC, 22% PLC
groups
· Data for some primary outcomes
not shown
· Pharmaceutical company
funded and supported trial
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Table 7: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Vermetten
et al. 1999)
RCT
Grade 1-
Country:
Netherlands
Beclomethasone
D-inh 200 mg bd +
Salmeterol
D-inh 50 mg bd
V
Beclomethasone
diskinh
400 mg bd
Run-in:
2 weeks
Treatment:
12 weeks
Inclusion:
Age 18-66 yrs
6+ weeks prior:
ICS BEC/BDP
200-400 mg daily
³15% reversibility in PEF
Exclusion:
Asthma exacerbation
requiring change to
medication in run-in period
233 12 weeks
(average of last 2 weeks of
treatment period)
Mean AM PEFR L/min
Baseline L/min
Treatment period L/min
Mean PM PEFR L/min
Baseline L/min
Treatment period L/min
Diurnal variation in PEFR%(se)
Baseline
Treatment period
(proportion of days with)
Asthma symptoms
Day        Baseline  period
Day        Treatment period
Night      Baseline period
Night      Treatment period
Av. No. of blisters per day of
rescue medication-baseline
                        Treatment
Av. No. of blisters per night of
rescue medication-baseline
                        Treatment
BEC+
SLM
404
N/A
431
N/A
9.5% (0.8)
6.6% (0.6)
0.56 (0.04)
0.37 (0.04)
0.43 (0.04)
0.33 (0.04)
0.88 (0.09)
0.48 (0.07)
0.47 (0.06)
0.30 (0.06)
BEC
390
N/A
413
N/A
8.8% (0.6)
7.2% (0.7)
0.54 (0.03)
0.38 (0.04)
0.41 (0.03)
0.34 (0.04)
0.84 (0.09)
0.61 (0.10)
0.47 (0.05)
0.37 (0.06)
P value
P=.066
P=.036
n.s.
n.s.
n.s.
P<0.05
n.s.
· Mean age 42 and female 47%,
AM PEFR(l/min) 404, PM PEFR 431
in BEC+SLM group; mean age 42
and female 62%, AM PEFR(l/min)
390, PM PEFR 413 in BEC group
· Differences in baseline
demographics for % female and
AM/PM PEFR values
· Of the 233 patients randomized
202 completed study. Whether or
not ITT analysis not specified. No
detail on randomisation, blinding
and concealment methodology.
· Treatment endpoints are
averages over the last 2 weeks.
· Some primary PEFR data values
are not reported, only p values
given
· Pharmaceutical company
supported trial
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Table 7: Summary of studies investiga ing the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Pauwels
et al. 1997)
RCT
Grade 1+
Country:
9 countries
Run-in period:
Budesonide inh
800 mg  bd
terbutaline 250 mg
inh as needed
Treatment:
Budesonide inh
100 mg bd  +
placebo inh bd
V
Budesonide 100
mg inh bd +
formoterol inh 12
mg bd
V
Budesonide inh
400 mg bd +
placebo inh bd
V
Budesonide 400
mg inh bd +
formoterol inh 12
mg bd
terbutaline 250 mg
inh rescue
medication
Run-in:
4 weeks
Treatment:
52 weeks
Inclusion:
Age 18-70 yrs
Patients with FEV1 ³ 50%PV
and
15+% increase from
baseline FEV1 after
inhalation of 1 mg
terbutaline
Exclusion:
Patients taking 2000+ mg
daily beclomethasone or
1600+ mg daily mdi or 800+
mg daily budesonide inh
3+ courses OCS or
asthma requiring
hospitalization previous 6
months
852 52 weeks
Yearly rate of asthma
exacerbations (no/patient/yr)
Severe
Mild
Episode free days (mean % of
year)
Asthma symptom score Day
Night
Rescue medication during
day no of inhalations
Yearly rate of asthma
exacerbations (no/patient/yr)
Severe
Mild
Episode free days (mean % of
year)
Asthma symptom score
Day
Night
Rescue medication during
day (no of inhalations)
Low dose
BDP +
placebo
0.91
35.4
41.7%
0.57
0.37
0.91
Low dose
BDP + FRM
0.67
21.3
51.1%
0.46
0.31
0.57
P Value
Higher vs
lower dose
of BDP
P<.001
P<.001
P=.16
P=.01
P=.01
P<.001
High dose
BDP +
placebo
0.46
22.3
45.7%
0.53
0.38
0.82
High dose
BDP+ FRM
0.34
13.4
54.8%
0.33
0.20
0.44
· Mean age 42 and female 49%,
FEV1 76 in low BDP + placebo
group; mean age 41 and female
50%, FEV1 76 in low BUD + FRM
group; mean age 44 and female
52%, FEV1 76 in high BDP +
placebo group; mean age 42
and female 53%, FEV1 76%PV high
BUD + FRM group
· International based study (9
countries)
· Post-randomisation, 158 patients
did not complete study, 44 of
these did not fulfil the entry
criteria and were incorrectly
randomised. Whether ITT analysis
not clearly defined
· Pharmaceutical company
funded and supported trial
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Table 7: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Juniper et
al. 1999)
RCT
Grade 1-
Country:
5 countries
Run-in period:
Budesonide inh
800 mg  bd
terbutaline 250 mg
inh as needed
Treatment:
Budesonide inh
100 mg bd  +
placebo inh bd
V
Budesonide 100
mg inh bd +
formoterol inh 12
mg bd
V
Budesonide inh
400 mg bd +
placebo inh bd
V
Budesonide 400
mg inh bd +
formoterol inh 12
mg bd
Terbutaline 250
mg inh rescue
medication
Run-in:
4 weeks
Treatment:
52 weeks
Inclusion:
Age 18-70 yrs
Patients with FEV1 ³ 50%PV
and
15+% increase from
baseline FEV1 after
inhalation of 1 mg
terbutaline
IGS previous 3+ months
with patients taking <2000
mg daily beclomethasone
or <1600 mg daily mdi or
<800 mg daily budesonide
inh
470 52 weeks
AQLQ total score change
High dose
BDP+ FRM
0.21
P Value
Cf. other
groups
P=.028
NNT
(provided
Result)
11.9
· Mean age 42 and female 51% in
low BDP + placebo group; mean
age 42 and female 48% in low
BDP + FRM group; mean age 44
and female 51% in high BDP +
placebo group; mean age 44
and female 59% in high BDP +
FRM group
· International based study (9
countries)
· Earlier study acknowledgement
to (Pauwels et al. 1997) This
study’s primary outcome
measure is asthma quality of life
assessment using AQLQ. Clinical
results previously reported in
earlier study
· Post-randomisation, 114/470
(24%) of patients did not
complete study after 52 weeks.
4/470 patients did not fill in AQLQ
at baseline are excluded from
analysis
· Insufficient data detail for analysis
of AQLQ results
· Pharmaceutical company
funded and supported trial
NEW ZEALAND HEALTH TECHNOLOGY ASSESSMENT: ASTHMA THERAPEUTICS
LONG ACTING BETA-AGONISTS - CHRONIC ASTHMA
38
Table 7: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Kips et al.
2000)
RCT
Grade 1-
Country:
Canada,
England,
Belgium
Run-in period:
Budesonide inh
800 mg  bd
terbutaline 0.25
mg inh as
needed
Budesonide 100
mg inh bd +
formoterol inh 12
mg bd
V
Budesonide inh
400 mg bd +
placebo inh bd
Run-in:
4 weeks
Treatment:
52 weeks
Inclusion:
Age 18-70 yrs
Patients with FEV1  ³ 50%PV
and
15+% increase from
baseline FEV1 after
inhalation of 1 mg
terbutaline
Exclusion:
Patients taking 2000+ mg
daily beclomethasone or
1600+ mg daily mdi or 800+
mg daily budesonide inh or
800+ mg daily fluticasone
inh
3+ course OCS or
asthma requiring
hospitalization previous 6
months
60 52 weeks
Yearly rate of asthma
exacerbations (no/patient/yr)
Severe (se)
Mild (se)
Episode free days (mean % of
year) (se)
Mean AM PEFR L/min
Mean PM         L/min
BDP + FRM
0.29 (0.14)
18.3 (6.92)
41.3%
(7.0)
N/A
N/A
BDP +
placebo
0.47 (0.24)
14.6 (5.42)
30.4%
(6.0)
N/A
N/A
P value
n.s.
n.s.
n.s.
n.s.
n.s.
P<.05
· Mean age 35 and female 59%,
ICS mg daily 676, FEV1 L start run-in
2.87, end run-in 2.93 in BDP + FRM
group; mean age 38 and female
61%, ICS mg daily 706.5, FEV1 L
start run-in 2.52, end run-in 2.71 in
BDP + placebo group
· Differences in baseline FEV1
(lower in BDP+ placebo group),
ICS usage higher here also. Not
significant according to study
· International based study (3
countries)
· Primary efficacy outcome
markers of airway inflammation in
induced sputum. Only secondary
outcomes appraised. Lung
function data detail not reported
· Whether ITT analysis not clearly
defined. No information on study
drop out rates during treatment
· Pharmaceutical company
funded and supported trial
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Table 7: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Crompton
et al. 1999)
RCT
Grade 1+
Country:
3 European
countries
Bambuterol po
10 mg nocte (1
week) 20 mg
nocte (5 weeks)
+ placebo mdi
V
Salmeterol
mdi   50 mg bd +
placebo
Run-in:
2 weeks
Treatment:
6 weeks
Inclusion:
Age 18+ yrs
4+ weeks prior:
ICS BDP/BEC
800-2000 mg daily other
than with turbuhaler
or FP/BUD 400-2000 mg
daily via turbuhaler
or OCS such as prednisone
at £ 20 mg daily
³1 nocturnal/early morning
awakening req rescue
medication
³15% decr in overnight
PEFR on 3/7 days
preceding entry
Exclusion:
Asthma requiring
hospitalization
Previous 4 weeks
135 6 weeks
Median AM PEFR L/min
Baseline L/min
Treatment period L/min
Change from baseline
Median change (cf. baseline)
Evening PEFR L/min
Percent overnight fall in
PEFR%
Percent nights an awakening
%
No.  puffs rescue medication
during day
No.  puffs rescue medication
during night
Asthma symptoms, day
                           night
BMB
276
310
50
12
-11%
-21%
-0.33
-0.28
-0.17
-0.32
SLM
272
327
55
3
-14%
-29%
-0.57
-0.26
-0.11
-0.32
P value
N/A
N/A
P=.53
P=.82
P=.17
P=.22
P=.24
P=.88
P=.48
P=.57
· Mean age 41 and female 60%,
FEV1 66%PV in BMB group; mean
age 41 and female 56%, FEV1
68%PV in SLM group
· International based study (3
countries)
· Of the 135 patients randomized
118 completed study. Of the
total, 126 patients were
considered valid and are
included in the analysis. Not strict
ITT analysis
· Treatment endpoints are
calculated during weeks 3 to 6
Both median and mean values
calculated and appropriate
statistical measures used
· Pharmaceutical company
funded and supported trial
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Table 8: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus theophylline) in chronic asthma
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Pollard et
al. 1997)
RCT
Grade 1+
Country:
United
States
Salmeterol mdi
(42 mg bd)
V
Theophylline po
(Individual dose
titrated slo-bd)
V
Placebo
Inh and po
12 weeks
Inclusion:
Age 12+ yrs
FEV1 > 50%PV
15+% increase in FEV1 with
salbutamol inh
Exclusion:
Other bronchodilators
484 12 weeks
Mean change AM PEFR(cf.
baseline) (L/min)
Mean change (cf. baseline)
Nighttime awakenings/wk
Asthma symptom score
Salbutamol use puffs/day
Drug related adverse event
SLM
+10.3
-0.7
-0.11
-1.1
9%
THP
-4.5
-0.1
0.01
0.06
19%
P value
P£.02
P<.02
P<.02
P<.02
P<.05
· Mean age 31 and female 52% in
salmeterol group; mean age 30
and 54% in theophylline group
· 54% patients on concurrent ICS
therapy
· Pharmaceutical company funded
and supported trial
· Combined results of two identical
trials
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Table 8: Summary of studies investigating the effect of pharmaceutic ls (long-acting b-agonists versus theophylline) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
Comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Nutini et
al. 1998)
RCT
Grade 1-
Country:
Italy
Salmeterol inh 50
mg bd
V
Theophylline po
50 dose titrated
bd
12 weeks
(drug efficacy)
52 weeks
(drug safety)
Inclusion:
Age 18+ yrs
FEV1 50-80%PV
15+% increase in FEV1 with
200 mg salbutamol inh
Exclusion:
Variable smoking history
Asthma requiring
emergency care – past
month
112 12 weeks
Symptom free
Days
Nights
Days with no rescue
medication use
Days
Nights
QOL index score
Adverse drug events
SLM
65.7%
65.7%
68.7%
70.1%
9.7
9
THP
56.8%
60.2%
57.2%
63.0%
8.6
18
P value
P<.005
P<.01
P<.001
P<.001
N/A
N/A
NNT
11
18
9
14
· Mean age 46 and female 44%,
mean FEV1 (L) 2.21 in SLM group;
mean age 48 and 32% and mean
FEV1 (L) 2.10 in THP group
· Pharmaceutical company funded
and supported trial
· Open study design
· Intention to treat analysis
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Table 9: Smmary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus short-acting b-agonists) in chronic asthma
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Kemp et
al. 1998)
RCT
Grade 1+
Country:
United
States
Salmeterol inh
(breath activated
device) 50 mg bd
+ placebo mdi
Qid
V
Salbutamol mdi
180 mg Qid +
placebo mdi bd
V
Placebo mdi Qid
12 weeks
Inclusion:
Age 18-79 yrs
FEV1 50-80%PV
FEV1 ³ +15% after 30
minutes inh of 180 mg
salbutamol
Exclusion:
Smoker
451
Mean Area Under Curve
AUC for FEV1 (L/hrs)
Day 1
Week 12
(12-hour serial pulmonary
function testing)
Mean FEV1 %PV from
Day 1
Week 12
Treatment related adverse
events % of patients
Baseline v
Weeks 1-12
Mean % of nights without
awakening (se)
Mean asthma symptoms
score
Mean puff/d of rescue
salbutamol use
SLM
5.5
6.1
81%
84%
10%
63 (2.9)
85 (1.9)
1.2 (0.07)
0.8 (0.06)
4.3 (0.2)
1.6 (0.2)
SLB
4.6
3.4
85%
82%
9%
68 (2.7)
71 (2.5)
1.0 (0.06)
0.9 (0.05)
4.3 (0.2)
2.2 (0.2)
P value
P<.001
P<.001
N/A
P<.001
P<.01
n.s.
· Mean age 31 and female 39%,
FEV1 65%PV, %race non-white
3% in SLM group; mean age 31
and female 43%, FEV1 66%PV,
race non-white 12% in SLB
group; mean age 31 and
female 43%, FEV1 65%PV, race
non-white 9% in PLC group
· Significant difference in ethnic
mix across groups
· Unchanged ICS or cromolyn
usage previous 3 months
· All patients on “as needed”
salbutamol use
· Two identically designed trials
with pooled data results
· Unclear if intention to treat
methodology used and
number of patients included in
analysis
· Pharmaceutical company
funded and supported trial
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Table 9: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus short-acting b-agonists) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Boulet et
al. 1997)
RCT
Grade 1+
Country:
Canada
Salmeterol inh 50
mg bd
V
Salbutamol
mdi 200 mg Qid
12 weeks
Inclusion:
Age 12-76 yrs
FEV1 50-80%PV
FEV1 ³ 15% 15 minutes after
inh of 200 mg  salbutamol
Exclusion:
Other b-agonists and OCS
ICS, IMM for at least 1
month pre-study
228
Between treatment groups:
Mean improvement over
baseline
FEV1 AM postdose time point
3-6 hours
       10-12 hours
(day1, weeks 4, 8, 10, 12)
Mean post-dose changes in
FEV1 %
Mean improvement in AM
PEFR(l/min)
% days no symptoms
% nights no awakenings
SLM
N/A
N/A
8.1%
35
29%
14%
SLB
N/A
N/A
9.7%
-3
15%
-1%
P value
P<.001
P£.012
N/A
P<.001
P=.012
P<.001
NNT
7
7
· Mean age 37 and female 44%,
FEV1 66%PV in SLM group;  age
40 and female 43%, FEV1
66%PV in SBM group
· Unclear if intention to treat
methodology
· Inadequate data results
reported for appraisal of
primary FEV1 measure of
efficacy
· Pharmaceutical company
funded trial
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Table 9: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus short-acting b-agonists) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Martin et
al. 1999)
CO
Grade 1+
Country:
United
States
Salbutamol po
(extended
release) 4mg AM,
8 mg PM bd
V
Salmeterol inh
42 mg  bd
Treatment
period(s)
3 weeks each
7-9 day washout
Inclusion:
Age 18-65 yrs
FEV1 50-80%PV
FEV1 > 12% after inh
salbutamol
Stable asthma for previous
30 days
Exclusion:
Systemic CS
b-agonists other than
rescue salbutamol
Theophylline (sustained
release)
47
Adjusted means
FEV1 (l)
PEFR L/min AM
% overnight change PEF
% overnight change FEV1
Rescue salbutamol (no.  of
inhalations/day)
% of no nighttime awakenings
SLM
2.70
420
-7.9
-5.1
2.20
84.6%
SLB
2.71
414
-7.2
-4.0
2.98
79.4%
P value
n.s..
n.s.
n.s..
n.s..
P=.001
P=.021
NNT
22
· Mean age 35 and female 48%,
FEV1 67%PV, 61% of patients on
ICS pre-study, 27% tobacco
use history.
· No baseline demographics for
randomized treatment groups
· Nocturnal asthma defined as ³
15% decrease in AM and night
FEV1 on 3/7 nights prior to
randomization
· 46/47 patients included in
analysis, 1 lost to follow-up
· Pharmaceutical company
funded and supported trial
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Table 9: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus short-acting b-agonists) in chronic asthma (continued)
Study
source,
design and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Ekstrom et al.
1998b)
RCT
Grade 1+
Country:
3
Scandinavian
countries
Formoterol inh 12
mg (delivered
dose 9 mg ) bd +
placebo
V
Terbutaline inh
0.5 mg Qid
V
Placebo inh Qid
12 weeks
Inclusion:
Age 18-82 yrs
FEV1 50-80%PV
FEV1 ³ 15% 15 minutes after
inh of 0.5 mg turbutaline
343
Mean difference in
improvement over baseline
PEFR L/min AM
                  PM
Asthma symptoms – night
Rescue medication (no.  of
inhalations)
Day
Night
P value
PEFR L/min AM
                  PM
Asthma symptoms – night
Rescue medication (no.  of
inhalations)
Day
Night
FRM
vs placebo
14.6
16.2
-0.20
-0.53
-0.67
P=.0022
P=.0001
P=.0025
P=.013
P=.0042
FRM vs
TEB
21.9
16.7
-0.16
-0.10
-0.11
P=.0001
P=.0001
P=.019
n.s..
n.s.
TEB vs
Placebo
-7.2
-0.6
-.0.05
-0.43
-0.56
n.s..
n.s.
n.s
P=.043
P=.015
· Mean age 49 and female 49%,
FEV1 62%PV , current/past
smoker 62% in SLM group;
mean age 48 and female 59%,
FEV1 61%PV, current/ex smoker
57% in TEB group; mean age 47
and female 49%, FEV1 60%PV,
current/ex-smoker 63% in PLC
group
· 89% of patients on ICS pre-
study. Patients allowed to use
ICS and terbutaline as rescue
medication
· International based study (3
countries)
· Unclear if intention to treat
methodology
· Pharmaceutical company
funded and supported trial
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Table 9: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus short-acting b-agonists) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Lipworth
et al. 1998)
RCT
Grade 1+
Country:
Scotland
Formoterol inh 6
mg (delivered
dose 4.5 mg ) bd +
placebo
V
Formoterol inh 24
mg (delivered
dose 9 mg -2
puffs) bd +
placebo
V
Formoterol inh 12
mg daily
(delivered dose 9
mg) + placebo
V
Terbutaline inh
500 mg Qid
V
Placebo inh Qid
Methacholine
challenge (MCh)
3.125 mg  - 6400
mg  to FEV1 PD20
2 weeks
Inclusion:
Age 16-65 yrs
FEV1 ³ 60%PV
PD20 (MCh) £1000 mg
Constant dosage of ICS
£2000 mg  BUD, BDP or FP
Exclusion:
Patients on OCS previous 4
weeks
Smoker previous 12 months
72 Methacholine protection
ratios compared with
placebo
Formoterol 24 mg bd
First dose
14 days
Formoterol 12 mg bd
First dose
14 days
Formoterol 6 mg bd
First dose
14 days
Terbutaline 500 mg Qid
First dose
14 days
Pre-challenge FEV1 1 hour
after use of medication
After 14 days of treatment
(as % ratio versus placebo)
Formoterol 24 mg bd
Formoterol 12 mg bd
Formoterol 6 mg bd
Terbutaline 500 mg Qid
Geometric
Mean fold
Protection
Ratio
10.2
1.4
6.4
1.5
5.5
1.6
3.4
1.9
109%
111%
109%
105%
95% CI
4.6 – 22.5
0.6 – 3.4
2.9 – 14.1
0.6 – 3.8
2.5 – 12.3
0.6 – 4.0
1.5 – 7.8
0.8 – 4.9
103,116%
105, 118%
102, 115%
99, 112%
P value
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
n.s.
n.s.
n.s.
n.s.
· Mean age 33 and female 47%,
FEV1 90%PV FRM 24 mg group;
mean age 36 and female 53%,
FEV1 87%PV in FRM 12 mg
group; mean age 39 and
female 71%, FEV1 85%PV in FRM
6 mg  group; mean age 42 and
female 50%, FEV1 88%PV in TEB
500 mg  group; mean age 38
and female 43%, FEV1 86%PV in
placebo group
· Unclear if intention to treat
methodology
· Pharmaceutical company
funded and supported trial
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Table 9: Summary of studies investigatng the effect of pharmaceuticals (long-acting b-agonists versus short-acting b-agonists) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Seberova
and
Andersson
2000)
CO
Grade 1-
Country:
Czech
Republic
5 study visits, with
single doses:
minimum 2 days
washout
Formoterol inh 4.5
mg or 9 mg
V
Salbutamol
mdi 100 mg or 200
mg
V
Placebo
Inclusion:
Age 18-64 yrs
FEV1 ³ 40%PV
FEV1 ³1.51
FEV1 ³ 15% 15 minutes after
inh of 0.5 mg terbutaline
Exclusion:
If FEV1 not within ±12% of
baseline FEV1 patients
asked to return another
day
Oral, inh long-acting
b-agonists, GCS during
study
36 FEV1 at 3 minutes after
inhalation
Salbutamol 100 mg
Salbutamol 200 mg
Formoterol 4.5 mg
Formoterol 9.0 mg
% Increase
in FEV1 (cf.
baseline
+10.0%
+11.4%
+11.7%
+11.8%
P value
cf. placebo
P<.001
P<.001
P<.001
P<.001
Between
groups
n.s.
· Mean age 34 and % female
unknown, mean FEV1 (L) 2.75
· No baseline demographics for
randomized treatment groups
· Treatment period undefined
· Randomized at each study visit
· No power analysis for study
sample size
· Pharmaceutical company
funded and supported trial
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Table 9: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus short-acting b-agonists) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Lipworth
et al. 1999)
RCT
Grade 1-
Country:
Scotland
Formoterol inh 12
mg mane
V
Formoterol inh 6
mg bd
V
Formoterol inh 24
mg bd
V
Terbutaline inh
500 mg Qid
2 weeks
Inclusion:
Age 18-45 yrs
FEV1 ³ 60%PV
PD20 in FEV1 response to
methacholine challenge of
1000 mg and 2-doubling
dose protection in
response to a single test
dose of formoterol inh 24
mg
Non-smoker
38
Mean values
AM PEFR(L/min)(se) run-in
                       Treatment
PM PEFR(L/min)(se) run-in
                       Treatment
* P<.05 difference between
run-in and treatment only in
formoterol 24 mg bd group
FRM
6 mg  bd
395 (55)
415 (59)
398 (50)
433 (59)
FRM
12 mg daily
367 (44)
391 (21)
417 (31)
421 (25)
FRM
24 mg bd*
447 (30)
490 (24)
471 (27)
502 (24)
TEB
500 mg Qid
429 (46)
428 (45)
435 (51)
445 (46)
· N=8, mean age 39 and female
38%, FEV1 80%PV in FRM 6 mg
group; N=10, age 41 and
female 40%, FEV1 84%PV in FRM
12 mg group; N=11, age 32 and
female 45%, FEV1 91%PV in FRM
24 mg  group; N=11, age 36
and female 44%, FEV1 87%PV in
TEB group
· Small numbers in each
treatment group, no significant
demographic differences
between groups
· All patients on regular ICS
therapy. On demand b-
agonists
· Unclear if intention to treat
methodology
· Results presented are only
secondary outcome measures.
Primary outcome
bronchoprotective sensitivity
· Pharmaceutical support in
provision of inhalers for trial
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Table 9: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus short-acting b-agonists) in chronic asthma (continued)
Study
Source,
design and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Tattersfield
2001)
RCT
Grade 1+
Country:
4 European
countries
As needed
basis:
Formoterol inh
4.5-54 mg daily
V
Terbutaline inh
0.5-6 mg daily
12 weeks
Inclusion:
Age 18-75 yrs
FEV1 ³ 50%PV
ICS mean dose 870 mg
daily previous 4 weeks
Requirement of b-agonists
average 3/8 times during
run-in period
Exclusion:
Patients inh 12+ rescue
medication
362 Number at risk (remaining
w/o severe asthma
exacerbation)
Days since randomization
0
20
40
60
80
Exacerbations: no. of
patients/no. of exacerbations
Need for OCS
Mean difference in change
over treatment (FRM-TEB)
AM PEFR(L/min)(95% CI)
PM PEFR(L/min)(95% CI)
Diurnal variation %
Symptom score – Day
                         Night
FRM
182
173
165
153
146
26 / 29
21/26
(81%)
11 (3,20)
8 (0,15)
-0.4
(-1.4,0.6)
-0.04
-0.02
TEB
180
159
144
132
127
43 / 48
31/43
(72%)
P value
P=.013
P=.009
P=.043
P=.44
P=.54
P=.68
· Mean age 46 and female 52%,
FEV1 74%PV in FRM group;
mean age 48 and female 62%,
FEV1 74%PV in TEB group
· Severe exacerbations defined
by need for OCS or fall in PEFR
of 30% from baseline on 2
consecutive days
· International study (4
countries)
· Pharmaceutical company
funded and supported trial
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Table 9: Summary of studies investigating the effect o  pharmaceuticals (long-acting b-agonists versus short-acting b-agonists) in chronic asthma (continued)
Study
Source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Ekstrom et
al. 1998a)
RCT
Grade 1-
Country:
4
European
countries
Formoterol inh 6
mg (delivered
dose 4.5 mg ) bd
V
Terbutaline inh
0.5 mg Qid
V
Placebo inh Qid
12 weeks
Inclusion:
Age 18-79 yrs
FEV1 40-80%PV
FEV1 ³ +15% and 200+ ml
after inh of 0.5 mg
terbutaline
397
PEFR L/min
AM
PM
FEV1
Symptoms:
Days
Nights
Rescue no.  of inhalations:
Day-time
Night-time
FRM vs TEB
10.9
8.0
0.13
-0.09
-0.11
-0.14
-0.15
95%CI
2.3, 19.5
-4.0, 16.5
0.05, 0.21
-0.18,-0.01
-0.20,-0.02
-0.36,-0.08
-0.31,-0.01
P value
P=.014
P=.061
P<.0017
P=.038
P=.015
P=.19
P=.074
· Mean age 49 and female 49%,
FEV1 62%PV FRM group; mean
age 46 and female 59%, FEV1
63%PV in TEB group; mean age
48 and female 49%, FEV1
62%PV in PLC group
· Pre-study 86% of patients on
ICS, 78% inh b-agonists. ICS
maintained 4 weeks prior and
during study
· Proportion of male/female in
terbutaline group differs from
others
· 54 patients in treatment group
not included in baseline
demographic analysis
· Undetermined number of
patients included in analysis of
results
· International based study (4
countries)
· Pharmaceutical company
funded and supported trial
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Table 10: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus long-acting b-agonists) in chronic asthma
Study
Source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Campbell
et al. 1999)
RCT
Grade 1+
Country:
United
Kingdom
and
Ireland
Eformoterol
Turbo inh 12 mg
bd
V
Salmeterol Accu
inh 50 mg bd
V
Salmeterol mdi
50 mg bd
Run-in 7-14 days
Treatment:
8 weeks
Crossover:
4 weeks
Inclusion:
Age 12+ yrs
FEV1 ³ 50%PV
 b-agonist 10+% increase in
PEFR or SA b-agonist bd on 4
of previous 7 days
 b-agonist 15+% in PEFR or
9+% increase than patient
%PV on entry
Exclusion:
Use of LA b-agonist – past
month
469 Results are for 8 week period
AM PEFR% increase (cf.
baseline)
PM PEFR% increase (cf.
baseline)
Symptom free days %
Patients with worsening
asthma %
(A)
Eformoterol
9.5%
6.5%
32.8
11.3
(B)
SLM inh
8.7%
4.6%
34.1
11.8
(C)
mdi
10.7%
8.3%
28.0
11.7
P value
Between
treatments
n.s.
P=.271 (AB)
P=.344(AC)
P=.078(BC)
n.s.
n.s.
· Female in study arm (A) 63%, (B)
45%, (C) 57%
· Cross-over period of 4 weeks
following 8 week period to assess
patient device and treatment
preference
· Pharmaceutical sponsored trial
(producers of eformeterol)
· Single blind randomisation
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Table 10: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus long-acting b-agonists) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Bateman
et al. 1998)
RCT
Grade 1+
Country:
Three
European
countries
and South
Africa
Combination:
Salmeterol/
fluticasone Diskus
inh (50/100 mg)
bd and Placebo
Diskus inh bd
V
Concurrent:
Salmeterol 50 mg
Diskus inh bd and
fluticasone 100
mg Diskus inh bd
12 weeks
Inclusion:
Age 12-78 yrs
Previous 4+ weeks:
Patients taking 400-500 mg
daily beclomethasone or
budesonide or fluticasone
200-250 mg daily
Run-in period:
Asthma symptom score 2+
on 3/7 run-in days
AM mean PEFR 50-85% of
their PEFR 15 min after 400
mg salbutamol
Exclusion:
Patients receiving any LA
inh b-agonists and OCS
previous 4 weeks
Exacerbation in asthma
requiring hospitalization
previous 12 weeks
10+ pack years smoking
244 12 weeks
(change in mean PEFR L/min)
AM
PM
Drug related adverse events
(%)
Combo
SLM/FP
42
36
15%
Concurrent
SLM and FP
33
30
14%
Difference
(combo-
concurrent)
(90% CI)
-9
(-17,0)
-5
(-13,2)
P value
P<.098
P<.241
n.s.
· Mean age 33 and female 56%,
FEV1 75%PV combination group;
mean age 33 and female 59%,
FEV1 76%PV, concurrent group
· International study (4 countries)
· Pharmaceutical company funded
and supported trial
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Table 10: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus long-acting b-agonists) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Wallaert
et al. 1999)
RCT
Grade 1-
Country:
France
Bambuterol po
20mg nocte +
placebo
V
Salmeterol
p-mdi 50 mg bd +
placebo
6 weeks
Inclusion:
Age 18-70 yrs
Previous 4 weeks:
I/OCS 800-2000 mg daily of
BUD, FLN, BDP mdi
Or 400-2000 mg daily BUD
inh and/or oral PDN 20 mg
daily
FEV1 40-85%PV
PM PEFR fall of ³15% in run-
in 3/7 nights
Nocturnal awakening
requiring rescue
medication
Exclusion:
Exacerbation in asthma
previous 4 weeks
117 6 weeks
(change cf. run-in)
AM PEFR L/min
PM
Mean fall in overnight PEFR%
% symptom free days (mean)
BMB
+28
P<.05
+20
P<.05
-8.3%
P<.001
+23%
SLM
+29
P<.01
+23
P<.001
-6.8%
P<.001
+14%
P value
P<.86
P<.73
N/A
P<.55
NNT
11
· Mean age 45 and female 56%,
FEV1 64%PV (mean L) 64.1 non-
smokers 66% in BMB group; mean
age 46 and female 55%, FEV1
65%PV 65, non-smokers 73% in SLM
group
· Treatment period efficacy
variables calculated over last 4
weeks
· No intention to treat analysis
· 21 patients discontinued
prematurely from study, treated
dropped out patients not included
in results, analysis accounts for
n=48 in BMB group and n=57 in SLM
group
· Pharmaceutical company
supported trial in manuscript
preparation
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Table 11: Summary of studies investigating the effect of pharmaceuticals (long-acting b-a onists versus leukotriene antagonists) in chronic asthma
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Villaran et al.
1999)
RCT
Grade 1+
Country:
12 countries
Salmeterol inh 50
mg bd
V
Montelukast po
10 mg daily
8 weeks
Inclusion:
Age 15-45 yrs
FEV1 improved by ³12% post
b-agonist
PC20 0 in FEV1 in response to
£ 4mg/ml methacholine or
histamine
£ 20 pack years smoking
Exclusion:
Asthma requiring
emergency care – past
month
197
Maximal % fall in FEV1 post
exercise (cf. baseline)
Recovery time to within 5% of
prechallenge level at 8 weeks
compared with pre
intervention (min)
Adverse respiratory events
(SLM cf. MNT)
MNT
17.2%
-23.9
39%
SLM
10.7%
-11.3
54%
P value
P < .001
P = .002
P < 0.05
NNH
7
· Mean age 27 and female 50%
· Exercise induced
bronchoconstriction
· Pharmaceutical sponsored trial
(producers of montelukast)
· Similar study design, authors and
sponsor to next study
(Edelman et al.
2000)
RCT
Grade 1+
Country:
United States
Salmeterol inh 50
mg bd
V
Montelukast po
10 mg nocte
8 weeks
Inclusion:
Age 15-45 yrs
FEV1 ³ 65%PV
<15 pack-years smoking
Exclusion:
Asthma or URTI requiring
emergency care – past
month
191
Maximal % challenge fall in
FEV1
MNT
57.2%
SLM
33.0%
P value
P = .002
· Mean age 26 and female 50%
· Mod-severe activity limitation in
60% in past month at baseline
· No baseline ethnicity data
presented
· Pharmaceutical company input
(producers of montelukast) in
funding, design, conduct and
analysis of trial
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Table 11: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus leukotriene antagonists) in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Busse et al.
1999a)
RCT
Grade 1+
Country:
United States
Salmeterol inh 42
mg bd
V
Zafirlukast po 20
mg bd
4 weeks
Inclusion:
Age ³ 12 yrs
FEV1 50-80%PV
Exclusion:
>10 pack years tobacco
smoking
289
Improvement in am PEFR
(L/min)
Symptom free days
% days with no rescue
medication use
SLM
29.6
22.4%
30.5%
ZAF
13.0
8.8%
11.3%
P value
P £ 0.001
P £ 0.001
P £ 0.001
NNT
7
5
· Mean age 38 and female 80%
· Mean FEV1 66%PV
· 80% on inhaled steroid pre-study
· Exercise induced
bronchoconstriction
· Unknown proportion of
participants identified through
advertisements – may limit
generalisability
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Short-acting beta-agonists
Chronic asthma
Table 12: Smmary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus short-acting b-agonists) in chronic asthma
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Kemp et
al. 1998)
RCT
Grade 1+
Country:
United
States
Salmeterol inh
(breath activated
device) 50 mg bd
+ placebo mdi
Qid
V
Salbutamol mdi
180 mg Qid +
placebo mdi bd
V
Placebo mdi Qid
12 weeks
Inclusion:
Age 18-79 yrs
FEV1 50-80%PV
FEV1 ³ +15% after 30
minutes inh of 180 mg
salbutamol
Exclusion:
Smoker
451
Mean Area Under Curve
AUC for FEV1 (L/hrs)
Day 1
Week 12
(12-hour serial pulmonary
function testing)
Mean FEV1 %PV from
Day 1
Week 12
Treatment related adverse
events % of patients
Baseline v
Weeks 1-12
Mean % of nights without
awakening (se)
Mean asthma symptoms
score
Mean puff/d of rescue
salbutamol use
SLM
5.5
6.1
81%
84%
10%
63 (2.9)
85 (1.9)
1.2 (0.07)
0.8 (0.06)
4.3 (0.2)
1.6 (0.2)
SLB
4.6
3.4
85%
82%
9%
68 (2.7)
71 (2.5)
1.0 (0.06)
0.9 (0.05)
4.3 (0.2)
2.2 (0.2)
P value
P<.001
P<.001
N/A
P<.001
P<.01
n.s.
· Mean age 31 and female 39%,
FEV1 65%PV, %race non-white
3% in SLM group; mean age 31
and female 43%, FEV1 66%PV,
race non-white 12% in SLB
group; mean age 31 and
female 43%, FEV1 65%PV, race
non-white 9% in PLC group
· Significant difference in ethnic
mix across groups
· Unchanged ICS or cromolyn
usage previous 3 months
· All patients on “as needed”
salbutamol use
· Two identically designed trials
with pooled data results
· Unclear if intention to treat
methodology used and
number of patients included in
analysis
· Pharmaceutical company
funded and supported trial
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Table 12: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus short-acting b-agonists) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Boulet et
al. 1997)
RCT
Grade 1+
Country:
Canada
Salmeterol inh 50
mg bd
V
Salbutamol
mdi 200 mg Qid
12 weeks
Inclusion:
Age 12-76 yrs
FEV1 50-80%PV
FEV1 ³ 15% 15 minutes after
inh of 200 mg  salbutamol
Exclusion:
Other b-agonists and OCS
ICS, IMM for at least 1
month pre-study
228
Between treatment groups:
Mean improvement over
baseline
FEV1 AM postdose time point
3-6 hours
       10-12 hours
(day1, weeks 4, 8, 10, 12)
Mean post-dose changes in
FEV1 %
Mean improvement in AM
PEFR(l/min)
% days no symptoms
% nights no awakenings
SLM
N/A
N/A
8.1%
35
29%
14%
SLB
N/A
N/A
9.7%
-3
15%
-1%
P value
P<.001
P£.012
N/A
P<.001
P=.012
P<.001
NNT
7
7
· Mean age 37 and female 44%,
FEV1 66%PV in SLM group;  age
40 and female 43%, FEV1
66%PV in SBM group
· Unclear if intention to treat
methodology
· Inadequate data results
reported for appraisal of
primary FEV1 measure of
efficacy
· Pharmaceutical company
funded trial
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Table 12: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus short-acting b-agonists) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Martin et
al. 1999)
CO
Grade 1+
Country:
United
States
Salbutamol po
(extended
release) 4mg AM,
8 mg PM bd
V
Salmeterol inh
42 mg  bd
Treatment
period(s)
3 weeks each
7-9 day washout
Inclusion:
Age 18-65 yrs
FEV1 50-80%PV
FEV1 > 12% after inh
salbutamol
Stable asthma for previous
30 days
Exclusion:
Systemic CS
b-agonists other than
rescue salbutamol
Theophylline (sustained
release)
47
Adjusted means
FEV1 (l)
PEFR L/min AM
% overnight change PEF
% overnight change FEV1
Rescue salbutamol (no.  of
inhalations/day)
% of no nighttime awakenings
SLM
2.70
420
-7.9
-5.1
2.20
84.6%
SLB
2.71
414
-7.2
-4.0
2.98
79.4%
P value
n.s..
n.s.
n.s..
n.s..
P=.001
P=.021
NNT
22
· Mean age 35 and female 48%,
FEV1 67%PV, 61% of patients on
ICS pre-study, 27% tobacco
use history.
· No baseline demographics for
randomized treatment groups
· Nocturnal asthma defined as ³
15% decrease in AM and night
FEV1 on 3/7 nights prior to
randomization
· 46/47 patients included in
analysis, 1 lost to follow-up
· Pharmaceutical company
funded and supported trial
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Table 12: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus short-acting b-agonists) in chronic asthma (continued)
Study
source,
design and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Ekstrom et al.
1998b)
RCT
Grade 1+
Country:
3
Scandinavian
countries
Formoterol inh 12
mg (delivered
dose 9 mg ) bd +
placebo
V
Terbutaline inh
0.5 mg Qid
V
Placebo inh Qid
12 weeks
Inclusion:
Age 18-82 yrs
FEV1 50-80%PV
FEV1 ³ 15% 15 minutes after
inh of 0.5 mg turbutaline
343
Mean difference in
improvement over baseline
PEFR L/min AM
                  PM
Asthma symptoms – night
Rescue medication (no.  of
inhalations)
Day
Night
P value
PEFR L/min AM
                  PM
Asthma symptoms – night
Rescue medication (no.  of
inhalations)
Day
Night
FRM
vs placebo
14.6
16.2
-0.20
-0.53
-0.67
P=.0022
P=.0001
P=.0025
P=.013
P=.0042
FRM vs
TEB
21.9
16.7
-0.16
-0.10
-0.11
P=.0001
P=.0001
P=.019
n.s..
n.s.
TEB vs
Placebo
-7.2
-0.6
-.0.05
-0.43
-0.56
n.s..
n.s.
n.s
P=.043
P=.015
· Mean age 49 and female 49%,
FEV1 62%PV , current/past
smoker 62% in SLM group;
mean age 48 and female 59%,
FEV1 61%PV, current/ex smoker
57% in TEB group; mean age 47
and female 49%, FEV1 60%PV,
current/ex-smoker 63% in PLC
group
· 89% of patients on ICS pre-
study. Patients allowed to use
ICS and terbutaline as rescue
medication
· International based study (3
countries)
· Unclear if intention to treat
methodology
· Pharmaceutical company
funded and supported trial
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Table 12: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus short-acting b-agonists) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Lipworth
et al. 1998)
RCT
Grade 1+
Country:
Scotland
Formoterol inh 6
mg (delivered
dose 4.5 mg ) bd +
placebo
V
Formoterol inh 24
mg (delivered
dose 9 mg -2
puffs) bd +
placebo
V
Formoterol inh 12
mg daily
(delivered dose 9
mg) + placebo
V
Terbutaline inh
500 mg Qid
V
Placebo inh Qid
Methacholine
challenge (MCh)
3.125 mg  - 6400
mg  to FEV1 PD20
2 weeks
Inclusion:
Age 16-65 yrs
FEV1 ³ 60%PV
PD20 (MCh) £1000 mg
Constant dosage of ICS
£2000 mg  BUD, BDP or FP
Exclusion:
Patients on OCS previous 4
weeks
Smoker previous 12 months
72 Methacholine protection
ratios compared with
placebo
Formoterol 24 mg bd
First dose
14 days
Formoterol 12 mg bd
First dose
14 days
Formoterol 6 mg bd
First dose
14 days
Terbutaline 500 mg Qid
First dose
14 days
Pre-challenge FEV1 1 hour
after use of medication
After 14 days of treatment
(as % ratio versus placebo)
Formoterol 24 mg bd
Formoterol 12 mg bd
Formoterol 6 mg bd
Terbutaline 500 mg Qid
Geometric
Mean fold
Protection
Ratio
10.2
1.4
6.4
1.5
5.5
1.6
3.4
1.9
109%
111%
109%
105%
95% CI
4.6 – 22.5
0.6 – 3.4
2.9 – 14.1
0.6 – 3.8
2.5 – 12.3
0.6 – 4.0
1.5 – 7.8
0.8 – 4.9
103,116%
105, 118%
102, 115%
99, 112%
P value
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
n.s.
n.s.
n.s.
n.s.
· Mean age 33 and female 47%,
FEV1 90%PV FRM 24 mg group;
mean age 36 and female 53%,
FEV1 87%PV in FRM 12 mg
group; mean age 39 and
female 71%, FEV1 85%PV in FRM
6 mg  group; mean age 42 and
female 50%, FEV1 88%PV in TEB
500 mg  group; mean age 38
and female 43%, FEV1 86%PV in
placebo group
· Unclear if intention to treat
methodology
· Pharmaceutical company
funded and supported trial
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Table 12: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus short-acting b-agonists) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Seberova
and
Andersson
2000)
CO
Grade 1-
Country:
Czech
Republic
5 study visits, with
single doses:
minimum 2 days
washout
Formoterol inh 4.5
mg or 9 mg
V
Salbutamol
mdi 100 mg or 200
mg
V
Placebo
Inclusion:
Age 18-64 yrs
FEV1 ³ 40%PV
FEV1 ³1.51
FEV1 ³ 15% 15 minutes after
inh of 0.5 mg terbutaline
Exclusion:
If FEV1 not within ±12% of
baseline FEV1 patients
asked to return another
day
Oral, inh long-acting
b-agonists, GCS during
study
36 FEV1 at 3 minutes after
inhalation
Salbutamol 100 mg
Salbutamol 200 mg
Formoterol 4.5 mg
Formoterol 9.0 mg
% Increase
in FEV1 (cf.
baseline
+10.0%
+11.4%
+11.7%
+11.8%
P value
cf. placebo
P<.001
P<.001
P<.001
P<.001
Between
groups
n.s.
· Mean age 34 and % female
unknown, mean FEV1 (L) 2.75
· No baseline demographics for
randomized treatment groups
· Treatment period undefined
· Randomized at each study visit
· No power analysis for study
sample size
· Pharmaceutical company
funded and supported trial
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Table 12: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus short-acting b-agonists) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Lipworth
et al. 1999)
RCT
Grade 1-
Country:
Scotland
Formoterol inh 12
mg mane
V
Formoterol inh 6
mg bd
V
Formoterol inh 24
mg bd
V
Terbutaline inh
500 mg Qid
2 weeks
Inclusion:
Age 18-45 yrs
FEV1 ³ 60%PV
PD20 in FEV1 response to
methacholine challenge of
1000 mg and 2-doubling
dose protection in
response to a single test
dose of formoterol inh 24
mg
Non-smoker
38
Mean values
AM PEFR(L/min)(se) run-in
                       Treatment
PM PEFR(L/min)(se) run-in
                       Treatment
* P<.05 difference between
run-in and treatment only in
formoterol 24 mg bd group
FRM
6 mg  bd
395 (55)
415 (59)
398 (50)
433 (59)
FRM
12 mg daily
367 (44)
391 (21)
417 (31)
421 (25)
FRM
24 mg bd*
447 (30)
490 (24)
471 (27)
502 (24)
TEB
500 mg Qid
429 (46)
428 (45)
435 (51)
445 (46)
· N=8, mean age 39 and female
38%, FEV1 80%PV in FRM 6 mg
group; N=10, age 41 and
female 40%, FEV1 84%PV in FRM
12 mg group; N=11, age 32 and
female 45%, FEV1 91%PV in FRM
24 mg  group; N=11, age 36
and female 44%, FEV1 87%PV in
TEB group
· Small numbers in each
treatment group, no significant
demographic differences
between groups
· All patients on regular ICS
therapy. On demand b-
agonists
· Unclear if intention to treat
methodology
· Results presented are only
secondary outcome measures.
Primary outcome
bronchoprotective sensitivity
· Pharmaceutical support in
provision of inhalers for trial
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Table 12: Summary of studies investigating the effect of pharmaceuticals (long-acting b-a onists versus short-acting b-agonists) in chronic asthma (continued)
Study
source,
design and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Tattersfield
2001)
RCT
Grade 1+
Country:
4 European
countries
As needed
basis:
Formoterol inh
4.5-54 mg daily
V
Terbutaline inh
0.5-6 mg daily
12 weeks
Inclusion:
Age 18-75 yrs
FEV1 ³ 50%PV
ICS mean dose 870 mg
daily previous 4 weeks
Requirement of b-agonists
average 3/8 times during
run-in period
Exclusion:
Patients inh 12+ rescue
medication
362 Number at risk (remaining
w/o severe asthma
exacerbation)
Days since randomization
0
20
40
60
80
Exacerbations: no. of
patients/no. of exacerbations
Need for OCS
Mean difference in change
over treatment (FRM-TEB)
AM PEFR(L/min)(95% CI)
PM PEFR(L/min)(95% CI)
Diurnal variation %
Symptom score – Day
                         Night
FRM
182
173
165
153
146
26 / 29
21/26
(81%)
11 (3,20)
8 (0,15)
-0.4
(-1.4,0.6)
-0.04
-0.02
TEB
180
159
144
132
127
43 / 48
31/43
(72%)
P value
P=.013
P=.009
P=.043
P=.44
P=.54
P=.68
· Mean age 46 and female 52%,
FEV1 74%PV in FRM group;
mean age 48 and female 62%,
FEV1 74%PV in TEB group
· Severe exacerbations defined
by need for OCS or fall in PEFR
of 30% from baseline on 2
consecutive days
· International study (4
countries)
· Pharmaceutical company
funded and supported trial
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Table 12: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus short-acting b-agonists) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Ekstrom et
al. 1998a)
RCT
Grade 1-
Country:
4
European
countries
Formoterol inh 6
mg (delivered
dose 4.5 mg ) bd
V
Terbutaline inh
0.5 mg Qid
V
Placebo inh Qid
12 weeks
Inclusion:
Age 18-79 yrs
FEV1 40-80%PV
FEV1 ³ +15% and 200+ ml
after inh of 0.5 mg
terbutaline
397
PEFR L/min
AM
PM
FEV1
Symptoms:
Days
Nights
Rescue no.  of inhalations:
Day-time
Night-time
FRM vs TEB
10.9
8.0
0.13
-0.09
-0.11
-0.14
-0.15
95%CI
2.3, 19.5
-4.0, 16.5
0.05, 0.21
-0.18,-0.01
-0.20,-0.02
-0.36,-0.08
-0.31,-0.01
P value
P=.014
P=.061
P<.0017
P=.038
P=.015
P=.19
P=.074
· Mean age 49 and female 49%,
FEV1 62%PV FRM group; mean
age 46 and female 59%, FEV1
63%PV in TEB group; mean age
48 and female 49%, FEV1
62%PV in PLC group
· Pre-study 86% of patients on
ICS, 78% inh b-agonists. ICS
maintained 4 weeks prior and
during study
· Proportion of male/female in
terbutaline group differs from
others
· 54 patients in treatment group
not included in baseline
demographic analysis
· Undetermined number of
patients included in analysis of
results
· International based study (4
countries)
· Pharmaceutical company
funded and supported trial
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Table 13: Summary of studies investigating the effect of pharmaceuticals (inhaled steroids versus short-acting beta-agonist) in chronic asthma
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Hancox et al.
1999b)
CO
Grade 1+
Country:
New Zealand
Budesonide inh
400 mg bd +
terbutaline inh
1000 mg Qid
V
Budesonide inh
400 mg bd
V
Terbutaline inh
1000 mg Qid
V
Placebo
6 weeks each
Inclusion:
Age 9-64 yrs
Exclusion:
Current or ex cigarette
smoker (>5 pack years)
Pharmaceutical limitations
61
D AM PEFR (cf. BDP)
(95%CI)
D am PEFR (cf. TER)
(95%CI)
Night awakening (%)
P value
Rescue medication use
(puffs/day)
P value
BDP/TEB
14
(5,23)
27
(17,37)
1.9
n.s.
0.3
n.s.
BDP
3.4
n.s.
0.5
n.s.
TEB
4.0
n.s.
0.5
n.s.
· Mean age 27 and female 69%
· Participants able to tolerate the
withdrawal of inh steroid
· Pharmaceutical company
involved in supplying inhalers and
supporting the lead author
· No baseline comparison post-
randomisation
(Aldridge et al.
2000)
CO
Grade 1+
Country:
New Zealand
Budesonide inh
400 mg bd +
terbutaline inh
1000 mg Qid
V
Budesonide inh
400 mg bd
V
Terbutaline inh
1000 mg Qid
V
Placebo
6 weeks each
Inclusion:
Age 16-64 yrs
FEV1 > 50%PV
Exclusion:
Current or ex-cigarette
smoker (>5 pack years)
Pharmaceutical limitations
34
AM PEFR (L/min)
Daytime wheeze (% days
present)
Nighttime wheeze (% days
present)
Rescue med use (Median %
days used)
1Combined versus BDP,
2combined versus TEB,
3BDP versus TEB
BDP/TEB
491
P =.0011
P < .0012
4
n.s.1
P = .022
3
n.s.1
P = .0032
0
P =.051
n.s.2
BDP
469
P = 0.043
9
n.s.3
4
n.s.3
0
n.s.3
TEB
450
18
12
0
· Mean age 39 and female 47%
· Mean FEV1 90%PV
· No baseline comparison post-
randomisation
· 82% of participants randomised
were analysed
· Pharmaceutical company
involved in supplying inhalers and
supporting the lead author
· Selected from participants in
(Hancox et al. 1999b)
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Table 13: Summary of studies investigating the effect of pharmaceuticals (inhaled steroids versus short-acting beta-agonist) in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Hancox et al.
1999a)
CO
Grade 1-
Country:
New Zealand
Budesonide inh
400 mg bd +
terbutaline inh
1000 mg Qid
V
Budesonide inh
400 mg bd
V
Terbutaline inh
1000 mg Qid
V
Placebo
6 weeks each
Inclusion:
Age 16-64 yrs
Exclusion:
Current or ex-cigarette
smoker (>5 pack years)
Pharmaceutical limitations
34
% fall FEV1 post methacholine
(95%CI)
BDP/TEB
25.9
(22.2, 28.2)
BDP
26.1
(22.3, 28.3)
TEB
26.9
(24.4, 28.5)
· Female 47%
· Mean FEV1 90%PV
· No baseline comparison post-
randomisation
· 76% of participants randomised
were analysed
· Pharmaceutical company
involved in supplying inhalers and
supporting the lead author
· Selected from participants in
(Hancox et al. 1999b)
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Table 14: Summary of studies investigating the effect of pharmaceuticals (short-acting b-agonists regular versus PRN treatment) in chronic asthma
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Richter et al.
2000)
CO
Grade 1+
Country:
Germany
Salbutamol/
Fenoterol Qid
and PRN
V
Salbutamol/
Fenoterol PRN
24 weeks each
Inclusion:
Age 18-75 yrs
All patients on regular b-
agonist and inhaled steroid
for at least 2 years
80
Asthma attack (n/day)
Night awakening (n/night)
Symptom score
Rescue med use (puffs/night)
Absence from work/school
(n)
ED treatment (n)
FEV1 %PV
PRN
0.58
0.15
1.46
0.34
16
12
85.2
Reg
0.45
0.09
1.40
0.26
9
5
81.2
P value
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
P= 0.003
· Mean age 48 and female 74%
· Mean FEV1 74%PV
· Single blind
· Analysed 91% of participants
randomised
· No data on baseline comparison
post-randomisation
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Acute asthma
Table 15: Summary of studies investigating the effect of pharmaceuticals (short-acting b-agonists + ipratropium versus short-acting b-agonists) in acute asthma
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Rodrigo
and
Rodrigo
2000)
RCT
Grade 1+
Country:
Uruguay
Salbutamol mdi
120 mg/puff +
Ipratropium mdi
21 mg/puff in a
dose of 4 puffs at
10 min intervals
(480 mg/84 mg)
V
Salbutamol mdi
120 mg/puff in a
dose of 4 puffs at
10 min intervals
(480 mg)
3 hours of
treatment (24
puffs or 2,880 mg
salbutamol and
504 mg
ipratropium per
hour)
Inclusion:
Age 18-50 yrs
FEV1/PEFR < 50% PV
180
Improvement over
salbutamol control group %
PEFR (95%CI)
FEV1 (95%CI)
Hospital admissions n (%)
Pre ED use of b-agonists by ipr
patients: increase in FEV1
previous use
no previous use
Symptoms
24+ hours
< 24 hours
FEV1£ 30PV%
       > 30PV%
SLB+IPR
+20%
(2.6,38.4)
+48%
(19.8,76.4)
18 (20%)
N/A
N/A
N/A
N/A
N/A
N/A
SLB
36 (39%)
N/A
N/A
N/A
N/A
N/A
N/A
P value
P=.02
P=.001
P=.01
P=.01
P=.03
P=.01
P=.09
P=.001
P=.60
NNT
5
· Mean age 35 and female 37%,
PEFR 32%PV in SLB+IPR group;
mean age 33 and female 34%,
PEFR 33%PV in SLB group
· Acute asthma, Emergency
Department setting
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Table 15: Summary of studies investigating the effect of pharmaceuticals (short-acting b-agonists + ipratropium versus short-acting b-agonists) in acute asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Weber et
al. 1999)
RCT
Grade 1+
Country:
United
States
All patients
received
prednisone po 60
mg
Salbutamol neb
10 mg/hour +
Ipratropium neb
1.0 mg/hour
V
Salbutamol neb
10 mg/hour +
Ipratropium neb
1.0 mg/hour
£ 3 hours of
treatment
Inclusion:
Age 18+ yrs
FEV1/PEFR < 70% PV after
2.5 mg Salbutamol in 3 mL
normal saline
67
Improvement over
salbutamol control group %
PEFR (95%CI)
Adjusted for baseline PEFR
 Median length of stay
(minutes)
Adjusted for baseline PEF
Hospital admissions n (%)
Adjusting for baseline PEF
OR (95%CI)
SLB+IPR
+6.3%
(-1.5,27%)
210
N/A
8 (23%)
0.88 (0.28,
2.8)
SLB
245
N/A
13 (39%)
P value
n.s.
P=.03
P=.26
N/A
· Mean age 46 and female 75%,
PEFR 50%PV and smoking history
48% in SLB+IPR group; mean age
49 and female 66%, PEFR 40%PV
and smoking history 74% in SLB
group
· Significant P<.05 baseline
differences in PEFR%PV and
smoking history. P<.10 differences
in previous hospitalization and
intubation
· Results have been adjusted for
baseline differences
· Acute asthma, Emergency
Department setting
· Pharmaceutical (producer of
ipratropium) involvement in supply
of ipratropium and pharmacy
costs
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Table 15: Summary of studies investigating the effect of pharmaceuticals (short-acting b-agonists + ipratropium versus short-acting b-agonists) in acute asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Lin et al.
1998)
RCT
Grade 1+
Country:
United
States
Salbutamol 2.5
mg + Ipratropium
0.5 mg (first dose
only) then every
20 min 2 more
doses of
salbutamol only
(total 3 doses)
neb
V
Salbutamol 2.5
mg + placebo
(first dose only)
then every 20 min
2 more doses of
salbutamol only
(total 3 doses)
neb
Treatment period
1 hour
Inclusion:
Age 18+ yrs
PEFR <200 L/min
Exclusion:
20 pack years+ smoker
b-agonists preceding 4
hours
55
Number of patients admitted
to hospital n (%)
Difference and 95%CI of
proportion admitted
PEFR L/min mean
BL
20 min
40 min
60 min
PEFR L/min %PV mean
BL
20 min
40 min
60 min
SLB+IPR
3 (11%)
25%
(3%,46%)
131
197
252
269
28
42
53
57
SLB
10 (36%)
142
197
218
228
29
37
45
47
P value
P=.03
Over  1
hour
period
P=.001
Over 1
hour
period
P<.001
NNT
41
· Mean age 40 and female 54% in
SLB + IPR group, mean age 41and
female 59% in SLB group
· Acute asthma. Convenience
sample selected from Emergency
Department
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Table 15: Summary of studies investigating the effect of pharmaceuticals (short-acting b-agonists + ipratropium versus short-acting b-agonists) in acute asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Rodrigo et
al. 1999)
MA
Grade 1+
Ipratropium inh
0.5 mg (single
dose) plus b-
agonists
(Salbutamol 8
studies, fenoterol
2 studies) after
arrival in ED
V
b-agonists alone
First 90 minutes of
treatment
Inclusion:
Age 16+ yrs
English language studies
RCT, double blind
Patients with acute
asthma, treated in ED with
b-agonists
Search:
1978-1999 (April)
MEDLINE, Science Citation
Index, Current Contents,
reviews (articles and
primary research), experts
1483
Overall effect size (std units)
cf. control group
FEV1  (95%CI)
Homogeneity test
Study specific effects
Mean FEV1 at admission
<35%PV (4 studies)
(95%CI)
Use of corticosteroids
(7 studies) (95%CI)
Hospital admissions (5 studies)
(Odds Ratio, 95%CI)
b-agonist  +
IPR
0.14
(0.04,0.24)
(10%) (2%,
18%)
(0.03-0.63)
0.38
(0.09,0.67)
0.14
(0.00,0.28)
0.62
(0.44,0.88)
P value
P=.008
P>.5
N/A
N/A
N/A
P=.007
NNT
18
· 10 studies included, acute asthma,
mean age 32 ± 13 years and
female 64%
· Mean methodology quality score
0.66 (max = 1)
· Criteria for discharge and
admission not clearly defined
· Reported adverse effects not
assessed nor delivery devices
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Table 15: Summary of studies investigating the effect of pharmaceuticals (short-acting b-agonists + ipratropium versus short-acting b-agonists) in acute asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Stoodley
et al. 1999)
MA
Grade 1+
Country:
Canada
Ipratropium plus
b-agonists mdi or
neb after arrival
in ED
V
b-agonists alone
30-90 minutes
duration of
treatment
Inclusion:
Age 18+ yrs
RCT (double blinding not
necessary but all included
studies double blind)
Patients with acute
asthma, treated in ED or
similar with b-agonists
Search:
MEDLINE (1966-97), EMBASE
(1980-97), CINAHL (1982-
97), Biological Abstracts
(1990-97), Cochrane
database and Current
Contents (1996-97)
1377
Overall effect size (std units)
cf. control group
PEFR/ FEV1 (95%CI)
% improvement in FEV1 (4
studies)
% improvement PEFR
(5 studies)
Hospital admissions (3 studies,
n=1064) (Relative Risk, 95%CI)
Effect size of studies with IV
steroids (4 studies) to all
enrolled patients
b-agonist  + IPR
0.38
(0.27,0.48)
7.3%
(3.8%, 10.9%)
22.1%
(11.0%, 33.2%)
.73 (53, .99)
.25
(.10,.40)
· 10 studies included, acute asthma,
mean age range for treatment
group 29.5-50.4 years, control
group 29.6-53.2.
· Study quality assessment limited to
randomization, double blinding
and inclusion of data for dropouts
and withdrawals
· Dosages of ipratropium not
specified
· Changes in airflow assessment FEV1
(4 studies) PEFR (5 studies) both (1
study)
· Significant Cochran Q test for
homogeneity (p=.047) suggesting
included trials were a
heterogeneous group. One trial
had much lower baseline PEFR
values. Removal resulted in Q test
P= .37, summary effect value 0.35
(.24,.47). Study results reported
including 10 studies.
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Table 15: Summary of studies investigating the effect of pharmaceuticals (short-acting b-agonists + ipratropium versus short-acting b-agonists) in acute asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Garrett et
al. 1997)
RCT
Grade 1-
Country:
New
Zealand
All patients
received IV
hydrocortisone
200 mg within 15
minutes of
treatment start
(Combivent)ä
Ipratropium neb
1.5 mg in a dose
+ Salbutamol neb
2.5 mg
V
Salbutamol neb
2.5 mg
Duration 90
minutes
Inclusion:
Age 18-55 yrs
FEV1< 70% PV
Exclusion:
Smoking history of 10+
pack years
Complicating illness eg
COPD
338
Mean absolute difference
over salbutamol group
Baseline FEV1ml (se)
45 minutes
90 minutes (primary efficacy)
FEV1< 1 L at baseline:
D FEV1 (mls)
FEV1³ 1 L/min at baseline:
D FEV1 (mls)
Hospital admissions (%)
SLB + IPR
40 (57)
93 (24)
113 (18)
22
176
15.3%
SLB
22.3%
P value
P=.4485
P=.03
P=.02
n.s.
P<.005
NNT
14
· Mean age 30 and % female not
specified, FEV1 40%PV in SLB+IPR
group; mean age 30, % female not
specified, FEV1 40%PV in SLB group
· Overall % female 61%, 17% Maori,
24% Pacific Island ethnicity
· 13% of patients reported using
OCS, 32% ICS, 80% inh b-agonist
within 6 hours of presentation to ED
· Acute asthma, Emergency
Department setting
· No intention to treat based
analysis, 58 patients (27 in
combiventä group and 31 in
salbutamol group) withdrawn after
treatment received (no FEV1
recorded).
· Pharmaceutical company
supported study
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Table 15: Summary of studies investigating the effect of pharmaceuticals (short-acting b-agonists + ipratropium versus short-acting b-agonists) in acute asthma (continued)
Study
source,
design and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(FitzGerald
et al. 1997)
RCT
Grade 1-
Country:
Canada
All patients
received
oxygen and IV
bolus of 125 mg
methyl-
prednisone
(within 15
minutes of
nebulization)
(Combination)
Ipratropium neb
0.5 mg in a dose
+ salbutamol
neb 3.0 mg
V
Salbutamol neb
3.0 mg
Duration 90
minutes
Inclusion:
Age 18-55 yrs
FEV1< 70% PV
Exclusion:
Smoking history of 10+
pack years
COPD or significant other
medical illness
342
Mean change from baseline
Baseline FEV1 L (se)
45 minutes
90 minutes (primary efficacy)
Hospital admissions (%)
SLB+IPR
1.62 (0.05)
0.58 (0.04)
0.61 (0.04)
5.9%
SLB
1.53 (0.05)
0.52 (0.04)
0.52 (0.04)
11.2%
P value
n.s.
n.s.
n.s.
NNT
19
· Mean age 31 and female 60%,
FEV1 1.62L in SLB+IPR group; mean
age 30, % female 64%, FEV1  1.53L
in SLB group
· Prior asthma medication in
combination and salbutamol
alone groups: 12% and 12% of
patients reported using OCS, 46%
and 40% ICS, 88% and 90% inh b-
agonist within 24 hours of
presentation to ED
· Acute asthma, Emergency
Department setting
· Poor description of randomisation,
concealment and blinding
methodology
· Not strict intention to treat based
analysis
· Criteria for discharge and
admission not clearly defined
· Pharmaceutical company partly
funded study
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Table 15: Summary of studies investigating the effect of pharmaceuticals (short-acting b-agonists + ipratropium versus short-acting b-agonists) in acute asthma (continued)
Study
source,
design and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Kamei et al.
1999)
RCT
Grade 1-
Country:
Japan
Fenoterol 1 puff
(200 mg/puff)
every 1 minute
for 5 minutes,
total 1000 mg +
Oxitropium
bromide 2 puffs
(100 mg/puff)
every 1 minute
for 5 minutes,
total 1000 mg
mdi with
InspirEase™
holding
chamber
V
Fenoterol 1 puff
(200 mg/puff)
every 1 minute
for 5 minutes,
total 1000 mg
Treatment
duration 60
minutes
Inclusion:
FEV1 < 70% PV
Exclusion:
Pulmonary emphysema
Complicating drugs
69 At 60 minutes
Mean value cf. baseline
PEFR L/min (se)
From baseline PEFR % impr
1   min
15 min
30 min
60 min
FRM + OTB
261 (18)
N/A
N/A
N/A
N/A
FRM
210 (17)
N/A
N/A
N/A
N/A
P value
P<0.05
P<0.02
P<0.01
P<0.02
P<0.001
· Mean age 55 and female 46%,
best FEV1 1.81L in FRM+OTB group;
mean age 56and female 65%, best
FEV1 1.86L in FRM group
· Acute asthma, Emergency
Department setting
· Open study, no detail on
randomisation nor statistical power
· Intention to treat based analysis
not evident, 31/34 and 33/35 in
respective randomised groups
analyzed for efficacy
· Some data results for primary
efficacy outcome not reported
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Table 16: Summary of studies investigating the effect of pharmaceuticals (short-acting b-agonists dose or administration methods) in acute asthma
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Nouira et al.
1999)
RCT
Grade 1+
Country:
Tunisia
Salbutamol neb
10 mg V 5 mg
30 minutes
Inclusion:
Age > 16 years
PEFR < 50%PV and ³ 2 of:
pulse>100, Resp rate > 30,
accessory muscle use,
pulsus paradoxus > 20.
Exclusion:
Incapable of performing
PEFR
Intubated
Age > 65 years and
history of severe
cardiopulmonary disease
40
% D PEFR
5 mg
12
10 mg
11
P value
n.s.
· Mean age 41 and female 40%
· Mean PEFR 29%PV
· All patients received
hydrocortisone 100 mg IV
· 90% power to detect a 20%
difference in PEFR at the 5%
significance level
(Emerman et al.
1999)
RCT
Grade 1+
Country:
United States
Salbutamol neb
2.5 mg (3 doses)
V
Salbutamol neb
7.5 mg (3 doses)
Inclusion:
Age 18-50 yrs
Presenting to ED for acute
asthma
Able to perform
spirometry
160
FEV1 %PV
Admitted (%)
Relapse within 7 days (%)
Side effects attributable to
salbutamol (%)
Low dose
50.6
43
17.1
49.4
High dose
56.3
39
16.7
44.2
P value
P = 0.06
P = 0.65
P = 0.70
P = 0.51
· Mean age 37 and female 77%
· Mean FEV1 40%PV
· 80% power to detect 17%
difference in increase in FEV1 from
baseline at 5% significance level
· Unclear whether ITT analysis was
used
(Karpel et al.
1997)
RCT
Grade 1+
Country:
United States
Salbutamol mdi
+ Spacer 540 mg
at time:
0, 30, 60, 90 mins
V
0, 60 mins
V
0 mins
2 hours
Inclusion:
Age 18-55 years
FEV1 £ 60%PV
Cigarette smoking £ 10
pack-years
Able to perform
pulmonary function tests
100
FEV1 (L)
Additional b-agonist use (%)
Received systemic steroid
(%)
Hospitalised (%)
4 dose
2.2
20.6
32.4
3.0
2 dose
2.2
23.5
20.6
5.9
1 dose
1.7
42.4
21.2
3.0
P value
P <.05
(4 V 1 dose,
 2 V 1 dose)
P <.05
(4 V 1 dose,
 2 V 1 dose)
n.s.
n.s.
· Mean age 32 and female 73%
· Mean FEV1 42%PV
· Financial support from
pharmaceutical company
· Randomisation process not
described
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Table 16: Summary of studies investigating the effect of pharmaceuticals (short-acting b-agonists dose or administration methods) in acute asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Besbes-Ouanes
et al. 2000)
RCT
Grade 1+
Country:
Tunisia
Salbutamol neb
27.5 mg over 6
hours:
Continuous
V
Intermittent
6 hours
Inclusion:
PEFR < 50%PV and 2 of
pulse ³ 120, resp rate ³
30, pulsus paradoxus ³ 15
mm Hg, accessory
muscle use, SaO2 < 92%
(room air), PaCO2 > 42
mm Hg
42
D PEFR (%)
D clinical severity score
Required supplemental
treatment (%)
INT
32
-6.1
9.5
CON
30
-6.3
14
P value
n.s.
n.s.
n.s.
· Mean age 40 and female 60%
· Mean PEFR 24%PV
· All patients received IV
hydrocortisone
· Some doubts about the success of
double blinding
· 80% power to detect a 13%
difference in PEFR at the 5%
significance level
(Bradding et al.
1999)
RCT
Grade 1-
Country:
United Kingdom
Salbutamol neb 5
mg q4h
V
Salbutamol 2.5-5
mg PRN
24 hrs post-hosp
admission to 24
hrs prior to
discharge
Inclusion:
Age 17-65 yrs
Presenting to ED for acute
asthma
46
Length of stay (days)
Number of nebs
Patients with tremor
Patients with palpitations
PRN
3.7
7.0
4
1
q4h
4.7
14.0
11
7
P value
P = 0.04
P = .003
P = 0.06
P = 0.05
· Mean age 30 and female 70%
· Open study
· Inadequate randomisation
method
(Hoffman and
Smithline 1997)
RCT
Grade 1-
Country:
United States
CirculaireÔ
nebuliser
V
Conventional
nebuliser (Airlife
Misty-NebÔ)
Single dose
Inclusion:
Presenting to ED requiring
b-agonist nebuliser
Exclusion:
Incapable of performing
PEFR
134
Median PEFR (L/min)
CIR
80
CNV
30
P value
P < .001
· Mean age 45 and female 45%
· Single blind
· Baseline difference in diastolic BP
· Circulaire nebuliser provided by
pharmaceutical company
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Steroids
Chronic asthma
Table 17: Summary of studies investigating the effect of pharmaceuticals (inhaled steroids versus theophylline) in chronic asthma
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Reed et al.
1998)
RCT
Grade 1+
Country:
United States
Beclomethasone
inh 84 mg Qid
V
Theophylline
1 year
Inclusion:
Age 6-65 yrs
FEV1 >50%PV
Exclusion:
>5 pack years tobacco
smoking
Resp infection in past 3
weeks
Pharmaceutical limitations
747
Moderately severe or worse
symptoms1
Systemic steroid use over
course of study
BEC
25.8%
20%
THP
30.5%
29%
P value
n.s.
P = .009
NNT
11
· Female 51%
· 45% previously taken theophylline,
4% beclomethasone
· 75% study completion rate
· Theophylline dose determined by
response
· Study supported by
phamaceutical company
producing beclomethasone
· No baseline data on mean age in
two study groups
· 1For any day in the 12th month.
There were significant differences
in earlier months that favoured
beclomethasone.
(Ukena et al.
1997)
RCT
Grade 1+
Country:
Germany,
Hungary, Austria
Beclomethasone
inh 200 mg bd
+ Theophylline
V
Beclomethasone
inh 400 mg bd
6 weeks
Inclusion:
Age 18-70 years
FEV1 50-85%PV
Asthma not controlled on
beclomethasone 400 mg
daily or equivalent
Exclusion:
Severe asthma attack or
lower resp infection within 1
month
Current smoker
Pharmaceutical limitations
133
D FEV1 (L)
Combined
0.26
BEC
0.19
P value
n.s.
· Median age 48 and female 44%
· FEV1 75%PV
· Data not presented but no
significant difference in rescue
med use between groups
· ITT analysis not presented in paper
but results similar to per protocol
analysis presented
· Producers of theophylline funded
and supported trial
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Table 17: Summary of studies investigating the effect of pharmaceuticals (inhaled steroids versus theophylline) in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Evans et al.
1997)
RCT
Grade 1+
Country:
United Kingdom
and Sweden
Budesonide inh
400 mg bd +
theophylline po
250 mg (if < 80
kg) or 375 mg (if ³
80 kg) bd
V
Budesonide inh
800 mg bd
3 months
Inclusion:
FEV1 > 50%PV
Exclusion:
Pharmaceutical limitations
Asthma exacerbation within
3 weeks of run in
62
Improvement in FEV1 (L)
Improvement in FVC (L)
Day time symptom scores
Night time symptom scores
Daytime rescue med use
Nighttime rescue med use
THP + BDP
0.21
0.26
N/A
N/A
N/A
N/A
BDP
0.11
0.18
N/A
N/A
N/A
N/A
P value
P = 0.03
P = 0.03
P = 0.26
P = 0.59
P = 0.57
P = 0.97
· Mean age 39 and female 60%
· Mean FEV1 75%PV
· Supported by pharmaceutical
company that produces
theophylline
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Table 18: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma
Study
source,
design and
evidence
grading
Intervention
Comparison
And study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Shrewsbury
et al. 2000)
MA
Grade 1+
Salmeterol +
inhaled
steroids (Beclo-
methasone 5
studies or
fluticasone 4
studies)
V
At least
doubling dose
of inhaled
steroids
(Beclo-
methasone 5
studies or
fluticasone 4
studies)
12+ weeks
Inclusion:
Age 12+ yrs
RCT, double blind
All languages
Patients with symptomatic
asthma, treated on current
dose of inhaled steroids
Search:
1985-1999 (September
1999 last search)
MEDLINE, EMBASE,
GlaxoWellcome
databases
3685 Treatment with salmeterol
plus inhaled steroids versus
increased dose inhaled
steroids (double+ dose)
Mean difference (95% CI) in
lung function
AM PEFR L/min
AM FEV1 L
Mean % difference (95% CI)
Days without symptoms
Nights without symptoms
Days without rescue
treatment
Nights without rescue
treatment
Difference (95% CI) in mean
numbers of patients with
exacerbation:
Any exacerbation
Moderate/severe
exacerbation
3 months
22.4 (15,30)
0.10
(0.04, 0.16)
11% (8,15)
5% (2,8)
16% (13,20)
9% (5,12)
2.73
(0.43,5.04)
2.42
(0.24,4.60)
6 months
27.7 (19,38)
0.08
(0.02,0.14)
15%(11,19)
6% (3,9)
19% (14,24)
9% (5,13)
P value
3 months
P<.001
P<.001
P<.001
P<.001
P<.001
P<.001
P=.02
P=.03
P value
6 months
P<.001
P<.01
P<.001
P<.001
P<.001
P<.001
· 9 studies included
· No evidence of heterogeneity
between studies for PEFR and
FEV1 and exacerbation analysis.
For symptoms and rescue
comparison P<.10 in all cases.
Comparison of 95% CI under fixed
and random effects model cited
by authors as small and clinically
unimportant (data not provided)
· Pharmaceutical company
supported meta-analysis
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Table 18: Summary of studies investigating the effect of pharmaceuticals (long-acting b go ists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Baraniuk
et al. 1999)
RCT
Grade 1+
Country:
United
States
Fluticasone  mdi
220 mg bd
V
Triamcinolone
mdi 600 mg bd
V
Fluticasone  mdi
88 mg bd +
salmeterol mdi 42
mg bd
12 weeks
Inclusion:
Age 12+ yrs
FEV1 40-65%PV
Patients with FEV1 65-
85%PV
15+% increase in FEV1 %PV
after 30 min with 180 mg
salbutamol
BDP dosage 252-672 mg, or
TAA 600-1000 mg, or FP
1000 mg daily 3+ months
pre-study
Exclusion:
Smoker
Serious asthma
exacerbation previous 4
weeks
680 12 weeks
(mean change cf. baseline)
(se)
AM FEV1 (L)
FEV1 (L) %PV
Symptom score
% symptom-free days
% rescue-free days
Adverse event related to
treatment (% patients)
(mean change cf. baseline)
(se)
AM FEV1 (L)
FEV1 (L) %PV
Symptom score
% symptom-free days
% rescue-free days
Adverse event related to
treatment (% patients)
FP plus SLM
0.58 (0.03)
16.7 (1.0)
-0.44(0.05)
29.2(2.9)
45.0(2.9)
14%
FP
0.48(0.03)
14.0(0.6)
-0.46(0.05)
22.6(2.6)
28.9(2.7)
13%
TAA
0.34 (0.03)
10.4 (0.80
-0.31(0.05)
11.9(2.1)
27.4(2,5)
8%
TAA
0.34(0.03)
10.4(0.80
-0.31(0.05)
11.9(2.1)
27.4(2,5)
8%
P value
P<.001
P£.004
P£.004
P£.004
P£.004
N/A
P£.027
P£.035
P£.035
P<.001
n.s.
N/A
NNT
NNH
17
NNT
NNH
20
· Mean age 41 and female 59%,
FEV1 63%PV, non-white ethnicity
13%  in FP + SLM group; mean
age 40and female 61%, FEV1
63%PV, non-white ethnicity 17% in
FP group; mean age 39 and
female 65%, FEV1 63%PV, non-
white ethnicity 11% in TAA group
· No detail on randomisation
method
· Pharmaceutical company
funded and supported trial
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Table 18: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Aubier et
al. 1999)
RCT
Grade 1+
Country:
Netherlands,
France
Combination:
Fluticasone 500
mg + salmeterol
50 mg bd Diskus
inh
and placebo bd
V
Concurrent:
Fluticasone  500
mg + salmeterol
50 mg bd Diskus
inh and placebo
bd
V
Fluticasone  500
mg bd diskus inh
and placebo bd
12 weeks
Inclusion:
Age 12-78 yrs
ICS 12 weeks prior to run-in
and BEC or BDP
1500-2000 mg or FP 750-
1000 mg daily 4 weeks prior
Symptomatic patients
(score ³2)
Patients with FEV1 50-
100%PV
PEFR 50-85%PV max PEFR
after 15 min with 400 mg
salbutamol
503 12 weeks
(adj mean difference cf.
baseline) (se)
Relative to FP plus SLM
combination. –ve values
indicate higher overall value
for combination therapy
AM PEFR (l/min)
*=90% CI
**=95% CI
PM PEFR (l/min)
*=90% CI
**=95% CI
28 weeks
Adverse event related to
treatment (% patients)
Combination
Concurrent
FP alone
FP plus SLM
concurrent
-3 (4.3)
-10, 4*
P=.535
-6 (4.3)
-13, 1*
P=.160
17%
14%
19%
FP
-21 (4.4)
-29, -12**
P<.001
-21 (4.3)
-29, -12**
P<.001
· Mean age 46 and female 43%,
FEV1 2.44L in FP + SLM combo
group; mean age 48 and female
50%, FEV1 2.32L in FP + SLM
concurrent group; mean age 50
and female 47%, FEV1 2.33L in FP
group
· Little detail on randomisation,
concealment and blinding
methodology
· Post-randomization 100 patients
withdrew, 19% of combo group,
16% of concurrent group and 25%
from FP group
· Pharmaceutical company
funded and supported trial
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Table 18: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Condemi
et al. 1999)
RCT
Grade 1+
Country:
United
States
Fluticasone mdi
88 mg bd +
Salmeterol mdi 42
mg bd
V
Fluticasone mdi
220 mg bd
2-4 weeks
pre-trial:
Fluticasone
88 mg bd and as
needed
salbutamol
Treatment
24 weeks
Inclusion:
Age 12-75 yrs
FEV1 40-65%PV
or 65-85%PV plus one or
more of:
³4 puffs salbutamol daily, 2
days AM/PM PEFR
variance ³20%, 2+ nights
asthma awakenings, 2+
days symptom score ³2
Exclusion:
Current tobacco use
Hospital asthma admission
previous month
437 24 weeks
(cf. baseline) (se)
(Change)
AM PEFR L/min
FEV1 (L)
Symptom free days %
Rescue salbutamol use
(Mean no.  puffs daily)
FP plus SLM
+46.5(3.5)
0.43 (0.04)
+26%
-2.51(0.17)
FP
+23.8(3.2)
0.33 (0.03)
+10%
-1.55(0.15)
P value
P<.001
P=.013
P<.001
P<.001
· Mean age 37 and female 62%,
FEV1 2.12L in FP + SLM  group;
mean age 37and female 60%,
FEV1 2.14L in FP group
· No detail on randomisation
methodology
· Pharmaceutical company
funded and supported trial
· Study drop out rate 9% in FP +
SLM group 14% in FP group
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Table 18: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Kavuru et
al. 2000)
RCT
Grade 1+
Country:
United
States
Fluticasone  100
mg plus salmeterol
50 mg bd Diskus
inh
V
Salmeterol 50 mg
bd Diskus inh
V
Fluticasone  100
mg bd Diskus inh
V
Placebo inh bd
12 weeks
Inclusion:
Age 12-70 yrs
Patients with FEV1 40-
85%PV and ±15% of the
screening FEV1
Either ICS previous 12
weeks and dose (either
BDP 252-420mg daily,TAA
600-1000 mg daily, FP 176
mg daily) previous 4 weeks
OR SLM 1+ weeks prior
Exclusion:
ICS group and 12+ puffs
salbutamol daily for 3+
days or SLM group 6+ puffs
daily or 3+ days
3+ nighttime awakenings
previous 7 days req
salbutamol
Smoker previous 12 months
>10 pack years smoker
356 12 weeks
(cf. baseline)
FEV1 (L) mean change (se)
Asthma symptom score
mean change (se)
% days no symptoms
mean change (se)
Adverse event related to
treatment (% patients)
(cf. baseline)
FEV1 (L) mean change (se)
Asthma symptom score
Mean change (se)
% days no symptoms
mean change (se)
Adverse event related to
treatment (% patients)
(cf. baseline)
FEV1 (L) mean change (se)
Asthma symptom score
Mean change (se)
% days no symptoms
mean change (se)
Adverse event related to
treatment (% patients)
FP plus SLM
0.51(0.05)
-0.7(0.11)
22.6(4.59)
3%
FP plus SLM
0.51(0.05)
-0.7(0.11)
22.6(4.59)
3%
FP plus SLM
0.51(0.05)
-0.7(0.11)
22.6(4.59)
3%
SLM
0.11(0.06)
-0.1(0.1)
8.0(3.29)
35%
FP
0.28(0.05)
-0.2(0.09)
7.2(4.09)
11%
Placebo
0.01(0.07)
0.4(0.10)
-3.8(3.01)
49%
P Value
P£.013
P£.013
P£.013
N/A
P<.001
P£.025
P£.025
N/A
P£.027
P£.013
P£.013
N/A
· Mean age 38 and female 41%,
no completing study 83% in FP +
SLM group; mean age 37 and
female 49%, completion rate 56%
in SLM group; mean age 39 and
female 48%, completion rate 74%
in FP group; mean age 35 and
female 49%, completion rate 34%
in placebo group
· Post-randomization, 21 patients
from one site excluded because
of poor practice standards. ITT
analysis excludes these, small
difference (non-quantified) in
results if included.
· Pharmaceutical company
funded and supported trial
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Table 18: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design and
evidence
grading
Intervention
comparison
and study duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(van Noord
et al. 1999)
RCT
Grade 1-
Country:
Netherlands
Low steroid requirement:
Fluticasone inh (100 mg bd
open) + Fluticasone inh (100 mg
bd blind)
OR
Fluticasone inh (100 mg bd
open) +
Salmeterol inh (50 mg bd blind)
V
High steroid requirement:
Fluticasone inh (250 mg bd
open) + Fluticasone inh (250 mg
bd blind)
OR
Fluticasone inh (250 mg bd
open) +
Salmeterol inh (50 mg bd blind)
Run in: 4 weeks
Treatment:
12 weeks
Inclusion:
Age 12-75 yrs
FEV1 ³ 50%PV
10+% increase in FEV1 PV
with
400mg salbutamol mdi or
800 mg inh (3 visits or pre-
run in period 4 weeks)
Daily symptom score ³1, or
diurnal var in PEFR 15+%, or
rescue salbutamol 2+ times
daily on 4/14 days run in
period
Exclusion:
Change in asthma
medication previous 6
weeks
OCS previous 3 months
274 12 weeks
PEFR L/min (mean increase
cf. baseline) (se)
AM
PM
FEV1 (L) visit 4 (4 weeks)
             visit 5 (12 weeks)
Odds Ratios
(FP high dose plus SLM
relative to FP low dose plus
SLM)
Rescue salbutamol use
                          Day
                          Night
Days with symptoms
FP
low dose
plus SLM
+18.6
(3.8)
+16.2
(4.0)
2.53 (0.8)
2.47 (0.8)
FP
High dose
plus SLM
N/A
N/A
2.45 (0.8)
2.48 (0.9)
1.47
2.19
1.52
P value
P<.001
P<.001
P=.04
P=.18
P=.03
P<.001
P=.04
· Mean age 46 and female 53%,
FEV1 (mean L) 2.33 in FP low
dose + SLM  group; mean age
47 and female 51%, FEV1 (mean
L) 2.34 in FP high dose group
· High and low steroid
requirements determined pre-
study and at run-in
· No detail on randomisation,
blinding and concealment
methodology
· Intention to treat based analysis
not evident. Study drop out rate
4% in FP low dose + SLM group
7% in FP high dose group
· Several key study results lack
data detail
· Pharmaceutical company
funded and supported trial
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Table 18: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Jenkins et
al. 2000)
RCT
Grade 1+
Country:
9 countries
Salmeterol disk
inh 50 mg +
Fluticasone  disk
inh 250 mg +
placebo turb inh
bd
V
Budesonide turb
inh 800 mg +
placebo disk inh
bd
24 weeks
Inclusion:
Age 14-80 yrs
4+ weeks pre-study:
FEV1 or PEFR³
50-85%PV
15+% increase in FEV1 or
mean AM PEFR£85% after
b-agonist
Salbutamol 2+ times daily
2+ daytime symptom score
on 4+/7 days
Exclusion:
Asthma requiring
hospitalization previous 4
weeks
Smoker
³10 pack years smoker
353 24 weeks
adjusted mean over
treatment period (se)
AM PEFR L/min
PM
Median % symptom-free days
Adverse events related to
treatment (% patients)
FP plus SLM
406 (3.67)
416 (3.14)
60%
14%
BDP
380 (3.81)
398 (3.25)
34%
19%
P value
P<.001
P<.001
P£.001
N/A
NNT
4
NNH
20
· Mean age 45 and female 50%,
FEV1 (mean% PV) 68 in FP + SLM
group; mean age 48 and female
50%, FEV1 (mean% PV) 72 in BDP
group
· International based study (9
countries)
· Little detail on randomisation,
blinding and concealment
methodology
· Pharmaceutical company
funded and supported trial
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Table 18: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Pearlman
et al. 1999)
RCT
Grade 1-
Country:
United
States
Placebo mdi bd
V
Salmeterol mdi 42
mg bd
V
Fluticasone mdi
88 mg bd
V
Fluticasone mdi
220 mg bd
V
Salmeterol mdi 42
mg bd +
Fluticasone mdi
88 mg bd
V
Salmeterol mdi 42
mg bd +
Fluticasone mdi
220 mg bd
4 weeks
Inclusion:
Age 12-62 yrs
FEV1 50-80%PV
15+% increase in FEV1 15
min after 180 mg
(2 puffs) salbutamol
Daily or as needed b-
agonists previous 6 months
Exclusion:
Smoker previous 12 months
>10 pack years
O/I/IVCS previous 1 month
Daily OCS previous 6
months
136 4 weeks
Placebo
SLM (42mg )
FP (88mg)
FP (220mg),
SLM (42mg) + FP (88mg)
SLM (42mg) + FP (220mg)
* vs placebo
^ vs SLM 42mg, FP 88mg and
FP220mg
Asthma symptom score
Placebo
SLM (42mg )
FP (88mg)
FP (220mg),
SLM (42mg) + FP (88mg)
SLM (42mg) + FP (220mg)
* vs placebo
^ vs FP 88mg
Baseline
FEV1 (L)
2.39 (0.13)
2.75 (0.1)
2.91 (0.13)
2.52 (0.14)
2.31 (0.12)
2.62 (0.12)
Baseline
1.3 (0.2)
1.3 (0.2)
1.2 (0.1)
1.3 (0.2)
1.2 (0.2)
1.1 (0.2)
Endpoint
mean
change
FEV1 (L)
0 (0.09)
0.29 (0.12)
0.27 (0.07)
0.30 (0.09)
0.59 (0.10)
0.75 (0.16)
Mean
change
-0.2 (0.2)
-0.5 (0.1)
-0.1 (0.1)
-0.3 (0.1)
-0.8 (0.2)
-0.4 (0.1)
P value
P£.05*
P<.05*^
P<.05*^
P<.05*
P<.05*^
· Poor comparative baseline
demographics between groups
· Placebo N=23, mean age 35 and
female 57%, Non-Caucasian 9%
· SLM (42mg ) N=21, mean age 29
and female 33%, Non-Caucasian
0%
· FP (88mg) N=23, mean age 27
and female 26%, Non-Caucasian
0%,
· FP (220mg), N=23, mean age 32
and female 43%, Non-Caucasian
9%
· SLM (42mg) + FP (88mg) N=25,
mean age 33 and female 60%,
Non-Caucasian 16%
· SLM (42mg) + FP (220mg) N=21,
mean age 26 and female 33%,
Non-Caucasian 19%
· Pharmaceutical company
funded and supported trial
· Study drop out rate 4% in FP low
dose + SLM group, 7% in FP high
dose group
· Several key study results lack
data detail
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Table 18: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Weersink et
al. 1997)
RCT
Grade 1-
Country:
Netherlands
Salmeterol mdi 50
mg bd
V
Fluticasone  mdi
250 mg bd
V
Fluticasone  mdi
250 mg bd +
salmeterol mdi 50
mg bd
Methacholine
challenge (MCh)
Or
Adenosine
5’mono-
phosphate
challenge (AMP)
To FEV1 PC20 or
MCh (19.6mg/ml)
or AMP
(640mg/ml)
6 weeks
Inclusion:
Age 18-45 yrs
Circadian variation in
PEFR15+%
BHR to MCh PC20 <9.6
mg/ml
IgE elevated to house dust
mite (RAST³2)
Short-acting b-agonist on
demand previous 4 weeks
Exclusion:
Smoker
Acute asthma
exacerbation, OCS
previous 8 weeks
ICS previous 4 weeks
50 6 weeks
Mean Circadian PEFR
variation 100*(highest-lowest
24-h value)/mean 24-h value
per day over 3 days
Baseline
End of period
FEV1 (L) (%PV increase cf.
baseline)
4 PM  (se)
4 AM  (se)
PC20 MCh (se)
4 PM
4 AM
SLM
22.4%
9.1%
+10.8%
(2.4)
+19.6%
(3.6)
+1.5(0.5)
+2.4(0.5)
FP
24.0%
7.9%
+7.6%
(3.4)
+15.9%
(3.0)
+2.1(0.5)
+3.0(0.5)
SLM+FP
24%
10%
+5.9%
(3.8)
+17.9%
(3.8)
2.5(0.6)
2.9(0.8)
P Value
Between
n.s.
Within
P<.0001
Between
P=.2
Within
P=.0001
Between
times
P=.0005
PC20 MCh
Between
P=.04
Within
P<.0001Bet
ween
times
P=.1
· Mean age 28 and female 50%,
FEV1 77%PV, in SLM group; mean
age 28 and female 56%, FEV1
88%PV, in FP group; mean age 26
and female 50%, FEV1 83%PV, SLM
+ FP group
· Baseline differences post-
randomisation
· Patients recruited from 1
outpatient clinic and newspaper
advertisements
· No intention to treat analysis, 4
treated patients not included in
analysis
· Pharmaceutical company
funded and supported trial
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Table 18: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Murray et
al. 1999)
RCT
Grade 1+
Country:
United
States
Beclomethasone
mdi 168 mg bd +
salmeterol mdi 42
mg bd
V
Beclomethasone
mdi 336 mg bd
24 weeks
Inclusion:
Age 18-82 yrs
FEV1 45-80%PV
12+% increase in FEV1 PV
with 180 mg salbutamol
Symptomatic while taking
336 mg beclomethsone or
800 mg triamcinolone daily
Constant immunotherapy
ok if 12+ weeks
Exclusion:
Patients on other asthma
medication except
theophylline, as needed
salbutamol and asthma
exacerbation medication
514 24 weeks
FEV1 (L) baseline
             24 weeks
(cf. BDP)
Symptom score (mean
change cf. baseline at 24
weeks)
Wheeze
Shortness of breath
Chest tightness
Asthma exacerbations %
patients
BDP + SLM
2.30
2.68
-0.49
-0.71
-0.62
17%
BDP
2.31
2.54
-0.27
-0.25
-0.33
18%
P value
P<.05
P£.05
P£.05
P£.05
n.s.
· Mean age 42 and female 59%,
FEV1 65%PV in BDP + SLM  group;
mean age 42 and female 55%,
FEV1 64%PV in BDP dose group
· Pharmaceutical company
funded and supported trial
· Several key study results
(salbutamol use, drug safety) lack
data detail
· Unclear if intention to treat
analysis used
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Table 18: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Kelsen et
al. 1999)
RCT
Grade 1+
Country:
United
States
Beclomethasone
mdi 168 mg bd +
Salmeterol
mdi 42 mg bd
V
Beclomethsone
mdi 336 mg bd
Run-in:
2 weeks
Treatment:
24 weeks
Inclusion:
Age 18-77 yrs
FEV1 45%-80%PV
³12% increase in FEV1 after
180 mg salbutamol
³3/7 days symptoms,
rescue medication in
previous week
ICS 336 mg daily BDP or 800
mg daily 2 weeks prior
Non-smoker
483 24 weeks
(mean change over
treatment period)
Mean AM PEFR L/min
Baseline L/min
Treatment period L/min
Mean PM PEFR L/min
Baseline L/min
Treatment period L/min
% of symptom free days
Mean change over 24 weeks
(se)
% nights with no awakenings
(baseline) (se)
mean change
% nights no salbutamol use
baseline (se)
mean change
n and % patients reporting
exacerbations
n and % patients with drug
related adverse events
BEC+
SLM
389.7
N/A
N/A
37.5
23.6%
67.0 (2.3)
18.8 (1.7)
60.2 (2.5)
23.2 (2.0)
38 (16%)
26 (11%)
BEC
390
N/A
N/A
14.8
12.5%
68.0 (2.2)
13.4 (1.6)
60.4 (2.4)
14.7 (1.9)
44 (18%)
34 (14%)
P value
P<.001
P<.001
P£.05
N/A
P£.05
N/A
P£.05
N/A
N/A
NNT
9
· Mean age 42 and female 57%,
FEV1 65%PV in BEC+SLM group;
mean age 42 and female 65%,
FEV1 64%PV in BEC group
· Of the 483 patients randomized
20.1% did not complete study.
Dropout rates 20% in each
treatment arm. Results use ITT
based analysis
· Some primary PEFR data values
are not reported, only p values
given
· Pharmaceutical company
funded and supported trial
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Table 18: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Nathan et
al. 1999)
RCT
Grade 1+
Country:
United
States
Salmeterol mdi 42
mg bd
V
Beclomethasone
mdi 84 mg Qid
V
Placebo mdi bd
Methacholine
challenge (MCh)
To FEV1 PC20 or
MCh 75 (mg/ml)
in neb
26 weeks
Inclusion:
Age 12+ yrs
FEV1 65-90%PV
12+% increase in FEV1
within 30 min of 180 mg
salbutamol mdi
Daily/as needed b-agonists
with no I/OCS previous 6
months
Exclusion:
Decline in FEV1 of
³ 15% after saline
inhalation
Asthma requiring
hospitalization previous 4
weeks
386 26 weeks
mean increase (se) over
treatment period
FEV1 (L)
Salbutamol free nights (mean
% increase)
Mean increase PD20
MCh (se)
Week 14
Week 26
SLM
0.28 (0.04)
23%
1.39 (0.24)
1.29 (0.26)
BEC
0.23 (0.04)
23%
1.57 (0.26)
1.42 (0.24)
Placebo
0.08 (0.04)
9%
0.16 (0.22)
0.24 (0.29)
P value
cf.
placebo
P£.014
P£.014
P<.001
P£.033
· Mean age 31 and female 54%,
FEV1 79%PV, AM PEFR(L/min) 405
in SLM group; mean age 30 and
female 57%, FEV1 78%PV,
PEFR(L/min) 394 in BDP group;
mean age 29 and female 50%,
FEV1 81%PV, PEFR(L/min) 417 in
placebo group
· Significantly higher baseline AM
PEFR in placebo group
· ITT analysis but 81/368 (22%)
withdrawals. Across treatment
arms 23% SLM, 18% BEC, 22% PLC
groups
· Data for some primary outcomes
not shown
· Pharmaceutical company
funded and supported trial
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Table 18: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Vermetten
et al. 1999)
RCT
Grade 1-
Country:
Netherlands
Beclomethasone
D-inh 200 mg bd +
Salmeterol
D-inh 50 mg bd
V
Beclomethasone
diskinh
400 mg bd
Run-in:
2 weeks
Treatment:
12 weeks
Inclusion:
Age 18-66 yrs
6+ weeks prior:
ICS BEC/BDP
200-400 mg daily
³15% reversibility in PEF
Exclusion:
Asthma exacerbation
requiring change to
medication in run-in period
233 12 weeks
(average of last 2 weeks of
treatment period)
Mean AM PEFR L/min
Baseline L/min
Treatment period L/min
Mean PM PEFR L/min
Baseline L/min
Treatment period L/min
Diurnal variation in PEFR%(se)
Baseline
Treatment period
(proportion of days with)
Asthma symptoms
Day        Baseline  period
Day        Treatment period
Night      Baseline period
Night      Treatment period
Av. No. of blisters per day of
rescue medication-baseline
                        Treatment
Av. No. of blisters per night of
rescue medication-baseline
                        Treatment
BEC+
SLM
404
N/A
431
N/A
9.5% (0.8)
6.6% (0.6)
0.56 (0.04)
0.37 (0.04)
0.43 (0.04)
0.33 (0.04)
0.88 (0.09)
0.48 (0.07)
0.47 (0.06)
0.30 (0.06)
BEC
390
N/A
413
N/A
8.8% (0.6)
7.2% (0.7)
0.54 (0.03)
0.38 (0.04)
0.41 (0.03)
0.34 (0.04)
0.84 (0.09)
0.61 (0.10)
0.47 (0.05)
0.37 (0.06)
P value
P=.066
P=.036
n.s.
n.s.
n.s.
P<0.05
n.s.
· Mean age 42 and female 47%,
AM PEFR(l/min) 404, PM PEFR 431
in BEC+SLM group; mean age 42
and female 62%, AM PEFR(l/min)
390, PM PEFR 413 in BEC group
· Differences in baseline
demographics for % female and
AM/PM PEFR values
· Of the 233 patients randomized
202 completed study. Whether or
not ITT analysis not specified. No
detail on randomisation, blinding
and concealment methodology.
· Treatment endpoints are
averages over the last 2 weeks.
· Some primary PEFR data values
are not reported, only p values
given
· Pharmaceutical company
supported trial
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Table 18: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Pauwels
et al. 1997)
RCT
Grade 1+
Country:
9 countries
Run-in period:
Budesonide inh
800 mg  bd
terbutaline 250 mg
inh as needed
Treatment:
Budesonide inh
100 mg bd  +
placebo inh bd
V
Budesonide 100
mg inh bd +
formoterol inh 12
mg bd
V
Budesonide inh
400 mg bd +
placebo inh bd
V
Budesonide 400
mg inh bd +
formoterol inh 12
mg bd
terbutaline 250 mg
inh rescue
medication
Run-in:
4 weeks
Treatment:
52 weeks
Inclusion:
Age 18-70 yrs
Patients with FEV1 ³ 50%PV
and
15+% increase from
baseline FEV1 after
inhalation of 1 mg
terbutaline
Exclusion:
Patients taking 2000+ mg
daily beclomethasone or
1600+ mg daily mdi or 800+
mg daily budesonide inh
3+ courses OCS or
asthma requiring
hospitalization previous 6
months
852 52 weeks
Yearly rate of asthma
exacerbations (no/patient/yr)
Severe
Mild
Episode free days (mean % of
year)
Asthma symptom score Day
Night
Rescue medication during
day no of inhalations
Yearly rate of asthma
exacerbations (no/patient/yr)
Severe
Mild
Episode free days (mean % of
year)
Asthma symptom score
Day
Night
Rescue medication during
day (no of inhalations)
Low dose
BDP +
placebo
0.91
35.4
41.7%
0.57
0.37
0.91
Low dose
BDP + FRM
0.67
21.3
51.1%
0.46
0.31
0.57
P Value
Higher vs
lower dose
of BDP
P<.001
P<.001
P=.16
P=.01
P=.01
P<.001
High dose
BDP +
placebo
0.46
22.3
45.7%
0.53
0.38
0.82
High dose
BDP+ FRM
0.34
13.4
54.8%
0.33
0.20
0.44
· Mean age 42 and female 49%,
FEV1 76 in low BDP + placebo
group; mean age 41 and female
50%, FEV1 76 in low BUD + FRM
group; mean age 44 and female
52%, FEV1 76 in high BDP +
placebo group; mean age 42
and female 53%, FEV1 76%PV high
BUD + FRM group
· International based study (9
countries)
· Post-randomisation, 158 patients
did not complete study, 44 of
these did not fulfil the entry
criteria and were incorrectly
randomised. Whether ITT analysis
not clearly defined
· Pharmaceutical company
funded and supported trial
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Table 18: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Juniper et
al. 1999)
RCT
Grade 1-
Country:
5 countries
Run-in period:
Budesonide inh
800 mg  bd
terbutaline 250 mg
inh as needed
Treatment:
Budesonide inh
100 mg bd  +
placebo inh bd
V
Budesonide 100
mg inh bd +
formoterol inh 12
mg bd
V
Budesonide inh
400 mg bd +
placebo inh bd
V
Budesonide 400
mg inh bd +
formoterol inh 12
mg bd
Terbutaline 250
mg inh rescue
medication
Run-in:
4 weeks
Treatment:
52 weeks
Inclusion:
Age 18-70 yrs
Patients with FEV1 ³ 50%PV
and
15+% increase from
baseline FEV1 after
inhalation of 1 mg
terbutaline
IGS previous 3+ months
with patients taking <2000
mg daily beclomethasone
or <1600 mg daily mdi or
<800 mg daily budesonide
inh
470 52 weeks
AQLQ total score change
High dose
BDP+ FRM
0.21
P Value
Cf. other
groups
P=.028
NNT
(provided
Result)
11.9
· Mean age 42 and female 51% in
low BDP + placebo group; mean
age 42 and female 48% in low
BDP + FRM group; mean age 44
and female 51% in high BDP +
placebo group; mean age 44
and female 59% in high BDP +
FRM group
· International based study (9
countries)
· Earlier study acknowledgement
to (Pauwels et al. 1997) This
study’s primary outcome
measure is asthma quality of life
assessment using AQLQ. Clinical
results previously reported in
earlier study
· Post-randomisation, 114/470
(24%) of patients did not
complete study after 52 weeks.
4/470 patients did not fill in AQLQ
at baseline are excluded from
analysis
· Insufficient data detail for analysis
of AQLQ results
· Pharmaceutical company
funded and supported trial
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Table 18: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Kips et al.
2000)
RCT
Grade 1-
Country:
Canada,
England,
Belgium
Run-in period:
Budesonide inh
800 mg  bd
terbutaline 0.25
mg inh as
needed
Budesonide 100
mg inh bd +
formoterol inh 12
mg bd
V
Budesonide inh
400 mg bd +
placebo inh bd
Run-in:
4 weeks
Treatment:
52 weeks
Inclusion:
Age 18-70 yrs
Patients with FEV1  ³ 50%PV
and
15+% increase from
baseline FEV1 after
inhalation of 1 mg
terbutaline
Exclusion:
Patients taking 2000+ mg
daily beclomethasone or
1600+ mg daily mdi or 800+
mg daily budesonide inh or
800+ mg daily fluticasone
inh
3+ course OCS or
asthma requiring
hospitalization previous 6
months
60 52 weeks
Yearly rate of asthma
exacerbations (no/patient/yr)
Severe (se)
Mild (se)
Episode free days (mean % of
year) (se)
Mean AM PEFR L/min
Mean PM         L/min
BDP + FRM
0.29 (0.14)
18.3 (6.92)
41.3%
(7.0)
N/A
N/A
BDP +
placebo
0.47 (0.24)
14.6 (5.42)
30.4%
(6.0)
N/A
N/A
P value
n.s.
n.s.
n.s.
n.s.
n.s.
P<.05
· Mean age 35 and female 59%,
ICS mg daily 676, FEV1 L start run-in
2.87, end run-in 2.93 in BDP + FRM
group; mean age 38 and female
61%, ICS mg daily 706.5, FEV1 L
start run-in 2.52, end run-in 2.71 in
BDP + placebo group
· Differences in baseline FEV1
(lower in BDP+ placebo group),
ICS usage higher here also. Not
significant according to study
· International based study (3
countries)
· Primary efficacy outcome
markers of airway inflammation in
induced sputum. Only secondary
outcomes appraised. Lung
function data detail not reported
· Whether ITT analysis not clearly
defined. No information on study
drop out rates during treatment
· Pharmaceutical company
funded and supported trial
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Table 18: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus inhaled steroids) in chronic asthma (continued)
Study
source,
design and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Crompton
et al. 1999)
RCT
Grade 1+
Country:
3 European
countries
Bambuterol po
10 mg nocte (1
week) 20 mg
nocte (5 weeks)
+ placebo mdi
V
Salmeterol
mdi   50 mg bd +
placebo
Run-in:
2 weeks
Treatment:
6 weeks
Inclusion:
Age 18+ yrs
4+ weeks prior:
ICS BDP/BEC
800-2000 mg daily other
than with turbuhaler
or FP/BUD 400-2000 mg
daily via turbuhaler
or OCS such as prednisone
at £ 20 mg daily
³1 nocturnal/early morning
awakening req rescue
medication
³15% decr in overnight
PEFR on 3/7 days
preceding entry
Exclusion:
Asthma requiring
hospitalization
Previous 4 weeks
135 6 weeks
Median AM PEFR L/min
Baseline L/min
Treatment period L/min
Change from baseline
Median change (cf. baseline)
Evening PEFR L/min
Percent overnight fall in
PEFR%
Percent nights an awakening
%
No.  puffs rescue medication
during day
No.  puffs rescue medication
during night
Asthma symptoms, day
                           night
BMB
276
310
50
12
-11%
-21%
-0.33
-0.28
-0.17
-0.32
SLM
272
327
55
3
-14%
-29%
-0.57
-0.26
-0.11
-0.32
P value
N/A
N/A
P=.53
P=.82
P=.17
P=.22
P=.24
P=.88
P=.48
P=.57
· Mean age 41 and female 60%,
FEV1 66%PV in BMB group; mean
age 41 and female 56%, FEV1
68%PV in SLM group
· International based study (3
countries)
· Of the 135 patients randomized
118 completed study. Of the
total, 126 patients were
considered valid and are
included in the analysis. Not strict
ITT analysis
· Treatment endpoints are
calculated during weeks 3 to 6
Both median and mean values
calculated and appropriate
statistical measures used
· Pharmaceutical company
funded and supported trial
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Table 19: Summary of studies investigating the effect of pharmaceuticals (inhaled steroids versus leukotriene antagonists) in chronic asthma
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Malmstrom et
al. 1999)
RCT
Grade 1+
Country:
Multinational
Beclomethasone
inh 200 mg bd
V
Montelukast po
10 mg nocte
V
Placebo
12 weeks
Inclusion:
Age ³ 15 yrs
FEV1 50-85%PV
Nonsmoker
Exclusion:
Pharmaceutical limitations
895
% D am FEV1
% D daytime symptom score
% D nocturnal awakenings
(n/wk)
Asthma attacks (% patients)
BEC
13.1
-0.62
-2.4
10.1
MNT
7.4
-0.41
-1.7
15.6
95%CI (diff)
3, 8.5
-0.33, -0.09
-1.08, -0.32
P value
P<0.05
NNT
18
· Median age 35 and female 61%
· Mean FEV1 65%PV
· Pharmaceutical company
funded and supported trial
· Baseline differences in gender
mix between interventions which
were of uncertain significance
· Unclear whether ITT analysis was
used
(Bleecker et al.
2000)
RCT
Grade 1+
Country:
United States
Fluticasone inh 88
mg bd
V
Zafirlukast po 20
mg bd
12 weeks
Inclusion:
Age ³12 yrs
FEV1 50-80%PV
Exclusion:
History of life threatening
asthma
Use of tobacco in past year
or >10 pack-years total
Resp infection within 2
weeks of screening
Pharmaceutical limitations
451
D am FEV1 (L)
D symptom free days (%)
D rescue free days (%)
D nights with no awakenings
(%)
FP
0.42
28.5
40.4
21.2
ZAF
0.2
15.6
24.2
8.0
P value
P<0.001
P<0.001
P<0.001
P<0.001
NNT
8
6
8
· Mean age 41 and female 50%
· Mean FEV1 68%PV
· Supported by fluticasone
producers
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Table 19: Summary of studies investigating the effect of pharmaceuticals (inhaled steroids versus leukotriene antagonists) in chronic asthma ( onti ued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Westbroek and
Pasma 2000)
CO
Grade 1+
Country:
Netherlands
Fluticasone inh
100 mg bd
V
Zafirlukast po 20
mg bd
2 weeks each
Inclusion:
Age 18-70 yrs
FEV1 ³ 50%PV
Non smoker
Exclusion:
Resp infection or asthma
admission within a month of
screening
Pharmaceutical limitations
30
PC20 histamine (mg/ml)
AM PEFR (L/min)
FP
1.61
409
ZAF
0.99
391
95%CI (diff)
0.05, 1.50
-0.08, 35.3
· Mean age 45 and female 70%
· Financial support from producers
of fluticasone
· No comparison of asthma
severity at baseline
· Adequate concealment could
not be determined
(Laviolette et al.
1999)
RCT
Grade 1+
Country:
18 countries
Montelukast po
10 mg nocte +
beclomethasone
inh 200 mg bd
V
Beclomethasone
inh 200 mg bd
V
Montelukast po
10 mg nocte
V
Placebo
Inclusion:
Age ³15 yrs
FEV1 50-85%PV
Non-smoker
Exclusion:
Resp infection within 3
weeks of screening
Pharmaceutical limitations
642
% D am FEV1
D daytime asthma symptom
score
D night awakenings (n/week)
Asthma attacks (% patients)
BEC/MNT
5.08
-0.13
-1.04
6.2
BEC
0.72
-0.02
-0.45
12.0
P value
P < 0.001
P = 0.04
P = 0.01
P = 0.06
· Mean age 39 and female 51%
· Mean FEV1 72%PV
· Other study comparisons not
presented in full
· Baseline differences in placebo
group from other interventions
· Pharmaceutical company
funded and supported trial
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Table 20: Summary of studies investigating the effect of pharmaceuticals (inhaled steroids versus short-acting beta-agonist) in chronic asthma
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Hancox et al.
1999b)
CO
Grade 1+
Country:
New Zealand
Budesonide inh
400 mg bd +
terbutaline inh
1000 mg Qid
V
Budesonide inh
400 mg bd
V
Terbutaline inh
1000 mg Qid
V
Placebo
6 weeks each
Inclusion:
Age 9-64 yrs
Exclusion:
Current or ex cigarette
smoker (>5 pack years)
Pharmaceutical limitations
61
D AM PEFR (cf. BDP)
95%CI
D am PEFR (cf. TER)
95%CI
Night awakening (%)
P value
Rescue medication use
(puffs/day)
P value
BDP/TEB
14
5,23
27
17,37
1.9
n.s.
0.3
n.s.
BDP
3.4
n.s.
0.5
n.s.
TEB
4.0
n.s.
0.5
n.s.
· Mean age 27 and female 69%
· Participants able to tolerate the
withdrawal of inh steroid
· Pharmaceutical company
involved in supplying inhalers and
supporting the lead author
· No baseline comparison post-
randomisation
(Aldridge et al.
2000)
CO
Grade 1+
Country:
New Zealand
Budesonide inh
400 mg bd +
terbutaline inh
1000 mg Qid
V
Budesonide inh
400 mg bd
V
Terbutaline inh
1000 mg Qid
V
Placebo
6 weeks each
Inclusion:
Age 16-64 yrs
FEV1 > 50%PV
Exclusion:
Current or ex-cigarette
smoker (>5 pack years)
Pharmaceutical limitations
34
AM PEFR (L/min)
Daytime wheeze (% days
present)
Nighttime wheeze (% days
present)
Rescue med use (Median %
days used)
1Combined versus BDP,
2combined versus TEB,
3BDP versus TEB
BDP/TEB
491
P =.0011
P < .0012
4
n.s.1
P = .022
3
n.s.1
P = .0032
0
P =.051
n.s.2
BDP
469
P = 0.043
9
n.s.3
4
n.s.3
0
n.s.3
TEB
450
18
12
0
· Mean age 39 and female 47%
· Mean FEV1 90%PV
· No baseline comparison post-
randomisation
· 82% of participants randomised
were analysed
· Pharmaceutical company
involved in supplying inhalers and
supporting the lead author
· Selected from participants in
(Hancox et al. 1999b)
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Table 20: Summary of studies investigating the effect of pharmaceuticals (inhaled steroids versus short-acting beta-agonist) in chronic asthma (conti ued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Hancox et al.
1999a)
CO
Grade 1-
Country:
New Zealand
Budesonide inh
400 mg bd +
terbutaline inh
1000 mg Qid
V
Budesonide inh
400 mg bd
V
Terbutaline inh
1000 mg Qid
V
Placebo
6 weeks each
Inclusion:
Age 16-64 yrs
Exclusion:
Current or ex-cigarette
smoker (>5 pack years)
Pharmaceutical limitations
34
% fall FEV1 post methacholine
(95%CI)
BDP/TEB
25.9
(22.2, 28.2)
BDP
26.1
(22.3, 28.3)
TEB
26.9
(24.4, 28.5)
· Female 47%
· Mean FEV1 90%PV
· No baseline comparison post-
randomisation
· 76% of participants randomised
were analysed
· Pharmaceutical company
involved in supplying inhalers and
supporting the lead author
· Selected from participants in
(Hancox et al. 1999b)
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Table 21: Summary of studies investigating the effect of pharmaceuticals (cromoglycate versus inhaled steroid) in chronic asthma
Study
source,
design
and
evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Hoshino et
al. 1998)
RCT
Grade 1+
Country:
Japan
Ketotifen po
1 mg bd
V
Disodium
cromoglycate
(DSCG) inh
2 mg Qid
V
Beclomethasone
inh 100 mg Qid
12 weeks
Inclusion:
Age 16-50 yrs
20+% increase in FEV1 or
PEFR
Daily/as needed b-agonists
with no I/OCS previous 6
months
Exclusion:
FEV1 PV < 50%
Smoker
I/OCS or DSCG in previous
4 months
32 12 weeks
Asthma symptoms
Median FEV1 (%PV)
Before
After
Median PEFR(L/min)
Before
After
Ketotifen
72.0
80.0
n.s.
450
500
n.s.
DSCG
63.2
72.5
P<.05
350
450
P<.01
BDP
66.0
74.3
P<.05
425
475
P<.01
P value
DSCG v
Ketotifen
P<.01
BDP v
Ketotifen
P<.05
DSCG v
Ketotifen
P<.05
BDP v
Ketotifen
P<.05
· N=13, mean age 27 and female
46%, FEV1 72%PV, PEFR(l/min) 450
in ketotifen group; N=9, age 26
and female 33%, FEV1 63%PV,
PEFR(l/min) 350 in DSCG group;
N=9, age 30 and female 30%,
FEV1 66%PV, PEFR(l/min) 425 in
BEC group
· Small numbers in study treatment
arms. Baseline differences in FEV1
PV% and PEF
· The study also included analysis
of fibreoptic bronchoscopy and
immunohistochemistry data
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Table 22: Summary of studies investigating the effect of pharmaceuticals (inhaled steroids versus inhaled steroids) in chronic asthma
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Raphael et al.
1999)
RCT
Grade 1+
Country:
United States
Fluticasone inh 88
mg bd, 220 mg bd
V
Beclomethasone inh
168 mg bd, 336 mg
bd
12 weeks
Inclusion:
Age ³ 12 yrs
FEV1 45 – 80%PV
Inh steroids 6 mths prior to
study
Exclusion:
Pharmaceutical
limitations
399
D FEV1 (L)
D Night awakenings
D % days with no symptoms
FP 88
0.31
P = .048 (cf.
Beclo168)
-0.03
n.s.
(cf. Beclo168)
14.0
P = .03
(cf. Beclo168)
BEC 168
0.18
-0.03
4.9
FP 220
0.36
P = .034 (cf.
Beclo336)
-0.12
n.s. (cf.
Beclo336)
8.7
P = .03 (cf.
Beclo336)
BEC 336
0.21
-0.07
4.4
· Mean age 39 and female
59%
· Mean FEV1 65%PV
· Financial support from the
producers of both drugs
(Pauwels et al.
1998)
CO
Grade 1+
Country:
Belgium
Fluticasone inh 0.5
BEC dose
V
Beclomethasone inh
1 mg, 1.5 mg, 2 mg
dose daily1
6 months on each
Inclusion:
Age 18-75 years
FEV1 ³ 40%PV
PO steroids for <6 weeks
during past year
Exclusion:
Change in asthma
medication, asthma
hospitalisation or resp
infection in past month
Pharmaceutical
limitations
340
Serum cortisol (mg%)
Serum osteocalcin (ng/ml)
D lumbar spine density (%)
QoL score
FP
13.3
1.72
1%
1.22
BEC
13.3
1.54
0%
1.20
P value
n.s.
P < .001
P = 0.05
P < 0.05
· Mean age 46 and female
42%
· Mean FEV1 80%PV
· Bone density measured in
61% of randomised
population
· Difference in duration of
inhaled steroid group
between the two study order
groups
· Supported by the producers
of fluticasone
· 1Dose set by response to run
in meds
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Table 22: Summary of studies investigating the effect of pharmaceuticals (inhaled steroids versus inhaled steroids) in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Egan et al.
1999)
RCT
Grade 1-
Country:
United Kingdom
Fluticasone inh 500
mg bd
V
Beclomethasone inh
1000 mg bd
2 years
Inclusion:
Age 18-50 years (Males),
18-40 years (Female)
Regular beclomethasone
or budesonide treatment
at 1000-2000 mg daily
33
Vertebral trabecular bone
mineral density (mg/cm3)
PEFR (L/min)
FP
161
431
BEC
148
513
Adjusted diff
(95%CI)
14 (1-26)
N/A
· Mean age 35 and female
52%
· Mean inhaled steroid dose
1390 mg daily
· 73% completed the study
· Mineral density assessed by
dual energy CT scan
· No statistical analysis of
difference in PEFR
· Study funded by fluticasone
producer
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Table 22: Summary of studies investigating the effect of pharmaceuticals (inhaled steroids versus inhaled steroids) in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Malo et al.
1999)
CO
Grade 1-
Country:
Canada
Fluticasone inh
(0.5 BEC dose) V
Beclomethasone
inh
4 mths each
Inclusion:
Age >18 yrs
FEV1 ³ 15% increase post
bronchodilator
Exclusion:
No po steroids continuously
for >1 year in the past 5
Tobacco use within 1 year
Pharmaceutical limitations
69
Asthma exacerbation (%)
³1 night awakening (%)
Cortisol change post cortrosyn
(mmol/dL)
Skin bruising score
Serum osteocalcin (ng/ml)
FP
13
22
422
1.24
3.5
BEC
12
14
357
1.64
2.8
P value
P = 0.4
P = 0.3
P = .005
P = .04
P = .003
· Mean age 48 and female 57%
· Mean FEV1 76%PV
· No baseline comparison post-
randomisation
· Concealment method not
described
· ITT analysis not clear
· Pharmaceutical company
producing fluticasone funded
and supported trial
(Heinig et al.
1999)
RCT
Grade 1+
Country:
4 countries
Fluticasone d-inh
2000 mg daily
V
Budesonide
turbuhaler 2000
mg daily
24 weeks
Inclusion:
Age 18-75 yrs
FEV1 ³ 15% increase post
bronchodilator
Exclusion:
Pharmaceutical limitations
395
Symptom free days (%)
Days free from rescue
medication use (%)
Participants with no asthma
exacerbation (%)
FP
31.5
42.7
60
BDP
22.8
33.7
68
P value
P = 0.02
P = 0.02
n.s.
NNT
11
11
· Mean age 48 and female 49%
· Supported financially by
producers of fluticasone
· Methods used to measure
outcomes poorly described
NEW ZEALAND HEALTH TECHNOLOGY ASSESSMENT: ASTHMA THERAPEUTICS
STEROIDS - CHRONIC ASTHMA
105
Table 22: Summary of studies investigating the effect of pharmaceuticals (inhaled steroids versus inhaled steroids) in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Ringdal et al.
2000)
CO
Grade 1-
Country:
Sweden,
Norway
Fluticasone inh
800 mg bd
V
Budesonide inh
800 mg bd
2 weeks each
Inclusion:
Age 18-75 yrs
FEV1 ³ 50%PV
Exclusion:
Resp infection within 4
weeks of visit 1
Pharmaceutical
limitations
48
AUC serum cortisol (nmol/L)
FP
783
BDP
791
P value
n.s.
· Mean age 50 and female
29%
· Mean FEV1 77%PV
· No information concerning
differences between groups
at baseline
· Staff employed by the
pharmaceutical company
producing fluticasone
included in the study
authors
(Steinmetz 1997)
RCT
Grade 1-
Country:
Germany
Fluticasone inh
250 mg bd
V
Budesonide inh
600 mg bd
6 weeks
Inclusion:
Age 18-70 years
FEV1 50-80%PV
Indication for treatment
with inh steroid but no use
of steroids within 3 weeks
of study commencement
457
D AM PEFR (L/min)
Days without asthma
symptoms
Patients with adverse events
judged as due to study
medication
FP
45
40
2
BDP
34
34
6
P value
P < 0.01
P < 0.05
n.s.
NNT
5
· Mean age 47 and female
51%
· Unblinded study
· No mention of
pharmaceutical company
involvement but the funding
source was not stated
(Berkowitz et al.
1998)
RCT
Grade 1+
Country:
United States
Beclomethasone
mdi   168 mg bd
V
Triamcinolone
mdi  with
extender 400 mg
bd
8 weeks
Inclusion:
Age 18-65 years
FEV1 50-90%PV
Exclusion:
Resp infection within 30
days
Admission to ICU for
asthma or admissions for
severe asthma
exacerbation in the past
Pharmaceutical
limitations
339
Patients having adverse
events (%)
D FEV1 (L)
BEC
50.0
0.27
TAA
57.4
0.22
P value
n.s.
n.s.
· Mean age 38 and female
63%
· Baseline difference in age
with older mean age in the
triamcinolone group
· Pharmaceutical company
funded and supported trial
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Table 22: Summary of studies investigating the effect of pharmaceuticals (inhaled steroids versus inhaled steroids) in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Bronsky et al.
1998)
RCT
Grade 1+
Country:
United States
Beclomethasone
inh 336 mg daily
V
Triamcinolone inh
800 mg daily
V
Placebo
8 weeks
Inclusion:
Age 18-65 years
FEV1 50-90%PV
Exclusion:
Smoking history
Resp infection within 30
days
Recurent admission for
severe asthma
exacerbation
Pharmaceutical limitations
328
% D FEV1
Mean D asthma score
BEC
11.95
-1.37
TAA
7.04
-0.58
P value
P = 0.08
P = 0.03
· Mean age 37 and female 53%
· Pharmaceutical company funded
and supported trial
· 75% of participants had outcomes
measured at 8 weeks.
(Bateman et al.
2000)
RCT
Grade 1-
Country:
Six countries
Triamcinolone
HFA inh 450 mg bd
V
Beclomethasone
CFC inh 500 mg
bd
12 weeks
Inclusion:
Age ³18 years
FEV1 60-90%PV
Exclusion:
History of life threatening
asthma
Recent hospitalisation or
acute exacerbation
requiring po steroid
Current smoker
Pharmaceutical limitations
284
% D AM PEFR
% D FEV1
D rescue med use (puffs/day)
D Night awakening
TAA
5.6
5.4
-0.67
-0.16
BEC
3.8
4.5
-0.11
-0.14
Diff
1.8
0.9
P value
P=0.04
P=0.83
95%CI
-2.5, 6.1
-3.1, 4.9
· Mean age 43 and female 53%
· Mean FEV1 76%PV
· Unblinded study
· Note difference in propellants
· Triamcinolone producer funded and
supported trial
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Table 22: Summary of studies investigating the effect of pharmaceuticals (inhaled steroids versus inhaled steroids) in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Condemi et al.
1997)
RCT
Grade 1+
Country:
United States
Fluticasone d-inh
250 mg bd
V
Triamcinolone inh
200 mg Qid
V
Placebo
24 weeks
Inclusion:
Age ³ 12 yrs
FEV1 50-80%PV
One documented
emergency care visit within
the past year for asthma
exacerbation
Exclusion:
Pharmaceutical limitations
291
D AM FEV1
D salbutamol use (puffs/day)
D rescue free days (%)
D night awakening
D symptom free days (%)
oropharyngeal candidiasis (%)
FP
0.27
-0.9
14
-0.03
14
8
TAA
0.07
-0.2
1
-0.01
12
3
P value
P < 0.05
P < 0.05
P < 0.05
n.s.
n.s.
n.s.
NNT
8
· Mean age 36 and female 51%
· Mean FEV1 67%PV
· Pharmaceutical producers of
fluticasone funded and supported
trial
· Lack of consistency between rescue
free days and symptom free days
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Table 22. Summary of studies investigating the effect of pharmaceuticals (inhaled steroids versus inhaled steroids) in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Newhouse et
al. 2000)
RCT
Grade 1-
Country:
Canada
Flunisolide inh 750
mg bd
V
Budesonide inh
600 mg bd
6 weeks
Inclusion:
Age 18-75 years
FEV1 40-85%PV
Requiring a dose of inhaled
steroid between 800 and
2000 mg daily
Exclusion:
Hospital admission for
asthma within 6 weeks
Upper resp infection within
30 days
Pharmaceutical limitations
154
D FEV1 (%PV)
D salbutamol use (puffs/day)
Nocturnal awakenings
(n/night)
Asthma symptom score
% patients with
oropharyngeal Candida
D plasma cortisol (mg/L) in
Cortrosyn Stimulation Test
(higher number = less adrenal
suppression)
FNS
-2.4
0.4
0.1
0.1
35
12.5
BDP
-0.5
0.1
0.1
0.1
42
10.5
P value
P = 0.4
P = 0.3
P = 0.9
P = 0.9
P = 0.4
P = 0.05
· Mean age 43 and female 58%
· Mean FEV1 81%PV
· Blinding and concealment status
not documented
· Significant baseline difference in
FEV1 %PV between randomised
groups
· 80% power to detect 33%
difference in cortisol level (a = 0.05)
(McFadden et
al. 1999)
RCT
Grade 1+
Country:
United States
Budesonide inh
400 mg mane for 6
weeks followed
by 200 mg mane
for 12 weeks
V
Budesonide inh
200 mg mane
V
Placebo
Inclusion:
Age 18-70 years
FEV1 ³ 80%PV if taking
steroids or 60-90%PV if not
taking steroids
Exclusion:
Hospital admission for
asthma within 2 months
Current smoking
309
D FEV1 (L)
D day symptom scores
D rescue salbutamol use
(puffs/day)
QoL scores
BDP400
0.11
-0.36
-1.09
5.55
BDP200
0.10
-0.23
-1.11
5.26
P value
n.s.
n.s.
n.s.
n.s.
· Mean age 37 and female 67%
· FEV1 82%PV
· Pharmaceutical company funded
and supported trial
· Identical intervention for last 12
weeks of study so low power to
detect a difference
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Table 22: Summary of studies investigating the effect of pharmaceuticals (inhaled steroids versus inhaled steroids) in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Foresi et al.
2000)
RCT
Grade 1+
Country:
Italy
Budesonide inh
100 mg bd +200
mg bd following
exacerbation
V
Budesonide inh
100 mg bd
+placebo
following
exacerbation
V
Budesonide inh
400 mg bd
+placebo
following
exacerbation
6 months
Inclusion:
Age 18-65 yrs
FEV1 50-90%PV
Daily inh b-agonist use
Exclusion:
Current and ex smokers
Pharmaceutical
limitations
209
Participants with ³1
exacerbation (%)
Participants with ³1
exacerbation (%)
Participants with ³1
exacerbation (%)
BDP 400 +
Placebo
16.9
BDP 400 +
Placebo
16.9
BDP 100 +
BDP200
18.7
Bud 100 +
Placebo
32.4
BDP 100 +
BDP200
18.7
BDP 100 +
Placebo
32.4
P value
P = 0.04
n.s.
n.s.
NNT
6
· Mean age 39 and female 37%
· Mean FEV1 74%PV
· All participants received
budesonide 800 mg bd for 1
month prior to randomisation
· Financial support from
pharmaceutical company
· Method of randomisation
unclear
(Kemp et al.
1999)
RCT
Grade 1+
Country:
United States
Budesonide inh
400 mg bd
V
Budesonide inh
200 mg bd
V
Placebo
12 weeks
Inclusion:
Age 18-70 years
FEV1 50-80%PV
Asthma symptoms on at
least 7 of 14 days pre-
randomisation
Exclusion:
Hospital admission for
asthma within a month
Pharmaceutical
limitations
273
% patients with normal basal
cortisol at baseline and
abnormal post-treatment
% patients with normal
stimulated cortisol at
baseline and abnormal
post-treatment
BDP 200
1
3
BDP 400
3
3
P value
n.s.
n.s.
· Mean age 39 and female 45%
· Mean FEV1 67%PV
· Efficacy also studied but no
absolute numerical figures
provided for these
comparisons
· Pharmaceutical company
involvement not mentioned
but no funding source
documented
· Lack of demographic data in
baseline comparison
· Method of randomisation not
described
· Study power not stated
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Table 22: Summary of studies investigating the effect of pharmaceuticals (inhaled steroids versus inhaled steroids) in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Miyamoto et al.
2000)
RCT
Grade 1+
Country:
Japan
Budesonide inh 400
mg bd
V
Budesonide inh 200
mg bd
V
Budesonide inh 100
mg bd
V
Placebo
6 weeks
Inclusion:
Age adult
PEFR 50-80%PV
Exclusion:
Steroid use within 1 month
Resp infection within 4
weeks
267
D PEFR (L/min)
Physician assessment of
significant improvement
BDP 800
71
76%
BDP 400
53
73%
BDP 200
45
57%
P value
P < .05
(800 V 200)
P < .001
(dose response)
· Mean age 51 and female
47%
· Baseline differences in
gender distribution,
treatment scores and
asthma scores (P = 0.05-
0.10)
· Lack of clarity in some
outcome measurements
· Some of the study authors
were employed by the
producer of budesonide
(Herjavecz et al.
1999)
RCT
Grade 1+
Country:
Hungary and
Spain
Budesonide inh 400
mg qd
V
Budesonide inh 200
mg bd
6 weeks
Inclusion:
Age 17-67 years
PEFR ³ 70%PV
Exclusion:
Asthma exacerbation within
2 months
Resp infection within 4
weeks
Pharmaceutical limitations
181
D FEV1 (L)
D b-agonist use (puffs/day)
qd
0.03
0.46
bd
0.06
0.38
Diff (95%CI)
-0.03
(-0.11, 0.06)
0.08
(-0.13, 0.28)
· Mean age 31 and female
59%
· Mean FEV1 93%PV
· 80% power to detect a
difference of 22 L/min in
PEFR (a = 0.05)
· Symptom scores higher in
bd treatment group at
baseline
NEW ZEALAND HEALTH TECHNOLOGY ASSESSMENT: ASTHMA THERAPEUTICS
STEROIDS - CHRONIC ASTHMA
111
Table 22: Summary of studies investigating the effect of pharmaceuticals (inhaled steroids versus inhaled steroids) in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Tukiainen et al.
2000)
RCT
Grade 1+
Country:
Finland
Budesonide inh 400
mg bd
V
Budesonide inh 100
mg bd
3 months
Inclusion:
Age ³ 18 yrs
Newly detected asthma
PC20 histamine £ 8 mg/ml
Exclusion:
Pharmaceutical limitations
101
D FEV1 (%PV)
D asthma symptom score
(day)
D asthma symptom score
(night)
D b-agonist inhalation
(day)
D b-agonist inhalation
(night)
BDP 200
1.7
-0.49
-0.20
-0.62
-0.22
BDP 800
0.6
-0.47
-0.24
-0.68
-0.24
P value
n.s.
n.s.
n.s.
n.s.
n.s.
· Mean age 39 and female
65%
· Mean FEV1 87%PV
· Baseline difference in
gender distribution between
the two study groups
(Female %: Bud 200 – 58,
Bud 800 – 72)
· Study material and
equipment supplied by the
producers of budesonide
· Study had 90% power to
detect a one dose step
difference in histamine PC20
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Table 22: Summary of studies investigating the effect of pharmaceuticals (inhaled steroids versus inhaled steroids) in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(van der Molen
et al. 1998)
RCT
Grade 1+
Country:
Netherlands
One month:
Budesonide inh
400 mg bd
V
Budesonide inh
100 mg bd
Both followed by
Budesonide inh
200 mg daily
Total duration 13
weeks
Inclusion:
Age 18-50 yrs
FEV1 > 50%PV
Required ³ 3 doses
bronchodilator per week for
the month before enrolment
Exclusion:
>20 pack-years tobacco
Asthma exacerbation within 2
months of enrolment
Pharmaceutical limitations
84
D AM PEFR at 4 weeks
(L/min)
D symptom score at 4
weeks
% D bronchodilator use
(13 weeks)
BDP400
27
-0.5
-38
BDP100
38
-0.6
-48
P value
n.s.
n.s.
n.s.
· Mean age 32 and female 56%
· Mean FEV1 84%PV
· Numerical values for PEFR and
symptom score not presented
at 13 weeks but no statistically
significant difference between
groups
· Unclear whether the drop outs
(25%) were included in the
analysis therefore the potential
for low study power exists
· Financial support from
budesonide producer
(Busse et al.
1998)
RCT
Grade 1+
Country:
United States
Budesonide inh
800 mg bd
V
Budesonide inh
400 mg bd
V
Budesonide inh
200 mg bd
V
Budesonide inh
100 mg bd
V
Placebo
12 weeks
Inclusion:
Age 18-70 years
FEV1 40-75%PV
Used inhaled steroid for the
past 6 months
Exclusion:
Pharmaceutical limitations
473
Withdrawal due to
exacerbation (%)
Day symptom score
Rescue med use
(puffs/day)
Stimulated cortisol levels
(nmol/L)
100bd
20
-0.19
0.72
-3
200bd
11
-0.24
-1.47
+6
400bd
8
-0.31
-1.48
-7
800bd
7 (P<.01 cf.
100bd). NNT 8
-0.24
-1.50
-7.5
· Mean age 44 and female 54%
· Mean FEV1 65%PV
· Financial support from the
producers of budesonide
· Unclear if ITT analysis was
performed
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Table 22: Summary of studies investigating the effect of pharmaceuticals (inhaled steroids versus inhaled steroids) in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Chisholm et al.
1998)
RCT
Grade 1-
Country:
Netherlands
Budesonide inh
200 mg qd
V
Budesonide inh
100 mg bd
8 weeks
Inclusion:
Age 18-70 years
Postbronchilator FEV1
>70%PV
Exclusion:
Acute asthma
exacerbation or lower
resp infection within 2
months
Pharmaceutical
limitations
76
D AM PEFR (L/min)
D rescue med use (day)
D rescue med use (night)
D symptom score (day)
D symptom score (night)
qd
1.7
.02
.06
-0.07
.02
bd
4.3
-0.21
-0.01
-0.06
-0.1
P value
n.s.
n.s.
n.s.
n.s.
n.s.
· Mean age 41 and female 59%
· Mean FEV1 86%PV
· Study aimed to determine
equivalence of the two dosing
regimens. The power of the
study was unclear.
· Patients were monitored by their
own GP
· Funding and support was
provided by the
pharmaceutical company
producing budesonide
(Campbell et al.
1998)
RCT
Grade 1-
Country:
United Kingdom
and Ireland
Budesonide 400
mg bd for 6 wks
followed by 400
mg nocte for 12
wks
V
Budesonide 400
mg nocte for 18
weeks
Inclusion:
Age ³ 12 years
Asthma symps in 2 of
past 7 days (prior to
study entry)
Exclusion:
PEFR < 60%PV
Pharmaceutical
limitations
682
D cough score (6 wks)
D cough score (18 wks)
D wheeze score (6 wks)
D wheeze score (18 wks)
D SOB score (6 wks)
D SOB score (18 wks)
D sleep disturbance (n/wk)
(6 wks)
D sleep disturbance (n/wk)
(18 wks)
BDP bd
initially
-0.47
-0.54
-0.58
-0.70
-0.62
-0.68
-1.04
-1.21
BDP nocte
-0.42
-0.49
-0.48
-0.59
-0.55
-0.71
-0.86
-1.06
P value
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
· Mean age 33 and female 56%
· Double blind for the first 6 weeks
followed by open design
· Higher drop out rate than
expected (10% expected, 33%
actual) resulted in not meeting
the 80% power target
· Sponsored by budesonide
producers
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Table 22: Summary of studies investigating the effect of pharmaceuticals (inhaled steroids versus inhaled steroids) in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Mahajan et al.
1997)
RCT
Grade 1+
Country:
United States
Fluticasone inh
250 mg bd
V
Fluticasone inh
100 mg bd
V
Fluticasone inh 50
mg bd
V
Placebo
12 weeks
Inclusion:
Age ³ 12 years
FEV1 50-80%PV
Exclusion:
Pharmaceutical limitations
342
Living with asthma score
(low = improved control)
Night awakenings
(n/week)
FP100
0.98
0.2
FP250
1.10
0.4
FP50
1.12
0.2
P value
P < 0.05
(F100 V F250 +
F100 V F50)
n.s.
· Mean age 35 and female 39%
· Pharmaceutical company
producing fluticasone funded
and supported trial
· Inconsistent dose response
relationship in the results
produces uncertainty about the
study
(Nathan et al.
2000)
RCT
Grade 1+
Country:
United States
Fluticasone inh
500 mg daily
V
Fluticasone inh
200 mg daily
V
Fluticasone inh
100 mg daily
V
Placebo
Inclusion:
Age 18-50 yrs
FEV1 > 50%PV
Required ³ 3 doses
bronchodilator per week for
the month before enrolment
Exclusion:
>20 pack-years tobacco
Asthma exacerbation within
2 months of enrolment
Pharmaceutical limitations
330
D AM FEV1 (L)
D asthma symptom score
D salbutamol use
(puffs/day)
D night awakenings
(n/night)
FP 500
0.30
-0.25
-0.90
-0.03
FP 200
0.27
-0.20
-0.19
-0.05
P value
n.s.
n.s.
P £ 0.05
n.s.
· Mean age 37 and female 42%
· Mean FEV1 63%PV
· Pharmaceutical company
producing fluticasone funded
and supported trial
· Other comparisons with
fluticasone 100 mg daily dosage
also presented in paper but no
significant differences in the
presented outcomes
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Table 22: Summary of studies investigating the effect of pharmaceuticals (inhaled steroids versus inhaled steroids) in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Westbroek et
al. 1999)
RCT
Grade 1+
Country:
19 countries
Fluticasone neb 2
mg bd
V
Fluticasone neb
0.5 mg bd
V
Placebo
12 weeks
Inclusion:
Age ³ 17 yrs
Continuous po steroid for 3
mths before study
Exclusion:
Changes in asthma
medication, resp infection
requiring antibiotics or
hospital admission for resp
disease in past 4 weeks
301
Median reduction po
steroid dose (%)
AM PEFR (L/min)
Nights not awoken (%)
2 mg bd
66.7
281
87
0.5 mg bd
50.0
291
74
P value
n.s.
n.s.
P = 0.05
NNT
7
· Female 45%
· 85% on inhaled steroid
· Pharmaceutical company
funded and supported trial
· Higher withdrawal rate in 0.5 mg
group
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Table 22: Summary of studies investigating the effect of pharmaceuticals (inhaled steroids versus inhaled steroids) in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Boulet et al.
2000)
RCT
Grade 1-
Country:
8 countries
Fluticasone inh
500 mg mane
V
Fluticasone inh
250 mg bd
12 weeks
Inclusion:
Age ³ 12 years
FEV1 60-90%PV
Previously received
beclomethasone 400-1200
mg daily (or equivalent)
No changes in asthma
medication in past 4 weeks
Exclusion:
Resp infection or ED therapy
in past 4 weeks
443
D AM PEFR (L/min)
D PM PEFR (L/min)
D FEV1 (L)
D day symptom score
D night symptom score
D day rescue med use
D night rescue med use
bd
16.7
10.4
0.08
-0.26
-0.07
-0.25
-0.11
Mane
0.7
4.9
0
-0.08
0.13
-0.10
0.05
90%CI
-20.5, -11.11
-9.7, -1.3
-0.14, -0.01
P value
P = 0.025
P < 0.001
n.s.
P = 0.003
· Mean age 36 and female 55%
· Pharmaceutical company
funded and supported trial
· Patients excluded from one
centre due to poor data quality
· ITT analysis not used
· 1 Outcome not equivalent
(Boulet et al.
2000)
RCT
Grade 1-
Country:
8 countries
Fluticasone inh
200 mg mane
V
Fluticasone inh
100 mg bd
12 weeks
Inclusion:
Age ³ 12 years
FEV1 70-90%PV
Previously received
beclomethasone up to 500
mg daily (or equivalent)
No changes in asthma
medication in past 4 weeks
Exclusion:
Resp infection or ED therapy
in past 4 weeks
461
D AM PEFR (L/min)
D PM PEFR (L/min)
D FEV1 (L)
D day symptom score
D night symptom score
D day rescue med use
D night rescue med use
bd
18.7
13.2
0.12
-0.23
-0.09
-0.23
-0.17
Mane
10.5
9.7
0.07
-0.25
-0.03
-0.23
-0.06
90%CI
-13.6, - 2.82
-8.3, -1.6
-0.12, -0.02
P value
n.s.
n.s.
n.s.
n.s.
· Mean age 38 and female 55%
· Pharmaceutical company
funded and supported trial
· ITT analysis not used
· 2 Outcomes equivalent
between dose regimens by
authors pre set criteria although
the null hypothesis (no
statistically significant difference
in outcome) was rejected
· Same study as one above.
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Table 22: Summary of studies investigating the effect of pharmaceuticals (inhaled steroids versus inhaled steroids) in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Busse et al.
1999b)
RCT
Grade 1+
Country:
United States
Beclomethasone
inh 800 mg daily
V
Beclomethasone
inh 400 mg daily
V
Beclomethasone
inh 100 mg daily
(Both HFA and
CFC propellants)
6 weeks
Inclusion:
Age > 18 years
FEV1 45-75%PV (between
run in and randomisation)
Exclusion:
Smoking within the
previous 12 months or >
15 pack-years smoking
Upper resp infection
within 4 weeks or lower
resp infection within 6
weeks
323
D am PEFR (L/min)
b-agonist use (puffs/day)
Nights free from asthma
related disturbance (%)
BEC 800
61.9
3.7
84.0
BEC 400
49.9
4.5
74.0
BEC 100
39.1
4.8
77.1
P value
(trend)
P < 0.05
P < 0.05
n.s.
· Female 61%
· Mean FEV1 53%PV
· Pharmaceutical company
producing beclomethasone (HFA
propellant) funded and supported
trial
· Results refer to HFA propellant only.
There were similar differences
between doses in the CFC
propellant group as those
presented for HFA propellant.
(Hampel et al.
2000)
RCT
Grade 1+
Country:
United States
and France
Beclomethasone
inh HFA 100 mg bd
V
Beclomethasone
inh HFA 50 mg bd
V
Placebo
6 weeks
Inclusion:
Age 18-65 years
FEV1 65-85%PV
No steroids for 3 months
Nonsmoker
Exclusion:
Pharmaceutical
limitations
270
D FEV1 (%PV)
D nights without sleep
disturbance (%)
D daily b-agonist use (n/day)
100bd
8.6
25.2
-1.04
50bd
6.7
21.4
-1.19
P value
n.s.
n.s.
n.s.
· Mean age 34 and female 57%
· Mean FEV1 76%PV
· Concealment methods not
described
· Labelled as blind but no
information on single or double
· Financial support from producers
of beclomethasone
· 90% power to detect a clinically
significant difference in outcome
between placebo and active
doses
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Table 22: Summary of studies investigating the effect of pharmaceutic ls (inhaled steroids versus inhaled steroids) in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(ZuWallack et al.
1997)
RCT
Grade 1+
Country:
United States
Flunisolide inh 500
mg bd
V
Flunisolide inh
1000 mg mane
V
Flunisolide inh
1000 mg nocte
V
Flunisolide inh 500
mg mane
12 weeks
Inclusion:
Age 6-70 years
FEV1 ³ 80%PV
Regular use of inhaled
steroids and clinically
stable after 4 weeks
flunisolide 500 mg bd
Non smoking ³ 1 year
and < 10 pack-years
total
366
D daytime symptoms
D night symptoms
D FEV1 %PV
500bd
0.00
0.00
-2.1
1000mane
0.06
0.06
-3.5
1000nocte
-0.04
-0.03
-0.7
500mane
0.21
P=.0002 (bd)
P=.002 (mane)
P=.0001 (nocte)
0.15
P=.003 (bd)
P=.02 (mane)
P=.002 (nocte)
-4.5
P=.03 (bd)
P>.05 (mane)
P=.01 (nocte)
· Mean age 30 and female 55%
· Funded by the pharmaceutical
producers of flunisolide
· Method of randomisation
unclear
(Pincus et al.
1997)
RCT
Grade 1-
Country:
United States
Triamcinolone inh
200 mg Qid
V
Triamcinolone inh
800 mg at 5.30PM
V
Triamcinolone inh
800 mg at 8 AM
4 weeks
Inclusion:
Age 20-68 years
FEV1 50-85%PV
Exclusion:
Smoking within 5 years
Upper resp infection
within 4 weeks
Pharmaceutical
limitations
60
% D FEV1
D AM PEFR (L/min)
D b-agonist use
(puffs/day)
D night awakening
Qid
21.1
46
-2.3
-3.0
5.30pm
15.2
13
-1.3
-2.0
8.00am
14.7
-2
-1.6
-1.0
P value
n.s.
P = 0.005
(Qid v 8)
P = 0.05
(5.30 v 8)
n.s.
n.s.
· Mean age 33 and female 46%
· No description of concealment
or blinding
· Unclear whether ITT analysis was
used
· Funded by pharmaceutical
company
(Lipworth 1999)
SR
Grade 1-
Adverse effects
of inhaled
steroids.
Comparison
between steroids
Inclusion:
RCTs
Route of drug
administartion
documented
21
studies Urinary cortisol
suppression (slope
gradient)
95%CI cf. fluticasone
FP
63.2
BEC
32.5
(1.0, 60.6)
TAA
17.3
(3.7, 88.1)
BDP
14.7
(20.9, 76.1)
· No demographic details
· Limited database search
· No assessment of study quality
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Table 23: Summary of studies investigating the effect of pharmaceuticals (inhaled steroids versus oral steroids) in chronic asthma
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Meijer et al.
1999)
RCT
Grade 1+
Country:
Netherlands
Fluticasone D-
inh 2000 mg daily
V
Fluticasone D-
inh 500 mg daily
V
Prednisolone po
30 mg daily
2 weeks
Inclusion:
Age 18-56 yrs
PC20 methacholine £ 8
mg/ml
Exclusion:
Exacerbation of asthma
requiring prednisolone
Pharmaceutical limitations
120
D FEV1 %PV
Serum cortisol (nmol/L)
Rescue med (n/day)
FP 2000
6.5
-155
0.0
FP 500
6.3
0.0
0.0
Pred
4.4
-118
0.57
P value
P = .13
P = .005
(Pred +
Flu2000 v
Flu500)
P £ .05
(Pred V both
Flu doses)
· Median age 27 and female 66%
· Mean FEV1 80%PV
· Fluticasone 2000 is a high dose
· Financial support from fluticasone
producer
· Randomisation methodology
provided in detail
(Li et al. 1999)
RCT
Grade 1-
Country:
United States
Fluticasone inh
220 mg bd
V
Fluticasone inh
88 mg bd
V
Triamcinolone
inh 400 mg Qid
V
Triamcinolone
inh 200 mg Qid
V
Prednisone po
10 mg daily
V
Placebo
4 weeks
Inclusion:
Age 18-50 yrs
FEV1 ³ 50%PV
Exclusion:
Pharmaceutical limitations
128
%D 8 hour cortisol (AUC)
FP 88/220
-2.6%/-5.7%
TAA
200/400
-6.4%/
-13.0%
Pred
-32.5%
P value
P £.001
(FP + TAA V
PRED)
· Mean age 31 and female 30%
· Mean FEV1 86%PV
· ITT analysis not used
· All aspects of the study (including
financial support) assisted by
fluticasone producer
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Table 23. Summary of studies investigating the effect of pharmaceuticals (inhaled steroids versus oral steroids) in chronic a thma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Aaronson et al.
1998)
RCT
Grade 1-
Country:
United States
Budesonide inh
1600 mg bd
V
Budesonide inh
800 mg bd
V
Budesonide inh
400 mg bd
V
Prednisone po
10 mg daily
V
Placebo
6 weeks
Inclusion:
Age 18-65 yrs
FEV1 ³ 65%PV
Exclusion:
Hospitalisation for asthma
in past 4 weeks
Resp infection in past 4
weeks
Corticosteroid therapy
within 6 months
64
D postcosyntropin plasma
cortisol (nmol/L)
(P values compared with
prednisone)
BDP1600
-90
P=0.03
BDP800
-137
P=0.08
BDP3200
-249
n.s.
Pred
-292
· Mean age 31 and female 23%
· ITT analysis not used
· Budesonide turbuhaler producer
funded and supported trial
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Acute asthma
Table 24: Summary of studies investigating the effect of pharmaceuticals (steroids) in acute asthma
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Rowe et al.
1999)
RCT
Grade 1+
Country:
Canada
Budesonide inh
1600 m g daily +
Prednisone po
50 m g daily
V
Prednisone po
50 m g daily
3 weeks
Inclusion:
Age 16-60 yrs
PEFR < 80%PV
Exclusion:
Oral or inhaled steroid within
1 week of ED presentation
188
Relapse within 21 days (%)
QoL score
FEV1 %PV
b-agonist activation (%)
Night awakening (mean)
Hoarseness (%)
Sore throat (%)
BDP + Pred
12.8
5.9
79
2.4
6.2
25
22
Pred
24.5
5.2
79
4.2
5.4
46
41
P value
P = .05
P = .001
n.s.
P = .01
P = .001
P = .02
P = .02
NNT
9
NNH
5
5
· Mean age 28 and female 61%
· Mean PEFR 50%PV
· Inhalers supplied by company
producing budesonide
· Baseline difference in sex, age and
severity (the latter favouring
prednisone alone)
(Rodrigo and
Rodrigo 1999)
SR
Grade 1+
IV steroid
V
po steroid1
High/mod dose
steroid
V
Low dose
steroid2
Inclusion:
Age > 18 yrs
RCT
English language
1571
3692
Pulm fn (favouring po over IV
treatment)
Pulm fn (favouring medium
and high doses over low dose
steroid)
Effect size
-0.14
0.12
95%CI
-0.8, 0.31
-0.18, 0.32
· Mean age 32
· Hydrocortisone equiv range
(mg/kg/day) 4.2-83.3. Low dose <
13 mg/kg/day
· Study identification inadequate –
limited databases, English
language only, no attempt to
identify unpublished data.
· Study quality assessed using an
instrument that did not consider
blinding or use of ITT analysis.
(Nana et al.
1998a)
RCT
Grade 1-
Country:
Thailand
Budesonide inh
1600 mg bd
V
Prednisolone po
starting 40 mg
then daily 30,
25, 20, 15, 10, 5
mg.
1 week
Inclusion:
Age 16-50 yrs
FEV1 20-50%PV on acute
presentation
81
% D FEV1
BDP
17.3
Pred
17.6
P value
n.s.
· Mean age 38 and female 63%
· Mean FEV1 64%PV
· FEV1 %PV lower in budesonide
group
· ITT analysis not used since
treatment withdrawals (4%) were
not analysed
· Study power not stated
· Pharmaceutical company funded
and supported trial
NEW ZEALAND HEALTH TECHNOLOGY ASSESSMENT: ASTHMA THERAPEUTICS
STEROIDS - ACUTE ASTHMA
122
Table 24. Summary of studies investigating the effect of pharmaceuticals (steroids) in acute asthma (continued)
Study
source, design
and evidence
grading
Intervention
Comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(FitzGerald et al.
2000)
RCT
Grade 1+
Country:
Canada
Budesonide inh
600 mg Qid
V
Prednisone po
40 mg mane
7-10 days
Inclusion:
Age 15-70 yrs
FEV1 > 50%PV post
bronchodilator
Discharged from ED
Exclusion:
Pharmaceutical limitations
185
Relapse rate (%)
FEV1 (L)
BDP
10
3.06
Pred
14
3.00
95%CI
(Diff)
-7.5, 11
n.s.
· Mean age 28 and female 57%
· Mean FEV1 75%PV
· Budesonide producer funded and
supported trial
· Despite authors claiming
therapeutic equivalence the
95%CI was not entirely within the
preset ± 10% criteria for relapse
NEW ZEALAND HEALTH TECHNOLOGY ASSESSMENT: ASTHMA THERAPEUTICS
THEOPHYLLINE - CHRONIC ASTHMA
123
Theophylline
Chronic asthma
Table 25: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus theophylline) in chronic asthma
Study
source,
design
and
evidence
grading
Intervention
Comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Pollard et
al. 1997)
RCT
Grade 1+
Country:
United
States
Salmeterol mdi
(42 mg bd)
V
Theophylline po
(Individual dose
titrated slo-bd)
V
Placebo
Inh and po
12 weeks
Inclusion:
Age 12+ yrs
FEV1 > 50%PV
15+% increase in FEV1 with
salbutamol inh
Exclusion:
Other bronchodilators
484 12 weeks
Mean change AM PEFR(cf.
baseline) (L/min)
Mean change (cf. baseline)
Nighttime awakenings/wk
Asthma symptom score
Salbutamol use puffs/day
Drug related adverse event
SLM
+10.3
-0.7
-0.11
-1.1
9%
THP
-4.5
-0.1
0.01
0.06
19%
P value
P£.02
P<.02
P<.02
P<.02
P<.05
· Mean age 31 and female 52% in
salmeterol group; mean age 30
and 54% in theophylline group
· 54% patients on concurrent ICS
therapy
· Pharmaceutical company funded
and supported trial
· Combined results of two identical
trials
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Table 25: Summary of studies investigating the effect of pharmaceuticals (long-acting b-agonists versus theophylline) in chronic asthma (continued)
Study
source,
design
and
evidence
grading
Intervention
Comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Nutini et
al. 1998)
RCT
Grade 1-
Country:
Italy
Salmeterol inh 50
mg bd
V
Theophylline po
50 dose titrated
bd
12 weeks
(drug efficacy)
52 weeks
(drug safety)
Inclusion:
Age 18+ yrs
FEV1 50-80%PV
15+% increase in FEV1 with
200 mg salbutamol inh
Exclusion:
Variable smoking history
Asthma requiring
emergency care – past
month
112 12 weeks
Symptom free
Days
Nights
Days with no rescue
medication use
Days
Nights
QOL index score
Adverse drug events
SLM
65.7%
65.7%
68.7%
70.1%
9.7
9
THP
56.8%
60.2%
57.2%
63.0%
8.6
18
P value
P<.005
P<.01
P<.001
P<.001
N/A
N/A
NNT
11
18
9
14
· Mean age 46 and female 44%,
mean FEV1 (L) 2.21 in SLM group;
mean age 48 and 32% and mean
FEV1 (L) 2.10 in THP group
· Pharmaceutical company funded
and supported trial
· Open study design
· Intention to treat analysis
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Table 26: Summary of studies investigating the effect of pharmaceuticals (inhaled steroids versus theophylline) in chronic asthma
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Reed et al.
1998)
RCT
Grade 1+
Country:
United States
Beclomethasone
inh 84 mg Qid
V
Theophylline
1 year
Inclusion:
Age 6-65 yrs
FEV1 >50%PV
Exclusion:
>5 pack years tobacco
smoking
Resp infection in past 3
weeks
Pharmaceutical limitations
747
Moderately severe or worse
symptoms1
Systemic steroid use over
course of study
BEC
25.8%
20%
THP
30.5%
29%
P value
n.s.
P = .009
NNT
11
· Female 51%
· 45% previously taken theophylline,
4% beclomethasone
· 75% study completion rate
· Theophylline dose determined by
response
· Study supported by
phamaceutical company
producing beclomethasone
· No baseline data on mean age in
two study groups
· 1For any day in the 12th month.
There were significant differences
in earlier months that favoured
beclomethasone.
(Ukena et al.
1997)
RCT
Grade 1+
Country:
Germany,
Hungary, Austria
Beclomethasone
inh 200 mg bd
+ Theophylline
V
Beclomethasone
inh 400 mg bd
6 weeks
Inclusion:
Age 18-70 years
FEV1 50-85%PV
Asthma not controlled on
beclomethasone 400 mg
daily or equivalent
Exclusion:
Severe asthma attack or
lower resp infection within 1
month
Current smoker
Pharmaceutical limitations
133
D FEV1 (L)
Combined
0.26
BEC
0.19
P value
n.s.
· Median age 48 and female 44%
· FEV1 75%PV
· Data not presented but no
significant difference in rescue
med use between groups
· ITT analysis not presented in paper
but results similar to per protocol
analysis presented
· Producers of theophylline funded
and supported trial
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Table 26: Summary of studies investigating the effect of pharmaceuticals (inhaled steroids versus theophylline) in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Evans et al.
1997)
RCT
Grade 1+
Country:
United Kingdom
and Sweden
Budesonide inh
400 mg bd +
theophylline po
250 mg (if < 80
kg) or 375 mg (if ³
80 kg) bd
V
Budesonide inh
800 mg bd
3 months
Inclusion:
FEV1 > 50%PV
Exclusion:
Pharmaceutical limitations
Asthma exacerbation within
3 weeks of run in
62
Improvement in FEV1 (L)
Improvement in FVC (L)
Day time symptom scores
Night time symptom scores
Daytime rescue med use
Nighttime rescue med use
THP + BDP
0.21
0.26
N/A
N/A
N/A
N/A
BDP
0.11
0.18
N/A
N/A
N/A
N/A
P value
P = 0.03
P = 0.03
P = 0.26
P = 0.59
P = 0.57
P = 0.97
· Mean age 39 and female 60%
· Mean FEV1 75%PV
· Supported by pharmaceutical
company that produces
theophylline
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Inhaler devices
Chronic asthma
Table 27: Summary of studies investigating inhaler devices in chronic asthma
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Nelson et al.
1999)
RCT
Grade 1+
Country:
United States
Salbutamol dry
powder inh 216
mg Qid
V
Salbutamol mdi
180 mg Qid
V
Placebo
12 weeks
Inclusion:
Age ³ 12 yrs
Nonsmoker
Exclusion:
No changes in current
asthma meds, no hospital
admissions or ED visits for
asthma within 4 weeks
283
FEV1 (L)
DPI
2.27
mdi
2.43
P value
n.s.
· Mean age 34 and female
55%
· Mean FEV1 64%PV
· Text stated no significant
difference in asthma
exacerbation, use of rescue
med and symptom score
(Specific data not provided)
· Unclear whether ITT analysis
was used
· Study power not defined
· Grant provided by the
producers of the dry powder
inhaler
(Seppala et al.
1998)
CO
Grade 1+
Country:
Germany
Salbutamol dry
powder inh
(TaifunÔ)
V
Salbutamol mdi
+ spacer
Single dose each
Inclusion:
Age 20-69 yrs
FEV1 35-70%PV
Exclusion:
Pharmaceutical limitations
36
D FEV1 (%)
DPI
47.2
mdi
44.7
90%CI
(DPI, mdi  ratio)
95%, 120%
· Mean age 44 and female
41%
· Mean FEV1 58%PV
· Results reported on 90% of
randomised population
· No data on equivalence at
baseline
· Pharmaceutical company
involved at authorship level
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Table 27: Summary of studies investigating inhaler devices in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Geoffroy et al.
1999)
CO
Grade 1-
Country:
United States
Salbutamol
Spirosä dry inh
180 mg Qid
V
Spirosä dry inh 90
mg Qid
V
mdi  180 mg Qid
V
mdi  90 mg Qid
V
Placebo
1 day each
Inclusion:
Age 18-65 yrs
FEV1 40-70%PV
Within ± 20% ideal body
weight
Exclusion:
Use of tobacco products
within 6 months
60
FEV1 max (L)
Time to FEV1 ³ 15% baseline
(min)
Duration when FEV1 ³ 15%
baseline (min)
mdi  180
2.91
47.6
234.6
DPI 180
2.92
56.1
221.2
mdi  90
2.82
59.6
174.9
DPI 80
2.82
38.1
212.4
· Mean age 30 and female 45%
· No significant differences
between treatment results
presented
· 73% of randomised population
included in analysis
· Pharmaceutical company
producing Spirosä inhaler
funded and supported trial
· No baseline comparison data
presented post-randomisation
· Power of study not clear
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Table 27. Summary of studies investigating inhaler devices in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Lofdahl et al.
1997)
CO
Grade 1-
Country:
Sweden
Salbutamol
turbuhaler (TBH)
200 mg daily
V
Salbutamol
turbuhaler (TBH)
50 mg daily
V
Salbutamol mdi
400 mg daily
V
Salbutamol mdi
100 mg daily
V
Placebo
Single dose each
Inclusion:
Age 18-70 yrs
FEV1 ³ 35%PV
50
FEV1 ratio %
95%CI
TBH50/mdi 100
102.0
99.7, 104.3
TBH200/mdi 400
99.0
96.8, 101.3
TBH200/TBH50
102.8
100.5, 105.2
mdi400/mdi100
105.9
103.6, 108.3
· Mean age 46 and female 46%
· Mean FEV1 65%PV
· No baseline data post-
randomisation
· Pharmaceutical company
involvement at authorship level
· Study power not documented
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Table 27: Summary of studies investigating inhaler devices in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Vink-van
Wijngaarden et
al. 1998)
RCT
Grade 1+
Country:
Netherlands
Beclomethasone
rotahaler 400 mg
bd
V
Beclomethasone
cyclohaler 400 mg
bd
16 weeks
Inclusion:
Age 18-60 yrs
FEV1 > 50%PV
Stabilised on 800 mg BEC
daily for at least 6 months
Exclusion:
Resp infection within 6
weeks
Asthma exacerbation within
2 months
Pharmaceutical limitations
182
AM PEFR (L/min)
Diff (CYC – ROT)
5
90%CI
-20, 31
· Mean age 41 and female
41%
· Mean FEV1 82%PV
· No significant difference in
rescue med use or symp
score (Specific data not
provided)
· Unclear if ITT analysis was
used
(Galant et al.
1999)
RCT
Grade 1+
Country:
United States
Fluticasone inh
500 mg bd
Diskus
V
Diskhaler
V
Placebo
12 weeks
Inclusion:
Age ³ 12 yrs
FEV1 50-80%PV
Exclusion:
PO or parenteral steroids
within 4 weeks of the study
229
D AM FEV1 (L)
D salbutamol use (puffs/day)
D night awakenings (n/week)
D symptom score
DU
0.52
-1.54
-0.03
-0.20
DH
0.40
-1.41
0.00
-0.10
P value
n.s.
n.s.
n.s.
n.s.
· Mean age 33 and female
45%
· Mean FEV1 67%PV
· Data excluded from two sites
since it didn’t meet quality
standards
· Power to detect a difference
in FEV1 of 0.25 L < 80% due to
withdrawal of the 2 study
sites. Inadequate power to
comment on equivalence.
· Pharmaceutical company
funded and supported trial.
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Table 27. Summary of studies investigating inhaler devices in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Pieters et al.
1998)
RCT
Grade 1-
Country:
Netherlands
Fluticasone 250
mg bd
Diskus/
Accuhaler (D/A)
V
Diskhaler (DH)
12 weeks
Inclusion:
Age 18-79 yrs
FEV1 50-90%PV
Required between 400 and
1000 mg steroid per day at
study start
Exclusion:
Pharmaceutical limitations
364
D AM PEFR (L/min)
Median symptom score
Median % rescue free days
Median % rescue free nights
D/A
19
0
63
93
DH
20
0
60
96
P value
n.s.
n.s.
n.s.
n.s.
· Mean age 49 and female 43%
· Mean FEV1 69%PV
· ITT not used since noncompliant
patients were not included in
analysis
· Pharmaceutical company
producing both interventions
involved at authorship level
· Study power not stated
(Wolfe et al.
2000)
RCT
Grade 1+
Country:
United States
Salmeterol diskus
50 mg bd
V
Salmeterol mdi
42 mg bd
V
Placebo
12 weeks
Inclusion:
Age ³ 12 yrs
FEV1 50-85%PV
Less than 10 pack-years
tobacco use and non
smoker for 1 year and not
exposed to secondary
smoke for ³ 4 hours/day
Exclusion:
Resp or middle ear infection
within 6 weeks of entry
498
D days without rescue med
use (%)
D nights without awakening
(%)
D days without symptoms (%)
mdi
29
16
20
DU
23
12
19
P value
n.s.
n.s.
n.s.
· Mean age 34 and female 53%
· Mean FEV1 68%PV
· Pharmaceutical company
funded and supported trial
· Statistical power not stipulated
so unable to assess equivalence
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Acute asthma
Table 28: Summary of studies investiga ing inhaler devices in acute asthma
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Nana et al.
1998b)
RCT
Grade 1+
Country:
Thailand
Salbutamol
turbuhaler
V
mdi
(turbuhaler
doses half mdi
doses. Eight
doses over 90
mins)
Inclusion:
Age 16-50 yrs
FEV1 20-50%PV
Attending ED
86
D FEV1 at 55 mins (L)
Symptom score
TBH
0.47
8
mdi
0.46
6
P value
n.s.
n.s.
· Mean age 38 and female 63%
· Mean FEV1 37%PV
· Pharmaceutical company
involved in all study aspects
· Primary endpoint was measured at
half way point in the dosing
schedule
· 80% power to detect a difference
in the increase in FEV1 that was at
least 62% of the standard deviation
at the 5% significance level
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Propellants
Chronic asthma
Table 29: Summary of studies investigating the effect of pharmaceuticals (CFC V HFA propellant) in chronic asthma
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Gross et al.
1999)
RCT
Grade 1+
Country:
United States
Beclomethasone
HFA inh 400 mg
daily
V
Beclomethasone
CFC inh 400 mg
daily
V
Placebo
12 weeks
Inclusion:
Age ³ 12 yrs
FEV1 ³ 60%PV
Exclusion:
Current or recent smoker
History of life threatening
asthma
Pharmaceutical limitations
347
D AM PEFR (l/min)
HFA
-5.3
CFC
-14.0
P value
n.s.
· Mean age 34 and female 53%
· Mean FEV1 67%PV
· PO steroid given for 7-12 days
before randomisation
· Symptom score, rescue
medication use and D AM PEFR
defined as equivalent outcomes
between propellants.
· Partial concealment only with HFA
and corresponding placebo
requiring half the puffs of CFC and
its corresponding placebo –
potential bias based on
compliance
· Pharmaceutical company funded
and supported trial
(Juniper and
Buist 1999)
RCT
Grade 1+
Country:
United States
Beclomethasone
HFA inh 400 mg
daily
V
Beclomethasone
CFC inh 400 mg
daily
V
Placebo
12 weeks
Inclusion:
Age ³ 12 yrs
FEV1 ³ 60%PV
Exclusion:
Current or recent smoker
History of life threatening
asthma
Pharmaceutical limitations
347 Asthma Quality of life:
Overall
Activity limitations
Symptoms
Emotions
Environment
HFA
5.66
5.86
5.50
5.62
5.62
CFC
5.55
5.70
5.44
5.52
5.51
P value
n.s.
n.s.
n.s.
n.s.
n.s.
· Same study as (Gross et al. 1999)
and same limitations
· No assessment of equivalence
made
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Table 29: Summary of studies investigating the effect of pharmaceuticals (CFC V HFA propellant) in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Dahl et al.
1997)
CO
Grade 1+
Country:
Denmark,
Norway
Beclomethasone
200-600 mg daily
HFA V CFC
4 weeks each
Inclusion:
Age ³ 18 yrs
FEV1 ³ 40%PV
Currently taking £ 600 mg
daily beclomethasone
Exclusion:
Upper resp infection within 2
weeks and lower resp
infection within 4 weeks
68
FEV1 (L)
AM wheeze
AM SOB
AM cough
Sleep disturbance
AM rescue med use
HFA
2.9
0.4
0.4
0.5
0.6
0.8
CFC
3.0
0.4
0.4
0.5
0.7
0.8
90%CI for HFA
-0.06, 0.04
-0.06, 0.02
-0.05, 0.05
-0.12, 0.01
-0.13, 0.02
-0.18, 0.10
Equiv level
-0.44, 0.44
-0.2, 0.2
-0.2, 0.2
-0.2, 0.2
-0.2, 0.2
-0.2, 0.2
· Mean age 49
· pm results were similar to the am
results presented (all met
equivalence criteria)
· No baseline data post-
randomisation presented
· Equivalence criteria were liberal
· Pharmaceutical company funded
and supported trial
(Milanowski et
al. 1999)
RCT
Grade 1+
Country:
United Kingdom,
Ireland, Poland
Beclomethasone
inh 100 mg Qid
HFA
V
CFC
6 weeks
Inclusion:
Age >12 years
FEV1 50-80%PV post
bronchodilator
Exclusion:
Recent hospitalisation for
asthma exacerbation
Recent therapy for URTI
119
FEV1 (L)
Proportion patients with
cough (%)
Proportion patients with
wheeze (%)
Any adverse event (%)
HFA
2.6
29.8
36.2
58
CFC
2.5
45.8
39.6
60
90%CI diff
-0.14, 0.35
P value
P = 0.11
P = 0.73
n.s.
· Mean age 39 and female 44%
· Mean FEV1 67%PV
· 90% power to detect a difference
in FEV1 between groups of >0.2L (
= 0.05)
· Pharmaceutical company funded
and supported trial
(Milanowski et
al. 1999)
RCT
Grade 1+
Country:
United Kingdom,
Ireland, Poland
Beclomethasone
inh 500 mg Qid
HFA
V
CFC
12 weeks
Inclusion:
Age >12 years
FEV1 50-80%PV post
bronchodilator
Taking 800-2000 mg daily
BEC-CFC
Exclusion:
Recent hospitalisation for
asthma exacerbation
Recent therapy for URTI
119
FEV1 (L)
Proportion patients with
cough (%)
Proportion patients with
wheeze (%)
Any adverse event (%)
HFA
2.3
36.2
40.4
73
CFC
2.4
48.9
46.8
86
90%CI diff
-0.34, 0.5
P value
P = 0.21
P = 0.53
n.s.
· Mean age 44 and female 55%
· Mean FEV1 70%PV
· 90% power to detect a difference
in FEV1 between groups of >0.2L at
5% significance level
· Same study as above
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Table 29: Summary of studies investigating the effect of pharmaceuticals (CFC V HFA propellant) in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Harrison et al.
1999)
RCT
Grade 1-
Country:
United States
Beclomethasone
inh HFA 800, 400,
200 mg daily
V
CFC 800 mg daily
V
Placebo
2 weeks
Inclusion:
FEV1 ³ 60%PV
No systemic steroids in past
3 months
Non-smoker
43
% D 24 hour urinary free
cortisol
HFA800
-37.3
CFC800
-47.4
P value
n.s.
· No demographic details provided
· No baseline comparison
· Producers of HFA preparation
funded and supported trial
· Statistical comparison between
HFA and CFC preparations limited
to the 800 mg dose
(Davies et al.
1998)
RCT
Grade 1+
Country:
United Kingdom
Beclomethasone
HFA 800 mg daily
V
Beclomethasone
CFC 1500 mg daily
12 weeks
Inclusion:
Age 18-65 years
PEFR 50-85%PV
Inadequate control on 400-
800 mg daily inh steroid
Exclusion:
Resp infection within 4
weeks of study start
233
D PEFR (L/min)
Wheeze
Cough
SOB
Chest tightness
HFA
-22.3
Mean diff
(HFA and
CFC)
0.05
0.04
-0.05
-0.00
CFC
-21.9
90%CI
-0.12, 0.22
-0.15, 0.23
-0.24, 0.13
-0.19, 0.18
P value for
equivalence
P < .001
· Mean age 40 andmale 56%
· Mean FEV1 66%PV
· Producer of the HFA preparation
funded and supported trial
· 89% of study participants
randomised were analysed
(Tonnel et al.
2000)
RCT
Grade 1+
Country:
France
Fluticasone inh
250 mg bd
HFA
V
CFC
4 weeks
Inclusion:
Age ³ 18 yrs
FEV1 50-90%PV Required
400-1000 mg daily
beclomethasone or
equivalent
Exclusion:
Required antibiotics,
hospitalised or received
po/parenteral steroids in 4
weeks preceding study
380
Adjusted mean AM PEFR
Median days with no rescue
med. use (%)
Adverse events (%)
HFA
399
83
26
CFC
400
83
27
Adj diff
-1
90%CI
-7,51
· Mean age 43 and female 49%
· Funded by pharmaceutical
company producing fluticasone
· 1Met criteria for therapeutic
equivalence
· Method of randomisation unclear
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Table 29: Summary of studies investigating the effect of pharmaceuticals (CFC V HFA propellant) in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Perruchoud et
al. 2000)
RCT
Grade 1+
Country:
4 countries
Fluticasone inh
500 mg bd
HFA
V
CFC
12 months
Inclusion:
Age ³ 16 yrs
FEV1 50-90%PV
Required 1-2 mg daily
beclomethasone or
equivalent
Exclusion:
Required antibiotics for resp
infection, or change in
regular asthma medication
in 4 weeks preceding study
PO/parenteral steroids ³ 2
times in previous 4 months
412
Adjusted mean D AM FEV1
Median symp score
Adverse events (%)
Serum cortisol (12
mth/baseline ratio)
HFA
0.18
0
82
0.96
CFC
0.11
0
78
0.96
Adj diff
0.07
90%CI
0.00, 0.141
0.89, 1.12
· Mean age 47 and female 52%
· Imbalance in gender distribution at
baseline
· Funded by pharmaceutical
company producing fluticasone
· 1Met criteria for therapeutic
equivalence
(Ayres et al.
2000)
CO
Grade 1+
Country:
United Kingdom
Fluticasone inh 1
mg bd
HFA
V
CFC
6 weeks each
Inclusion:
Age > 16 yrs
FEV1 £ 90%PV at
randomisation
Required 2-4 mg daily of
beclomethasone or
budesonide or £1 mg daily
fluticasone
Exclusion:
Current smoker or smoked
within previous 6 weeks
Change in regular asthma
meds, required antibiotics,
hospitalised for resp disease
or received po steroids (<10
mg daily) in 4 weeks
preceding study
119
D am PEFR (L/min)
Median % symp free nights
Median days no additional
bronchodilator
Median nights no additional
bronchodilator
% patients reporting an
adverse event
HFA
2
89
10
82
77
CFC
0
86
4
82
75
90%CI
-7,61
n.s.
n.s.
n.s.
n.s.
· Mean age 49 and female 57%
· No washout period
· Difference in mean PEFR at
baseline between sequence order
· Funded by producers of
fluticasone
· 1Met criteria for therapeutic
equivalence
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Table 29: Summary of studies investigating the effect of pharmaceuticals (CFC V HFA propellant) in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Welch et al.
1999)
RCT
Grade 1+
Country:
United States
Triamcinolone
HFA V CFC V
Placebo
Doses 150, 300,
600 mg daily for
HFA and CFC
8 weeks
Inclusion:
Age ³ 18 yrs
FEV1 50-80%PV at
randomisation
Exclusion:
Current smoker or past
history of ³ 10 pack-years
tobacco
History of life threatening
asthma
Upper resp infection within
30 days
514
HFA150
HFA300
HFA600
CFC150
CFC300
CFC600
D AM PEFR
9.2
36.4
44.9
24.3
23.4
33.7
n.s. but not
equivalent
D symptom
score
-1.52
-2.03
-2.57
-1.27
-2.01
-2.34
n.s. but not
equivalent
D nights
awake
-0.27
-0.58
-0.75
-0.37
-0.43
-0.57
Therapeutic
equivalence
· Mean age 39 and female 61%
· Mean FEV1 65%PV
· Pharmaceutical company funded
and supported trial
· 90% power to detect 10%
difference in FEV1 (compared with
placebo)
(Jacobson et al.
1999)
RCT
Grade 1+
Country:
United States
Triamcinolone
HFA 450, 900,
1800 mg daily
V
Triamcinolone
CFC 450, 900 mg
daily
V
Placebo
12 weeks
Inclusion:
Age ³ 18 yrs
FEV1 40-80%PV
Exclusion:
History of life threatening
asthma
Recent hospitalisation for
asthma exacerbation
Upper resp infection
538
% D FEV1
Symp score
Night awakening (n/night)1
Any adverse event (%)
HFA450
22.2
-1.7
-0.4
65.3
HFA900
23.1
-2.0
-0.5
71.1
CFC450
11.5
-2.0
-0.4
69.4
CFC900
18.4
-1.9
-0.6
66.7
· Mean age 40
· Mean FEV1 61%PV
· All presented results had non-
significant differences between
CFC and HFA propellant (which
extended to HFA1800 mg dose)
· Pharmaceutical company funded
and supported trial
· 1Therapeutic equivalence
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Table 29: Summary of studies investigating the effect of pharmaceuticals (CFC V HFA propellant) in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Baumgarten et
al. 2000)
RCT
Grade 1+
Country:
Germany
Salbutamol inh
100 mg PRN
HFA
V
CFC
4 weeks
Inclusion:
Age ³ 18 yrs
FEV1 50-100%PV
Average of at least 1
actuation per day and not
more than 12 actuations
over 2 days in the last 7
days of run-in
Exclusion:
Changes in regular asthma
medication or a
deterioration in or
exacerbation of asthma 4
weeks prior to start of run-in
phase
Pharmaceutical limitations
423
Median salbutamol use
(puffs/4 weeks)
Median symp score
Adverse e
vents
Adjusted D am PEFR (L/min)
Asthma exacerbation (%)
HFA
110
1
26
5
4
CFC
111
1
19
4
5
P value
n.s.
n.s.
n.s.
90%CI
-4,6
0,0
· Mean age 48 and female 49%
· Patient maintained on usual
regular treatment
· Some FEV1 /PEFR measurements
may have been bronchodilator
influenced
· Pharmaceutical company funded
and supported trial
(Bleecker et al.
1998)
RCT
Grade 1+
Country:
United States
Salbutamol HFA
180 mg Qid
V
Salbutamol CFC
180 mg Qid
V
Placebo
12 weeks
Inclusion:
Age 18-65 years
FEV1 40-80%PV
Able to withhold inh
bronchodilators for ³ 8 hours
Exclusion:
Recent resp infection
Oral steroid use within 4
weeks of study start
Smoking history within 2
years
565
Responders (%)
HFA
73
CFC
74
90%CI diff
-0.07, 0.071
· Mean age 36 and female 59%
· Pharmaceutical producer of HFA
preparation funded and
supported trial
· 1Met criteria for equivalence
· Responder if FEV1 execeeded
baseline by at least 15% within 30
minutes post dose at that visit
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Table 29. Summary of studies investigating the effect of pharmaceuticals (CFC V HFA propellant) in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Tinkelman et al.
1998)
RCT
Grade 1+
Country:
United States
Salbutamol HFA
180 mg Qid
V
Salbutamol CFC
180 mg Qid
V
Placebo
12 weeks
Inclusion:
Age 18-65 years
FEV1 40-80%PV
Able to withhold inh
bronchodilators for ³ 8 hours
Exclusion:
Recent resp infection
Oral steroid use within 4
weeks of study start
Smoking history within 2
years
565
Increased asthma symptoms
within 15 mins of drug use (%)
HFA
2
CFC
2
P value
n.s.
· Same study as (Bleecker et al.
1998)
· Mean age 36 and female 59%
· Pharmaceutical producer of HFA
preparation funded and
supported trial
(Furukawa et al.
1999)
RCT
Grade 1+
Country:
United States
Cromolyn Sodium
HFA inh 2 mg Qid
V
Cromolyn Sodium
CFC inh 2 mg Qid
V
Placebo
12 weeks
Inclusion:
Age ³ 12 yrs
FEV1 ³ 60%PV
Exclusion:
Current or recent smoker
History of life threatening
asthma
Pharmaceutical limitations
280
D symptom score n (%)
D PEFR (l/min)
D rescue med use (%)
FEV1 (L)
Physician rated the
intervention as moderately or
very effective (%)
Patient rated the intervention
as moderately or very
effective (%)
Adverse event reported (%)
CFC
0.63 (-22)
5.7
-13
3.00
63
73
74
HFA
0.83 (-22)
21.9
-27
2.80
56
77
76
P value
n.s.
n.s.
n.s.
n.s.
P = .04
n.s.
n.s.
· Mean age 29 and female 55%
· FEV1 74%PV
· Study had 90% power to detect a
difference in the symptom score of
0.3 at the 5% significance level
· Producers of HFA preparation
funded and supported trial
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Table 29. Summary of studies investigating the effect of pharmaceuticals (CFC V HFA propellant) in chronic asthma ( ontinued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Blumenthal et
al. 1998)
RCT
Grade 1+
Country:
United States
Cromolyn sodium
inh 2 mg Qid
HFA
V
CFC
V
Placebo
12 weeks
Inclusion:
Age ³ 12 years
FEV1 50-90%PV
Exclusion:
Current or recent smoker
History of life threatening
asthma exacerbations
Pharmaceutical limitations
366
FEV1 (L)
D symp score
D rescue med use (%)
HFA
2.95
-0.71
-33%
CFC
2.80
-0.74
-38%
P value
n.s.
n.s.
n.s.
· Mean age 31 and female 53%
· Mean FEV1 75%PV
· 90% power to detect a 0.3 point
difference in symptom score (5%
significance level)
· Pharmaceutical company funded
and supported trial
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Table 29: Summary of studies investigating the effect of pharmaceuticals (CFC V HFA propellant) in chronic asthma (continued)
Study
source, design
and evidence
grading
Intervention
comparison
and study
duration
Criteria for
Inclusion/
Exclusion
N Results/outcomes Comments
(Goldberg et al.
2000)
RCT
Grade 1+
Country:
Germany
Fenoterol inh 200
mg Qid
HFA
V
CFC
12 weeks
Inclusion:
Age 18-65 yrs
FEV1 40-80%PV
Current non-smoker with a
history of £ 10 pack-years
Exclusion:
Upper resp infection, or
hospitalisation due to
exacerbation of asthma 4
weeks prior to start of run-in
phase
Pharmaceutical limitations
290
Adverse events (%)
FEV1 (L)
HFA
29.9
2.2
CFC
28.0
2.1
P value
n.s.
n.s.
· Mean age 41 and female 46%
· Mean FEV1 62%PV
· Pharmaceutical company funded
and supported trial
· 81% of randomised population
analysed at endpoint
(Bronsky et al.
1999)
RCT
Grade 1-
Country:
United States
Salbutamol inh 2
puffs bd + PRN
CFC
V
HFA
12 weeks
Inclusion:
Age 18-65 yrs
FEV1 40-80%PV
12 month history of asthma
requiring b-agonist for
symptom relief
51
Peak % D from predose FEV1
Adverse events (%)
D pulse
D BP
CFC
35.8
88
HFA
36.1
100
P value
n.s.
n.s.
n.s.
n.s.
· Mean age 37 years and female
57%
· Mean FEV1 61%PV
· No information on blinding, study
power or ITT analysis
· Salbutamol dosage not stated
· Pharmaceutical company funded
and supported trial
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Appendix 1
SEARCH STRATEGIES FOR ASTHMA THERAPEUTICS
Medline One
1      exp asthma/dt (2876)
2      randomized controlled trials/ or randomized controlled trial.pt. (44090)
3      controlled clinical trials/ or controlled clinical trial.pt. (9382)
4      2 or 3 (53209)
5      1 and 4 (798)
6      (child: or pediatric: or paediatric:).t . (43867)
7      5 not 6 (643)
8      (letter or review of reported cases).pt. (96620)
9      news.pt. (14510)
10    case report/ (143192)
11    or/8-10 (227583)
12     7 not 11 (631)
13     meta-analysis/ or meta-analysis.pt. (3589)
14     guidelines/ or practice guidelines/ or guideline.pt. (12819)
15     13 or 14 (16300)
16     1 and 15 (142)
17     (systematic: adj (review or overview)).mp. (1121)
18     1 and 17 (8)
19     16 or 18 (147)
20     12 not 19 (613)
21     from 20 keep 1-200 (200)
22     from 20 keep 201-400 (200)
23     from 20 keep 401-600 (200)
24     from 20 keep 601-613 (13)
25     exp anti-asthmatic agents/ (22855)
26     exp Anti-Asthmatic Agents/ad, ae, ct, tu (6097)
27     4 and 26 (1536)
28     exp asthma/ (9422)
29     27 and 28 (698)
30     limit 29 to human (697)
31     30 not 11 (687)
32     31 not 12 (181)
33     from 32 keep 1-181 (181)
34     Bronchodilator Agents/ad, ae, po, ct, tu, to (1504)
35     28 and 34 (814)
36     35 and 4 (321)
37     36 not 11 (319)
38     limit 37 to human (319)
39     38 not 20 (93)
40     39 or 33 (189)
41     from 40 keep 1-189 (189)
42     26 or 34 (6110)
43     13 or 14 or 17 (17031)
44     42 and 43 (179)
45     19 or 20 or 41 (939)
46     44 not 45 (77)
47     from 46 keep 1-77 (77)
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Medline Two
1     exp ASTHMA/ci, nu, dh, dt, px, rt, rh, su, th (4549)
2     limit 1 to (clinical trial or clinical trial, phase iv or controlled clinical trial or meta analysis or multicenter
study or randomized controlled trial) (1051)
3     child:.ti. (36346)
4     2 not 3 (856)
5     animal/ (437966)
6     human/ (1090130)
7     5 and 6 (137484)
8     4 and (6 or 7) (855)
9     research/ (7508)
10     Clinical Protocols/ (1880)
11     feasibility studies/ (3750)
12     reproducibility of results/ (27183)
13     research design/ (5737)
14     double-blind method/ (13842)
15     patient selection/ (5489)
16     random allocation/ (5354)
17     sample size/ (703)
18     or/9-17 (68066)
19     epidemiologic research design/ (185)
20     crossover studies/ (4948)
21     matched pair analysis/ (540)
22     sample size/ (703)
23     sensitivity.mp. and "specificity"/ (12423)
24     Single-Blind Method/ (2297)
25     or/19-24 (20555)
26     clinical trials/ (9996)
27     Clinical Trials, Phase IV/ (20)
28     controlled clinical trials/ (855)
29     multicenter trials/ (1496)
30     randomized controlled trials/ (7360)
31     or/26-30 (18323)
32     placebos/ (2285)
33     comparative study/ (148426)
34     "Outcome Assessment (Health Care)"/ (5040)
35     treatment outcome/ (55175)
36     medical futility/ (300)
37     treatment failure/ (3137)
38     or/32-37 (201054)
39     random:.mp. (67238)
40     single-blind:.mp. (2622)
41     double-blind:.mp. (15487)
42     triple-blind:.mp. (17)
43     double-dummy:.mp. (217)
44     mask:.mp. (5078)
45     sham.mp. (5564)
46     placebo:.mp. (15900)
47     control: trial:.mp. (7404)
48     efficacy.mp. (40563)
49     effectiveness.mp. (19336)
50     or/39-49 (129476)
51     8 and 25 and 38 (110)
52     8 and (25 or 31 or 38 or 50) (748)
53     52 not 51 (638)
54     8 and 18 (450)
55     8 and 25 (218)
56     8 and 31 (14)
57     8 and 38 (420)
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58     8 and 50 (685)
59     55 not 54 (52)
60     56 not 55 (14)
61 from 54 keep (SELECTED REFERENCES)
Embase
1     exp ASTHMA/pc, rt, dm, rh, dt, su, th (15382)
2     Major Clinical Study/ (503543)
3     Clinical Study/ (1085)
4     Clinical Article/ (546908)
5     Controlled Study/ (1080347)
6     PREVENTION/ (9035)
7     THERAPY/ (9171)
8     or/2-7 (1794449)
9     1 and 8 (6810)
10     limit 9 to yr=1997-2001 (2459)
11     (child: or pediatric: or infant:).ti. (141191)
12     10 not 11 (1985)
13     animal/ (6599)
14     human/ (2803280)
15     13 and 14 (1153)
16     12 and (14 or 15) (1897)
17     Controlled Study/ (1080347)
18     Case Control Study/ (5166)
19     randomized controlled trial/ (49059)
20     or/17-19 (1085585)
21     drug comparison/ (1788)
22     Clinical Trial/ (184432)
23     multicenter study/ (17496)
24     Phase 4 Clinical Trial/ (251)
25     or/21-24 (186669)
26     Major Clinical Study/ (503543)
27     medical research/ (20276)
28     clinical research/ (6842)
29     drug research/ (6605)
30     or/27-29 (32559)
31     Evidence Based Medicine/ (3327)
32     meta-analysis/ (10677)
33     outcomes research/ (7617)
34     or/31-33 (20997)
35     RANDOMIZATION/ (2624)
36     crossover procedure/ (10029)
37     double blind procedure/ (32575)
38     single blind procedure/ (2880)
39     placebo/ (24698)
40     or/35-39 (55833)
41     triple-blind.mp. (42)
42     double-dummy.mp. (646)
43     mask:.mp. (14340)
44     sham.mp. (15088)
45     placebo:.mp. (56007)
46     control: trial:.mp. (59723)
47     efficacy.mp. (186786)
48     effectiveness.mp. (62386)
49     or/41-48 (324858)
50     16 and (20 or 21 or 25 or 26 or 30 or 34 or 40 or 49) (1723)
51     limit 50 to yr=1997-2001 (1723)
52     16 and (20 or 21 or 25 or 26 or 30 or 34 or 40) (1669)
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53     limit 52 to yr=1997-2001 (1669)
54     16 and 20 (1229)
55     16 and 21 (0)
56     16 and 25 (986)
57     16 and 26 (881)
58     16 and 30 (4)
59     16 and 34 (69)
60     16 and 40 (669)
61     16 and 49 (1010)
62     or/54-61 (1723)
63     exp asthma/dt (13531)
64     63 and 8 (6057)
65     64 not 11 (4972)
66     65 and (14 or 15) (4807)
67     66 and (20 or 21 or 25 of 26.mp. or 30 or 34 or 40 or 49) (3437)
68     limit 67 to yr=1997-2001 (1313)
69     from 51 keep (SELECTED REFERENCES)
Embase Two
1     exp ASTHMA/pc, rt, dm, rh, dt, su, th (15382)
2     randomized controlled trial/ (49059)
3     Evidence Based Medicine/ (3327)
4     meta-analysis/ (10677)
5     RANDOMIZATION/ (2624)
6     double blind procedure/ (32575)
7     single blind procedure/ (2880)
8     placebo/ (24698)
9     triple-blind.mp. (42)
10   double-dummy.mp. (646)
11     mask:.mp. (14340)
12     sham.mp. (15088)
13     placebo:.mp. (56007)
14     control: trial:.mp. (59723)
15     controlled clinical trial.mp. (1824)
16     (systematic: adj review:).mp. (1701)
17     (systematic: adj overview).mp. (106)
18     practice guideline/ (21230)
19     or/2-18 (161913)
20     1 and 19 (3232)
21     limit 20 to yr=1997-2000 (1661)
22     (child: or toddler or infan:).ti. (127485)
23     adult:.ti. (43216)
24     22 and 23 (3236)
25     22 not 24 (124249)
26     21 not 25 (1421)
27     ((rhinitis or eczema) not asthma).ti. (2997)
28     26 not 27 (1418)
29     (healthy volunteer: or healthy subject: or human volunteer:).ti. (5584)
30     28 not 29 (1415)
31     from 30 keep (SELECTED REFERENCES)
32     from 30 keep (SELECTED REFERENCES)
33     from 32 keep (SELECTED REFERENCES)
34     from 30 keep (SELECTED REFERENCES)
35     from 34 keep (SELECTED REFERENCES)
36     31 or 33 or 35 (306)
37     from 30 keep (SELECTED REFERENCES)
38     37 not 36 (444)
39     (paediatric: or pediatric: or rhinitis or chronic obstructive or copd or child:).ti,ab. (221742)
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40     (child: or paediatric: or pediatric:).jw. (105360)
41     38 and (39 or 40) (45)
42     from 41 keep (SELECTED REFERENCES)
43     38 not 42 (430)
44     from 43 keep (SELECTED REFERENCES)
Embase Three
1     randomized controlled trial/ (49243)
2     meta-analysis/ (10712)
3     RANDOMIZATION/ (2628)
4     double blind procedure/ (32653)
5     single blind procedure/ (2890)
6     placebo/ (24762)
7     triple-blind.mp. (42)
8     double-dummy.mp. (647)
9     mask:.mp. (14369)
10     sham.mp. (15119)
11     placebo:.mp. (56121)
12     control: trial:.mp. (59936)
13     controlled clinical trial.mp. (1827)
14     (systematic: adj review:).mp. (1712)
15     (systematic: adj overview).mp. (106)
16     practice guideline/ (21364)
17     or/1-16 (160253)
18     asthma/dt (12762)
19     17 and 18 (2792)
20     limit 19 to yr=1997-2000 (1443)
21     letter:.ti. (26037)
22     case report/ (430369)
23     letter/ (200255)
24     or/21-23 (590898)
25     20 not 24 (1395)
26     (paediatric: or pediatric: or child:).jw. (105679)
27     25 not 26 (1288)
28     ((paediatric: or pediatric: or child:) and adult:).ti. (3231)
29     (paediatric: or pediatric: or child:).ti. (119959)
30     29 not 28 (116728)
31     27 not 30 (1133)
32     ((rhinitis or copd or chronic obstructive) and asthma).ti. (526)
33     (chronic obstructive or copd or rhinitis).ti. (6131)
34     33 not 32 (5605)
35     31 not 34 (1116)
36     limit 35 to yr=2000 (221)
37     limit 35 to yr=1999 (318)
38     limit 35 to yr=1998 (300)
39     limit 35 to yr=1997 (278)
40 40     vfrom 36 keep (SELECTED REFERENCES)
41 41     from 37 keep (SELECTED REFERENCES)
42 42     from 38 keep (SELECTED REFERENCES)
43 43     from 39 keep (SELECTED REFERENCES)
Cinahl
1  exp ASTHMA/dt, th [Drug Therapy, Therapy] (1561)
2     Double-Blind Studies/ (1712)
3     Random Assignment/ (3234)
4     placebos/ (968)
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5     random sample/ (4022)
6     simple random sample/ (151)
7     Stratified Random Sample/ (704)
8     systematic random sample/ (53)
9     random:.mp. (14963)
10     single-blind:.mp. (510)
11     double-blind:.mp. (2059)
12     triple-blind:.mp. (2)
13     double-dummy:.mp. (27)
14     mask:.mp. (737)
15     sham.mp. (203)
16     placebo:.mp. (2168)
17     (control: adj2 trial:).mp. (2586)
18     or/2-17 (17997)
19     1 and 18 (201)
20     limit 19 to yr=1997-2000 (145)
21     (child: or infant: or pediatric:).ti. (28390)
22     20 not 21 (120)
23     from 22 keep (SELECTED REFERENCES)
Current Contents
asthma.mp.
double blind:.ti,ab.
meta-analy:.ti,ab.
(systematic: adj (review or overview)).ti,ab.
randomized controlled trial:.ti,ab.
controlled clinical trial:.ti,ab.
or/2-6
1 and 7
limit 8 to yr=1997-2000
(child: or paediatric or pediatric).ti.
9 not 10
from 11 keep (SELECTED REFERENCES)
from 11 keep (SELECTED REFERENCES)
12 or 13
from 11 keep (SELECTED REFERENCES)
from 11 keep (SELECTED REFERENCES)
14 or 15 or 16
11 not 17
(child: or infan: or pediatric: or paediatric:).ti,ab.
18 and 19
from 20 keep (SELECTED REFERENCES)
18 not 21
Combined Premedline/Medline/Embase/Current Contents Cinahl - broad New Zealand
search
1     exp asthma/ (52742)
2     asthma.mp. (82944)
3     1 or 2 (83257)
4     new zealand/ or new zealand.mp. (30727)
5     new zealand.in. (57602)
6     4 or 5 (77006)
7     3 and 6 (1343)
8     limit 7 to yr=1997-2000 (691)
9     remove duplicates from 8 (355)
10     (letter or news).pt. (652061)
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11     9 not 10 (330)
12     case report/ or case report.mp. (647075)
13     11 not 12 (325)
14     (child: or infan: or pediatric: or paediatric:).ti. (365724)
15     13 not 14 (265)
Cochrane Library Controlled Trials Register
ASTHMA:ME
ASTHMA:TI
#1 OR #2
CHILD OR PEDIATRIC* OR PAEDIATRIC*:TI
#3 NOT #4
LIMIT TO YR 1997-2000
Review databases:  Cochrane Library Systematic Reviews & Protocols, DARE, HTA, NHS
EED, Best Evidence
Because these databases are small and of such high quality they were searched simply using the word asthma
then sifted manually for relevant references
Other databases and sources
Other databases and sources without indexing were searched using combinations of the headings and textwords
from the above strategies in simple, iterative searches such as:
Asthma AND guideline*
Asthma NOT (pediatric OR paediatric OR child* OR infan* OR copd OR chronic obstructive OR rhinitis)
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Appendix 2
EVIDENCE GRADING FORMATS
Intervention
Drug, dose, mode of delivery, duration of treatment.
Abbreviations:
BDP Budesonide
BEC Beclomethasone
BMB Bambuterol
CIR CirculaireÔ
CNV Conventional nebuliser
CON Continuous dose
CYC Cyclohaler
D/A Diskus/Accuhaler
DH Diskhaler
DPI Dry powder inhaler
DU Diskus
FNS Flunisolide
FP Fluticasone
FRM Formoterol
Int Intermittent dose
IPR Ipratropium
MNT Montelukast
PRD Prednisone
ROT Rotahaler
SLB Salbutamol
SLM Salmeterol
TAA Triamcinolone
TBH Turbuhaler
TEB Terbutaline
THP Theophylline
ZAF Zafirlukast
OCS Oral corticosteroids
ICS Inhaled corticosteroids
IGS Inhaled glucosteroids
Mode of delivery
Abbreviations:
CFC chlorofluorocarbon propellant
D-inh diskhaler
HFA hydrofluoroalkane propellant
Iv intravenous
Im intramuscular
Inh inhaler
MDI metered dose inhaler
Po oral
Neb nebuliser
NEW ZEALAND HEALTH TECHNOLOGY ASSESSMENT: ASTHMA THERAPEUTICS
A 2
159
Dose frequency
Abbreviations:
qd once daily
mane  once in morning
nocte once at night
bd twice daily
Qid four times daily
q4h every four hours
PRN as required
Criteria for inclusion and exclusion
Inclusion
§ Age range
§ FEV1 as a  % of predictive value if available or change in FEV1 as a percent change due to exercise
challenge or ICS or other medication challenge where FEV1  %pv not available.
§  Smoking history
Exclusion
§ Prior recent emergency care
§ Other relevant and important morbidity
Abbreviations
%PV = % of predicted value
ED = Emergency department
FEV1 = Forced expiratory volume in one second
ICU = Intensive care unit
PC20 = challenge (usually methacholine or histamine) concentration that caused a 20% fall in FEV1
PEFR = Peak expiratory flow rate
RCT = randomised controlled trial
URTI = upper respiratory tract infection
Results/outcomes
Generally these will relate to POEMs
Drug category in left column relates to drug of efficacy in the trial
Abbreviations:
NNT = numbers needed to treat using the drug of efficacy to achieve one favourable outcome
NNH = numbers needed to harm using the drug of least efficacy to achieve one unfavourable outcome
P value = probability measure of uncertainty
Comments
Specifics regarding population demographics e.g. mean age, sex distribution, and ethnicity, mean FEV1 % PV
Specific asthma subgroup e.g. exercise induced.
Important methodological issues, which might undermine study validity
Concurrent therapy
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Appendix 3
Methodology Checklist 1:   Systematic Reviews and Meta-analyses
Study identification
Include author, title, reference, year of publication
Checklist completed by:
SECTION 1:  INTERNAL VALIDITY
Evaluation criterion How well is this criterion addressed?
1.1 Does the review address an appropriate and clearly
focused question?
1.2 Does the review include a description of the
methodology used?
1.3 Was the literature search sufficiently rigorous to
identify all relevant studies?
1.4 Was study quality assessed and taken into account?
1.5 Does the review include all the potential benefits and
harms of the intervention?
1.6 Was it reasonable to combine the studies?
1.7 Do the conclusions flow from the evidence reviewed?
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SECTION 2:   OVERALL ASSESSMENT OF THE STUDY
2.1 How well was the study done to minimise bias?
Code ++, +, or -
2.2 If coded as +, or - what is the likely direction in which
bias might affect the study results?
2.3 Are the results of this study directly applicable to the
patient group targeted by this guideline?
SECTION 3:   DESCRIPTION OF THE STUDY
3.1 What types of study are included in the review?
Randomized Controlled Trials (RCT), Controlled
Clinical Trials (CCT), Cohorts, Case Control Studies
3.2 What interventions are considered?
3.3 What outcome measures are used?
i.e. benefits and harms
3.5 Are potential confounding factors considered?
This is particularly important where study types other
than RCTs are included in the review.
3.6 What are the characteristics of the study population?
e.g. age, sex, disease characteristics of the population,
disease prevalence.
3.7 What are the characteristics of the study setting?
e.g. rural, urban, hospital inpatient or outpatient,
general practice, community.
SECTION 4:   GENERAL NOTES AND COMMENTS
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Methodology Checklist 2: Randomised Controlled Trials
Study identification
Include author, title, reference, year of publication
Checklist completed by:
SECTION 1:  INTERNAL VALIDITY
Evaluation criterion How well is this criterion addressed?
1.1 Does the study address an appropriate and clearly
focused question?
1.2 Was the assignment of subjects to treatment groups
randomised?
1.3 Were the treatment and control groups similar at the
start of the trial?
1.4 Was an adequate concealment method used?
1.5 Were subjects and investigators kept ‘blind’ about
treatment allocation?
1.6 Are all relevant outcomes measured in a standard,
valid and reliable way?
1.7 Apart from the treatment under investigation, were the
groups treated equally?
1.8 What percentage of the individuals or clusters recruited
into the study are included in the analysis?
Statistical poweradequacy
1.9 Were all the subjects analysed in the groups to which
they were randomly allocated?
1.10 Degree of pharmaceutical company involvement
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SECTION 2:   OVERALL ASSESSMENT OF THE STUDY
2.1 How well was the study done to minimise bias?
Code ++, +, or -
2.2 If coded as +, or - what is the likely direction in which
bias might affect the study results?
If the study reports an evaluation or comparison of diagnostic tests, please complete a diagnostic
studies checklist before completing the next section.
SECTION 3:   DESCRIPTION OF THE STUDY
3.1 How many patients participated in the study?
Overall number, and in each arm of the study.
3.2 What was the scale and direction of the measured
effect?
3.3 What are the characteristics of the study population?
e.g. age, sex, disease characteristics of the population,
disease prevalence.
3.4 Are there any specific issues raised by this study?
Make any general comments on the study results and
their implications
